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Abstract 
Regenerative medicine and tissue engineering are being revolutionised by 
developments in the field of stem cell science. Mesenchymal Stem Cells (MSCs) are 
emerging as a desirable tool in regenerative medicine and cell therapy due to their wide 
ranging differentiation potential, large expansion capacity, and their lack of immune 
rejection following transplantation. Early in vivo studies have demonstrated therapeutic 
effects of hMSCs; however to clinically exploit the potential of hMSCs, the adherent 
cell type must be expanded to therapeutically relevant lot sizes (10
9
 to 10
12
 cells). Hence 
now there is a need to develop protocols for stable, controlled in vitro expansion, 
isolation and preservation of a homogenous population of functionally viable cells. 
Specifically a practical, clinically safe and scalable system which adheres to current 
GMP guidelines is required to develop reproducible and cost effective therapeutic 
products. 
Here we describe the design, manufacture and characterisation of 
biofunctionalised hydrogel microcarriers containing ECM derived adhesion peptides 
and a range of compressive moduli for adipose derived stem cell expansion. 
Microfluidic devices were employed to produce monodisperse spherical particles which 
were polymerised in situ. In addition, these microcarriers have tunable characteristics 
which make them a particularly useful tool for the systematic investigation of cellular 
responses. Microcarriers modified to contain fibronectin and laminin derived peptides 
supported ADSC attachment and growth in a concentration dependent manner. ADSCs 
cultured on peptide modified microcarriers were capable of differentiating into 
osteocytes, chondrocytes and adipocytes, indicating cells cultured on microcarriers 
maintained multipotency.  Substrate compressibility was found to effect ADSC 
differentiation, corroborating previous literature reports. Bioreactor culture 
demonstrated successful ADSC expansion with fold increases in cell number far higher 
than have previously been reported in the literature. High cell seeding densities 
produced large quantities of viable cells. However, decreasing initial cell seeding 
density, increased the total fold expansion and reduced cell doubling rates.  
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1.1 Regenerative medicine and stem cells   
Regenerative medicine is a rapidly progressing scientific and medical discipline 
which aims to develop therapeutics to replace, restore or maintain damaged tissues or 
organs in the body, in order to recover normal function (1, 2). It is hoped that evolving 
technologies will generate therapeutic remedies for disorders where current chemical 
treatments are inadequate. Cell therapy and tissue engineering constitute the wider field 
of regenerative medicine, with a primary goal of delivering safe, effective and reliable 
therapies. Stem cells within the body provide endogenous mechanisms for repair and 
regeneration (3), and regenerative medicine hopes to utilise these stem cells as a key 
tool to repair or replace damaged tissues. Stem cells have two definitive properties; they 
are capable of self-renewal, and can differentiate, generating lineage specific progeny.  
Candidates for cell therapies in regenerative medicine include Embryonic Stem 
Cells (ESCs), induced Pluripotent Stem Cells (iPSCs) and adult stem cells, such as 
Multipotent Stromal Cells (Mesenchymal Stem Cells or MSCs). Human Embryonic 
Stem cell lines are derived from the inner cell mass of pre-implanatation embryos at the 
blastocyst stage (4), and have a potentially unlimited capacity for self-renewal whilst 
remaining karyotypically and phenotypically stable (5). In addition, ESCs are 
pluripotent and are capable of differentiating into derivatives of all three germ layers, 
ectoderm, endoderm and mesoderm, both in vitro and in vivo (4). This potential of ESCs 
to generate an unlimited supply of 220 cell types, make them excellent candidates for 
use in regenerative medicine and tissue replacement (6). ESCs are currently being 
developed to treat a wide variety of diseases including Parkinson’s disease (7), several 
types of cancer (8) and blindness (9). In addition, clinical trials in both the UK and US 
have tested hESC based cellular therapies to treat spinal cord injury and macular 
degeneration (10).  The ability of ESCs to propagate in in vitro culture indefinitely 
under controlled conditions, also make ESCs a valuable research tool. ESCs are 
currently being utilised in toxicology testing and to study human development and 
investigate genetic disease (11). However, there are legal and ethical concerns 
associated with ESC based therapies, in particular the initial isolation, which requires 
the destruction of a fertilised embryo (12). Further drawbacks include teratoma 
formation (an encapsulated tumour derived from all three germ layers) and elicited 
immune rejection after allogeneic ESCs transplantation (13). Problems concerning 
histocompatibility may be overcome by therapeutic cloning, also known as Somatic 
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Cell Nuclear Transfer (SCNT), whereby a nucleus from an oocyte is substituted with a 
nucleus from an adult somatic cell taken from the patient requiring a transplant. The 
resulting egg is stimulated to form a blastocyst, where the inner cell mass can be used to 
generate ESC lines that are genetically identical to the patient (14). Other strategies 
employed include novel immunosuppressants, stem cells banks and reprogramming 
patients’ own somatic cells with defined factors to generate iPSCs (15). 
iPSCs are pluripotent stem cells that are artificially derived from a non-
pluripotent cell by inducing overexpression of specific genes using variable sets of 
transcription factors (16). iPSCs share similar, but not identical characteristics to ESCs, 
displaying comparable pluripotency, as demonstrated by embryoid body and teratoma 
formation assays, in addition to similar expression of genes, proteins and chromatin 
methylation patterns (17). iPSCs have been differentiated into multiple functional cell 
types, including cardiomyocytes (18) hematopoeitic cells and neurons (19, 20). Hence, 
iPSCs hold great potential as renewable sources of autologous cells for regenerative 
medicine. However, the method of iPSC generation can result in significant risks that 
could limit their potential use in humans. One example is if viruses are used to alter 
gene expression within cells, this could potentially trigger the expression of unwanted 
oncogenes (21). Further developments have introduced a technique to remove 
oncogenes after pluripotency induction, increasing the potential for iPSC use (21), 
however both methods require integrating exogenous sequences into the target cell 
genome which is undesirable. A method has been developed to introduce the necessary 
proteins via poly-arginine anchors without loss in pluripotent potential to create protein-
induced pluripotent stem cells (piPSC) (22). iPSCs, like ESCs, also pose a risk of 
possible teratoma formation (23), and although it was hoped that as iPSCs are generated 
form a patient’s own somatic cells this would circumvent any immunogenic responses, 
in vivo experiments have shown an immune response after transplantation  (24). 
MSCs are present in a number of postnatal organs and connective tissue, and 
hold great potential for the treatment of various degenerative diseases and immune 
disorders because of their differentiation and immunoregulatory capacity, and because 
they do not suffer from many of the problems of ESCs and iPSCs detailed above (25).  
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1.2 Mesenchymal stem cells  
MSCs were first isolated, cultured and differentiated through the osteogenic 
lineage from the stromal compartment of rat marrow by Friedenstein and Petrakova in 
1966 (26). Later studies have found MSCs are rare and quiescent populations, which 
reside within specialised niches in numerous fully specialised tissues (27). MSCs are 
capable of self-renewal and possess multipotent potential with the ability to differentiate 
into multiple mature cell types of mesodermal lineage including cartilage, bone, fat and 
muscle under defined conditions in vitro. It was postulated that the differentiation 
potential of adult stem cells is constricted to that of the tissue of origin and mesodermal 
lineages (28). However, recent studies have confirmed the plasticity of MSCs by 
demonstrating their capacity to trans-differentiate into cells of all three germ layers 
(mesodermal, endodermal and ectodermal) both in vitro and in vivo (27, 29-33). These 
findings could dramatically increase the potential uses of MSCs in regenerative 
medicine. Most commonly isolated from the bone marrow (BM), BM-MSCs are the 
most widely studied MSC and possess a spindle-shaped, fibroblast-like morphology, 
and are thought to function as a stromal support system for haematopoietic stem cells, in 
addition to participating in BM tissue homeostasis and in the turnover of skeletal cell 
types (32). 
Evidence suggests cultured MSCs consist of a heterogeneous population of cells, 
containing subsets of stem cells in addition to more lineage committed (progenitor) cells 
(34). There are inconsistencies in the literature regarding both the biological properties 
and the correct nomenclature to describe such a heterogeneous population of cells. Like 
other stem cell types, MSCs can be characterised immunologically by a specific panel 
of markers, however there is controversy over which accurate, unique and definitive 
cellular markers to use. In response to this, the International Society for Cellular 
Therapy has published guidelines that suggest plastic adherent cells, isolated from any 
adult tissue should be designated multipotent mesenchymal stromal cells (35). The term 
Mesenchymal stem cell should be reserved for cultured cells that meet a specific set of 
criteria. Firstly, MSCs should be isolated using a plastic adherent technique. Secondly, 
MSCs should be expanded using standard in vitro culture methods and express the cell 
surface markers CD73, CD90, CD105 but lack CD11b, CD17, CD19, CD79a, CD45 
and HLA-DR expression. Lastly MSCs should remain multipotent in vitro, and 
classically be able to undergo tri-lineage differentiation into adipocytes, chondrocytes 
and osteocytes (35).  
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1.3 ADSCs 
Adult bone marrow is now a standard site for MSC isolation, however more 
recently MSCs have been isolated from nearly all adult tissues, including synonovium, 
dermis, periosteum, deciduous teeth and in solid organs (e.g., liver, spleen, lung) (36). 
Human subcutaneous adipose tissue is gaining increasing interest as a promising source 
for MSCs (denoted as adipocyte derived stem cells (ADSCs)). Worldwide obesity is a 
growing pandemic, and has resulted in increased incidence of subcutaneous fat deposits, 
which are easily accessible using the elective cosmetic surgical procedure liposuction 
(37, 38). In the United states, approximately 400,000 liposuction procedures are 
performed annually, and each procedure can generate between 100mL to over 3L of 
lipoaspirate tissue (39). Liposuction surgery yields large quantities of aspirate material 
and is relatively safer and better tolerated than bone marrow aspiration (40). This is 
routinely considered clinical waste and discarded, however fat tissue comprises 
adipocytes and a stroma vascular fraction (SVF), and within the latter resides a 
relatively abundant source of ADSCs and progenitor cells. Isolated relatively recently, 
(2002) studies have isolated 0.5-2.0 x 10
6
  SVF cells/gram of adipose aspirate and it is 
estimated as many as 3% are stem and progenitor cells (41). This is more frequent than 
the traditional source of MSCs from bone marrow aspirates, which typically yields a 
SVF fraction of 6x10
6
 cells, within which 0.001-0.002% of cells are BM-MSCs (37, 41-
44). Furthermore, ADSCs can be plated at a lower seeding density (3,000cells/cm
2
) 
when compared to BM-MSCs (>50,000cells/cm
2
). There are defined in vitro 
differentiation protocols that comply with regulations whereby ADSCs can differentiate 
down multiple cell lineages reproducibly (45).  
There are several terms used to describe the multipotent population of cells 
isolated form adipose tissue. These include “adipose-derived adult stem (ADAS) cells,” 
“adipose derived adult stromal cells,” “adipose-derived stromal cells (ADSC),” 
“adipose stromal cells (ASC),” “adipose mesenchymal stem cells (AdMSC),” 
“preadipocytes,” “processed lipoaspirate (PLA) cells,” and “adipose-derived 
stromal/stem cells (ASCs)”. As the reported isolation procedures and biological and 
phenotypic characteristics are similar, it is presumed that these terms describe the same 
cell population. This prompted the International Fat Applied Technology Society 
(IFATS) to eliminate the discrepancy in reporting findings and for the field to use a 
common term adipocyte derived stromal/stem cells. This definition concurs with the 
terms used to define MSCs whereby the population isolated from adipose tissue must be 
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plastic adherent, be expanded by passage in vitro and have a tri-lineage differentiation 
potential (46, 47). 
BM-MSCs and ADSC share several similarities, they both have a multipotent 
differentiation potential, share similar morphology, behaviour and cell surface markers 
and they share an >90% identical immunophenotype (32, 41). Contrastingly there are 
differences in surface protein expression between the two cell types. Notably CD34 is 
present on ADSCs (early passage) but absent on BM-MSCs (32, 48). There are several 
conflicting reports in the literature regarding specific cell surface markers. For instance, 
evidence has demonstrated that the classic BM-MSC cell surface marker, the Stro-1 
antigen, is both present and absent in human ADSCs (41, 49, 50). The differences could 
possibly be attributed to different antibody sources and antigen detection methods e.g. 
immunocytochemistry versus flow cytometry.  
1.4 Clinical uses of MSCs  
MSCs have become a desirable tool in regenerative medicine and cell therapy 
due to their wide-ranging differentiation potential, large expansion capacity and lack of 
immune rejection following transplantation. In addition ADSCs can be isolated in 
clinically relevant amounts from multiple adult tissues. MSCs have demonstrated an 
immunosuppressive action and reduced immunogenic properties in in vivo studies 
which make them attractive candidates for allogeneic MSC therapies, by which a single 
donation of cells can be expanded and applied to multiple patients (51, 52). Possible 
clinical applications include the repair and regeneration of damaged tissue and the 
treatment of chronic inflammatory conditions. Currently (July 2012) over 227 clinical 
trials are ongoing, testing the efficacy and safety of MSCs in numerous conditions 
including cardiovascular disease, brain and spinal cord injury, cartilage and bone injury 
and diabetes (clinicaltrials.gov). In order to utilise MSCs for clinical therapies, they 
must be isolated at high cell quantities using a minimally invasive procedure with little 
risk to the patient. In addition they must be expanded in culture, and still be able to be 
differentiated into a wide range of lineages (53).  
Initially it was postulated that possible MSC based therapies would be harnessed 
from their multipotent differentiation ability, in particular from mature differentiated 
osteoblasts, to treat fractures and osteogenesis imperfecta (54). However, clinical trials 
observed a therapeutic effect of infused MSCs despite a lack of homing and engraftment 
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into the targeted host tissue long term (55). Despite a lack of attachment and 
differentiation, inﬂammation and apoptosis were reduced in several disease models, 
including myocardial infarction and kidney disease (56-59). In vitro experiments 
suggest the observed immunomodulatory effects are attributable to MSC trophic 
modulators, such as secretion of multiple bioactive molecules (e.g. cytokines) and pro-
angiogenic and anti-apoptotic factors (52, 60, 61). Evidence suggests the 
immunoregulatory potential is due to the suppression of many T, B, K and dendritic cell 
functions. It is thought infused MSCs also provide protective micro-environmental cues 
and stimulate tissue-resident progenitor populations to repair (62). This has driven many 
clinical trials to examine the therapeutic benefits of MSCs to treat and prevent diseases 
such as graft-versus-host disease, Crohn’s disease and certain haematological 
malignancies, based solely on their immunoregulatory properties (63).  
Consequently, administration of MSC therapy has transitioned from local 
delivery to systemic administration. Infusions are less invasive and are more 
convenient, particularly when treatments require multiple dosing procedures (54). 
Typically, relatively high doses of MSCs are infused at 150-300 million cells per 
treatment in clinical trials. However, evidence suggests that by using this technique less 
than 1% of the infused MSCs reach the target tissue. Instead cells often become trapped 
in capillaries inside the liver, lung and spleen due to their relatively large size and 
because they express multiple cell surface adhesion receptors (64-67).  Benefits have 
been observed in various clinical studies where MSCs have been systemically infused, 
including different preclinical models of acute lung injury, myocardial infarction, 
diabetes and multiple sclerosis, as well as renal and hepatic failure (52, 68).   
Prochymal
TM
 is an allogeneic human BM-MSC based stem cell product being 
developed for clinical use by Osiris Therapeutics, and is currently the only stem cell 
therapeutic to have FDA approval (69). Prochymal
TM
 is being developed for multiple 
indications and is currently being evaluated in 14 Phase 3 clinical trials to treat several 
conditions, including Crohn’s disease and acute graft versus host disease (GvHD) (70). 
Prochymal
TM
 has been used to treat Chronic Obstructive Pulmonary Disease (COPD). 
Preliminary reports after 6 months post treatment displayed reduced C reactive protein 
and hence reduced systemic inflammation, however pulmonary function was not 
significantly improved (71). In addition, Prochymal
TM
 is currently being developed to 
treat degenerative conditions including repairing heart tissue following myocardial 
infarction (69).   Single MSC infusions have been used in trials in both rats and humans 
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who have suffered a myocardial infarction (MI). Results showed a reduction in scarring 
and increased cardiac output in phase I clinical trials (72, 73). A trial using 
Prochymal
TM
 has demonstrated the potential of MSCs in allogeneic therapies. Patients 
treated with a single cell dose, 10 days post-acute MI experienced a four-fold reduction 
in arrymthias and premature ventricular contractions. Furthermore, patients generally 
displayed improved overall health in relation to the placebo control (74). The precise 
mechanism of MSC action is unknown, though in vivo experiments attempting to treat 
myocardial infarction in animals have shown systemically infused MSCs can 
differentiate into tissue specific cell types including cardiomyocytes (75).  
Approximately 40% of patients who undergo bone marrow and hematopoietic 
stem cell transplantation develop Graft vs Host Disease (GvHD), a severe complication 
of immune rejection of stem cells. GvHd is typically treated with steroids, however this 
isn’t always effective and patients often become ‘steroid-resistant’. Advances have been 
made in using MSCs to treat GvHD. Successful results were observed in Phase I and II 
trials with patients displaying a lack of severe adverse side effects. Despite promising 
initial results, two multicentre phase III trials conducted in 2009 were unable to achieve 
their primary endpoints, with data showing no significant differences to placebo 
controls (76, 77).  
These pre-clinical and clinical trials have demonstrated the potential of using 
MSCs for therapeutic benefit. The results from phase I and II clinical trials have been 
promising however the results are preliminary and treatment efficacy has not been 
conclusively established (78). The fate of MSCs after injection and the mechanisms by 
which they exert therapeutic effects, in particular how they modulate the immune 
system, are mostly unidentified (79).  Conflicting clinical data should be resolved in 
order to develop routine clinical therapies by improving the understanding surrounding 
MSC biology and function, and their fate after systemic infusion (65). Outstanding 
difficulties that need to be overcome in order to develop MSC cell therapies include 
producing standardised protocols for MSC isolation and developing efficient expansion 
methods to generate homogenous undifferentiated MSCs in vitro (80). Research is 
currently ongoing to determine the role of endogenous stem cells in many adult tissues 
and organs and how various stem cell niches act to control these populations (81). 
Development of in vivo cell trackers and progress in biomaterials in vitro will aid this 
research (82, 83).  
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1.5 MSCs for Tissue Engineering 
For regenerative medicine and tissue engineering purposes, local delivery into 
damaged tissue sites is preferred to systemic infusion. To ensure the MSCs are retained 
in the target damaged tissue they can be combined (differentiated or undifferentiated) 
with either natural or synthetic biomaterial scaffolds prior to in vivo implantation (84).  
Tissue engineering using cell laden constructs have been proved effective in the 
treatment of cartilage and long-bone repair (85). Using a delivery vehicle, cells can be 
controlled and manipulated at the site of damage, reducing side effects to other organs 
and tissues (86). Improvements in scaffolds in terms of enhancing MSC compatibility 
and grafting into the host tissue will develop the technology for reliable and effective 
clinical therapy (69). In addition, more work is needed to identify how these stem cells 
respond to host-cell interactions after implantation, for example how such cells respond 
to local differentiation cues in vivo, and how they evade rejection as seen with many 
autologous/allogeneic treatments (as discussed in Section 1.4) (87). 
 
 
Figure 1: Isolation, expansion and mesodermal differentiation of stem cells. 
Stem cells can be isolated from a variety of sources and it is a considerable challenge to expand these 
cells into therapeutically relevant lot sizes, whilst maintaining mesodermal differentiation potential.  
(Modified from Invitrogen.com) 
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1.6 Methods to expand MSCs  
Early in vivo studies have demonstrated therapeutic effects of hMSCs; however 
to clinically exploit the potential of hMSCs, the adherent cell type must be expanded to 
therapeutically relevant lot sizes (88). For example, a typical single clinical treatment 
dose (intravenous administration) can potentially require 3 x 10
8
 MSCs. Multiple 
autogenic treatments, or the potential to use MSCs for allogenic therapies will increase 
this several fold. Alternatively, to generate cellularised tissue engineered scaffolds, a 
range of cell seeding densities from 10
6 
to 10
7
 cells per cm
2
 is required (89). Hence, 
there is now a need to develop protocols for stable controlled in vitro expansion, 
isolation and preservation of a homogenous population of functionally viable cells (89). 
MSCs are now considered as advanced therapy medicinal products (ATMPs) by the 
European Medicines Agency (EMA) by regulation No. [EC] 1394/2007 of the European 
Commission and must be produced in compliance with Good Manufacturing Practices 
(GMP) to ensure reproducibility, efficacy and safety of the therapeutic product. The 
defined GMP standards ensure that cells are produced under highest standards of 
sterility, quality control and documentation following a standard operating procedure. 
Regulatory authorities mandate cell production according to GMP-grade system with 
appropriate and rigorous process validation and quality controls. Quality controls must 
include bacteriological tests, phenotypic control, viability, safety and efficacy of the 
final product. Hence, a practical, safe and scalable system which adheres to current 
GMP guidelines is required to develop therapeutic products that are both reproducible 
and cost-effective. Unfortunately, as the current cell culture technologies are both 
expensive and limited, few GMP compliant MSC based therapies are currently 
available. Several GMP compliant MSC specific media and tissue culture flasks have 
been developed and are commercially available. In addition to the materials used, 
several automated robots capable of seeding, maintaining and harvesting MSCs from 
multi-layer tissue culture flasks in a GMP compliant manner (93).  
Optimally, the in vitro culture conditions should be performed in a closed, sterile 
container as prevention of contamination is paramount for a  clinical treatment and to 
protect clinical personnel from exposure to bloodborne pathogens (90). In addition to 
the culture vessel, MSC culture must be developed to eliminate animal products and 
serum from expansion methods to prevent complications from prion and viral 
transmission or other xenogeneic infections (46). To develop a routine clinical therapy, 
protocols will need to be developed to optimize how to store ADSCs, including which 
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containers and labels to use, the optimal shelf life and how to deliver the MSCs to the 
point of care destination (46). This is of paramount importance as extended culture of 
human ADSCs in vitro demonstrated the ability to form tumours when transplanted to 
immunodeficient mice (91). In the future the safety and terminal fate of injected ADSCs 
long term will also need to be examined.  
1.6.1 Tissue culture plastic/2D planar formats 
Conventionally, anchorage-dependant cells are cultured in a 2D planar format on 
tissue culture treated plastic in the form of plates or flasks. Theoretically, therapies 
requiring 100-400 billion MSCs will require a culture area of 3-5million cm
2 
(88). 
Using 2D planar tissue culture plastic is reliable and well defined, however the potential 
to use this format for scale-up is restricted as it is labour intensive, prone to 
contamination, costly and cell expansion is greatly limited by available surface area 
(92).  To increase the potential for cell expansion using flask based processes, 
multilayer stacked plate systems were developed over 30 years ago for large scale cell 
culture. Currently, adherent stem cells (and other therapeutic primary cells) for 
allogeneic therapies are expanded in tissue culture treated 10 layer vessels for closed 
system processing in compliance with GMP regulations (93). These systems have been 
commercially developed, for example parallel plate flasks from Nunc (cell factories) 
and Corning (cell stacks). 
To maximise the quantity of expanded cells in planar vessels, the total surface 
area per unit and the number of layers in 2D vessels must be increased. Standard 10 
layer vessels have been successfully scaled up to 120 layers to generate a total surface 
area of approximately ~60,000 cm
2 
(Hyperstack). However, the increase in stacks 
within a multi-layer vessel decreases the possible yield of viable cells that can be 
recovered. In order to avoid contamination from manual handling, automated robotic 
instrumentation for multi-layer vessels have been developed. Using automation, 120-
layer vessels can be manipulated and this is a potential avenue to scale up cell 
production and to generate millions of cells per run (dependant on cell type).  
As well as the total surface area for cell growth, another major bottleneck of a 
2D scaled system is the cell density at harvest. Variables that can affect harvested cell 
densities are media composition, cell donor, cell type and confluency at the time of 
passage. These variables also fluctuate between cell types, which generate different cell 
densities at confluency (due to differences in the surface area of individual cells). For 
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example, ESCs are small and grow in tight colonies, however they can be unstable and 
prone to spontaneous differentiation. In future, as further robust embryonic cell lines are 
developed it is possible that 1 trillion ESCs could be achieved per lot (88). However, 
generating similar quantities of large, flat fibroblastic adult primary cells such as MSCs 
in 2D systems would be difficult to achieve without substantial automation and parallel 
processing.   
Traditional 2D culture systems are limited as they require large volumes of 
culture media, incubator space, expense and are labour intensive (92). Due to limited 
surface area for cell expansion, cell passaging is frequently required, leading to 
extensive manual handling and increased cultivation times which can increase the 
possibility of undesired genetic changes within genetically unstable cells such as MSCs 
(94). Multilayer vessels inherently have inefficient gas–liquid oxygen transfer, intrinsic 
concentration gradients, and difficulties with monitoring and control. In addition, they 
are also restricted to one log of expansion. Industrial developments have attempted to 
optimise planar systems to increase the possible surface area efficiently, and to add 
bioreactor control which can automate culture variables such as (dissolved) O2, CO2 and 
pH in addition to using robotics to control several other processes. A comparison of 
different bioreactors including parallel plate vessels have been summarised in Figure 2. 
Commercially available products include the RepliCell (Aastrom) (95) which is a fully 
automated, closed, aseptic expansion system which can increase multiple bone marrow 
cell types in 14 days.  
1.6.2 Packed Bed cultures 
Adherent and non-adherent cells can be cultured on immobilized substrates, 
such as beads, porous structures, fibres and hollow fibers within Packed Bed Bioreactor 
(PBR) culture systems. The substrates can be composed of various materials including 
glass beads and ceramic, polyester, and polyurethane materials. In addition, scaffolds 
can be used in a smooth, porous, woven, or nonwoven configuration and are packed into 
two main configurations; i) with the medium reservoir integral to the packed bed or ii) 
external to it (96-98).    
Traditionally PBRs have been used for the large scale culture of antibody and 
protein producing cells. The desired cell products are secreted into the medium and are 
continuously collected without disturbing or removing attached cells. Recently, PBRs 
 12 
 
have become favourable candidate systems for the efficient expansion of adherent 
dependent therapeutic cells, such as MSCs and hESCs in commercial research (99-101).   
Using PBR perfusion based systems, high cell densities can be achieved per 
millilitre of packed bed volume. The system can also be closed, preventing potential 
contamination and the essential culture parameters such as (pH, dO2, temp, perfusion, 
agitation) can be controlled in real time, an essential tool in cultures that last weeks to 
months (98). Substrates can also allow 3D culture of cells, an emerging factor known to 
effect stem cell behaviour (102). Lack of diffused oxygen, the accumulation of 
catabolites and inefficient CO2 clearance can be detrimental to cell proliferation and 
multipotency. In addition, PBRs provide a low shear stress environment, relative to 
stirred suspension culture systems, such as aggregate and microcarrier cultures 
(discussed in section 1.7.2).  
Cells cultured on porous beads or woven or non-woven fibres are able to reach 
densities of 100 million cells/mL, (typically the total volume of a PBR system is 
between 10mL and 40mL) depending on the cell and carrier type and culture conditions 
(88). PBR systems typically contain a surface area 119x10
3
/m
2
, an advantage over 
multilayered planar flask systems which is relatively lower at ~0.5x10
3
/m
2
 (98). The 
quantity of harvested cells can vary depending on the cell type, scaffold type and culture 
conditions. 
Several different PBRs have been developed as optimisation is required for each 
cell type to maximise the quantity and quality of harvested cells. Factors to be optimised 
can be separated into initial seeding efficiency, maximum expansion limit and 
harvesting. Factors that can potentially affect initial cell seeding efficiency include, 
scaffold properties (size, shape, charge, chemistry, porosity and structure), total media 
volume and media flow, cell attachment potential and packed bed dimensions.  
To maximise expansion during the culture phase, important parameters can be 
controlled in real time using automated processes (103). A potential limiting factor in 
PBRs is efficient transfer of nutrients (glucose and lactose) and oxygen throughout the 
entire packed bed culture volume, both in the radial and axial dimensions. This is 
essential to ensuring homogenous cell density, an important factor when scaling up the 
total volume. This can be aided by impellers which increases media transfer throughout 
the vessel, however this can also cause the cells to experience shear stress, which is 
known to impact cell behaviour and expansion (discussed in section 1.7.2). 
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Lastly, adherent cell removal from the scaffolds can be a challenging aspect of 
PBRs culture. Cell harvesting must generate a high yield of healthy, undamaged cells 
for therapeutic use. PBRs are attractive candidates for primary adult cell scale up, due to 
the large surface area and variability of the scaffolds and bioreactor’s control over key 
culture parameters. Currently, only small packed-bed bioreactors are commercially 
available for cell production (104).  
1.6.3 Suspension cultures 
Suspension culture is a method whereby stem cells are cultured as aggregates. 
The technique does not require microcarrier scaffolds or extracellular matrix (105). The 
method requires single cell seeding to maintain high cell viability. The system often 
requires stabilising inhibitors and growth factors, such as ROCK inhibitors (as 
discussed in Section 1.11.3) (106). Controlling aggregate size is difficult, and large 
clumps require dissociation usually with manual passaging every few days (107). This 
can be labour intensive, increase the probability for contamination, and represents a 
significant challenge for high cell density cultures. In addition, maintaining fine control 
over stem cell function and pluri/multi-potency as volumes increase remains a challenge 
(108).    
Both hESCs and iPSCs have been successfully cultured in aggregates (106, 
109). Furthermore, MSCs have also been cultured at relatively low cell densities in 
aggregates; however results indicated a reduced doubling rate (110). In addition, like 
microcarrier cultures, aggregates in suspension are subject to shear stresses, which can 
result in unstable cell growth and unwanted spontaneous cell differentiation (111). More 
research into this system is required to ensure product consistency and efficacy.  
1.7 Microcarriers  
Microcarriers are small spherical particles or beads originally described in 1967 
by Van Wezel (112) for the culture and expansion of anchorage-dependant cells and 
production of viral vaccines and pharmaceuticals. Microcarriers have a high surface-
area to volume ratio and are therefore frequently used for growing high-density cell 
cultures in a suspension culture system. With the development of several commercially 
available microcarriers and the improvement of bioreactors, they have become popular 
in large-scale industrial cell culture.  
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Figure 2: Summary of the main characteristics of different bioreactors used for mesenchymal stem 
cell culture. 
1.7.1 Microcarrier properties 
Microcarrier properties have been shown to significantly affect cell attachment, 
growth rates and cell multi- or pluripotency and there are several different types of 
microcarriers that are commercially available with various bulk material properties 
(113, 114). Microcarriers can be made from cross-linked dextran matrices (Cytodex 1, 
GE Healthcare) (112, 115), or polystyrene  (HyQSphere, HyClone and Hillex, SoloHill 
Engineering) (116). In addition they can contain surface chemistry modifications to 
include whole animal protein (typically ECM components) such as covalently bound 
collagen (117) or gelatin (118, 119), (Cytodex 3, GE Healthcare and HyQsphere, 
Hyclone). Such protein coatings provide an in vivo-like element to the cell culture 
platform, a factor shown to improve cell adhesion and expansion (120). A comparison 
of different microcarrier properties is shown in Figure 2. 
Traditionally, microcarriers rely largely on charge potential for cell attachment 
(115), where cells are electrostatically attracted to the microcarrier surface (121). 
Microcarriers often contain a net charge (mainly positive and occasionally negative), by 
Bioreactor 
Type
Bioreactor Design Materials Key Features
Parallel plates 
bioreactor
•Multilayer vessels
•Tissue Culture plastic
•Up to 120 layers , equivalent to a cell 
culture area of ~60,000 cm2
• High productivities can be achieved 
• Medium-intensive culture system
• Accumulation of toxic metabolic side-products is 
minimized, but continuous removal of secreted factors may 
be detrimental
• Effects of hydrodynamic shear stress are unknown
Packed and 
ﬂuidised bed 
bioreactor
•Immobilised substrates
•Microcarriers
•Fibre and hollow fibres (either 
smooth, porous or woven) 
•Materials
•Glass beads
•Ceramic
•Polyester
•Polyurethane materials
• Provides 3D scaffolding for cell attachment and growth
• Spatial concentration gradients (in the ﬁxed bed 
conﬁguration)
• Cell–cell or cell–matrix interactions are possible,
providing a better mimic of the in vivo intricate structure
• Possible shear stress effects (in the ﬂuidised bed 
conﬁguration)
• Low volumes and difﬁculties in scaling-up, when compared
with other systems
Spinner flask 
bioreactors
• Compatible with microcarriers
• Requires mechanical agitation using
different types of impeller
• Can tightly regulate culture parameters 
such as gas exchange nutrient feeding 
and pH using probes and online 
monitoring.
• Simple design. Homogeneous conditions are achieved
• In addition to suspension culture (as cell aggregates or 
single cells), also allows adherent growth when microcarriers 
are used
• Bioreactor operation and sampling are easily performed
• Hydrodynamic shear stress due to mechanical agitation can 
be
harmful to cells
• Monitoring and control solutions are widely available 
• Microcarrier bridging and/or cell agglomeration may occur
Wave 
Bioreactors
•Compatible with microcarriers
•Rocking motion agitates cell 
microcarrier suspension .
•Removes need for an impeller. 
Potentially reducing shear stress damage 
to cells
• Disposable system and easily scalable
• Sampling, monitoring and control are not as simple as with
other systems
• Contamination issues are minimized and sterilization is not 
needed, rendering it suitable for GMP operations
• High-cost solution
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incorporating cross-linked diethylaminoethyl (DEAE) anion exchange groups. Other 
common  microcarrier materials include glass, (122) cellulose, (123, 124) gelatin, (118, 
125) and polyacrylamide (126).  Most microcarriers have smooth surfaces, however in 
order to increase surface area for cell adhesion, macroporous microcarriers containing 
cross linked cotton cellulose have been developed such as the Cytopore range (GE).      
Further advances in microcarrier composition include the incorporation of 
magnetic particles that can aid cell separation from beads and in vivo monitoring (127). 
Hexagonal Microcarrier’s μHex product (Nunc, Thermo Scientific) has flat surfaces, 
replicating conventional planar surfaces, whilst maintaining a high surface area: volume 
ratio synonymous with microcarrier technologies for spherical particles (92).  Maximum 
cell attachment and expansion in microcarrier culture systems is limited to the carrier 
diameter. The optimum microcarrier diameter has previously been determined to be 
between 100–400 μm), with a density typically between 1.02 and 1.10 g/ml) (128). 
Microcarriers are typically designed to have a density that allows them to be maintained 
in suspension (in culture medium) with gentle stirring.  
Biopharmaceutical uses of microcarriers in large scale bioreactors is applicable 
to large scale production of therapeutic adherent cells. Typical harvests are 1x10
6
 
cells/mL for MSCs and 1x10
6
 to 3x10
6
/mL for ESCs (88). Using large scale (>1,000L) 
bioreactor systems for stem cell expansion could potentially generate lot sizes of 
approximately 1 trillion cells.   
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1.7.2 Spinner flask bioreactors for cell expansion on microcarriers 
There are four types of bioreactors compatible with microcarrier based stem cell 
expansion; these include PBRs, Roller bottles, Spinner flasks and the Wave bioreactor 
(GE). In order to maximise the microcarrier surface area for cell attachment and growth, 
the particles must remain fully suspended in culture medium. In bioreactors, such as 
spinner flasks this is achieved using mechanical agitation. This also has the effect of 
homogenising the culture media, allowing nutrient transfer and diffusion of oxygen, 
whilst most importantly allowing CO2 release (129). Using spinner flask bioreactors 
parameters such as, gas exchange, nutrient feeding and pH can be tightly regulated 
using probes and online monitoring (130). A disadvantage of this technique is the 
agitation required can damage the attached cells, either by direct mechanical damage or 
by shear stress caused by continuous fluid flow (131). Cell laden microcarriers incur 
damage mainly due to particle-impeller and particle-particle collisions. This damaging 
effect increases with increasing particle size, concentration and agitation intensity. 
Under stirred culture conditions, cells are exposed to hydrodynamic shear stress. Cells 
cultured either in suspension, in aggregates or on microcarriers may become damaged 
when the turbulent eddy size has the same order of magnitude as the diameter of a 
single cell, aggregate, or microcarrier (132). With increasing agitation intensity, the 
eddy size decreases, hence cells adhered to microcarriers or in aggregates can be 
affected at much lower agitation rates compared to single cells (133). Factors that 
increase hydrodynamic stress include increasing impeller diameter and rpm, in addition 
to impeller geometry and location. Within bioreactors, probes and other internal vessel 
components can disrupt radial flow patterns and increase shear stress. When subjected 
to continuous shear stress, spontaneous undesirable differentiation of MSCs has been 
shown to occur and can be exacerbated under serum-free conditions (134, 135). Studies 
have shown that MSCs cultured on microcarriers expanded in spinner flasks, 
upregulated the expression of cell markers for early osteocytes and chondrocytes (135-
137). This indicates that shear stress experienced by cells in a microcarrier-based, 
stirred bioreactor has a potential priming effect on MSC differentiation. Several studies 
have confirmed this, reporting greater shear stress can induce upregulation of 
osteogenesis related genes (137). However, further microcarrier based spinner flask 
expansion studies using BM-MSCs and ADSCs cultured in xeno-free medium 
demonstrated a multi-lineage potential, suggesting the mesodermal progenitor 
properties remained intact (138). More recently, an alternative bioreactor has been 
designed (GE) which removes the need for an impeller. Microcarriers are cultured in a 
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single use bag termed a Wave bioreactor which applies a rocking motion to agitate the 
cell microcarrier suspension, potentially reducing the damaging effects of shear stress 
(139). The impact of agitation rates and mixing dynamics vary greatly between different 
style bioreactors and microcarrier properties and therefore individual optimisation is 
required to reduce shear stress and its potential effects. In addition to microcarrier 
properties, both cell culture medium and bioreactor system have been shown to affect 
cell proliferation, phenotype and differentiation potential (140). This has been observed 
in primary cells (human fibroblasts and bovine embryonic kidney cells). However, few 
studies have investigated the full effects of agitated culture of hMSCs.  
1.7.3 Harvesting cells from microcarriers 
Similarly to PBR systems, generating large cell yields relies on the ability to 
dissociate the therapeutic cells efficiently and completely from the scaffolds, whilst 
maintaining the cells’ integrity. Traditional enzymatic dissociation methods using 
proteases (i.e. collagenase, Accutase, dispase and Trypsin) are the most common means 
of cell-microcarrier separation (141). Typically this yields 60-70% cell recovery for 
smooth microcarriers and ~50% for macroporous microcarriers depending on the 
microcarrier properties. This poses a substantial drawback to using the currently 
available microcarriers for therapeutic cell expansion. In addition, significant 
optimisation and validation is required to guarantee that microcarriers and particulates 
can be fully separated from the therapeutic cell population, as any carryover will present 
a serious safety risk during intravenous administration (88). This risk can be reduced by 
using magnetically charged microcarriers, or by using microcarriers with biodegradable 
and thermosensitive elements (142).  
1.7.4 Microcarrier based expansion of primary cells  
In addition to providing a support for cell culture, microcarriers have also been 
used for tissue engineering purposes by providing a scaffold for delivering therapeutic 
cells to repair  damaged or degenerated tissue to restore function (143). To use 
microcarriers for musculoskeletal or dermatological purposes, biodegradable materials 
such as FDA approved hydrogels and natural polysaccharides have been shown by 
Wang et al. (2008) to support cell adhesion of anchorage dependant cells, and facilitate 
proliferation and differentiation of hMSCs and progenitor cells (144, 145). 
Biodegradable microcarriers have been developed, the typical materials used include 
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gelatin (CultiSpher family) (146), collagen (CellagenTM)(147), poly-lactic-co-glycolic 
acid (PLGA) (148), poly-L-lactic acid (PLLA) (149), and hydroxyapatite (150). Primary 
cell–laden microcarriers have been used successfully in in vivo experiments to treat 
various diseases in animal models including liver insufficiency (151),  cartilage repair 
(146, 152), skin repair (153), and Parkinson's disease (154). Clinical trials have 
demonstrated positive results for using gelatin based microcarriers laden with human 
retinal pigment epithelial cells for the treatment of Parkinson’s disease (155). 
Cytodex 3 has been successfully used as a support for the expansion and 
transplantation of primary hepatocytes, resulting in extended in vivo hepatocyte viability 
and function (151). Furthermore the transplanted hepatocytes in liver-damaged rats 
provided a restorative effect giving metabolic support and increasing survival rates 
(156). This has since been supported in other rat models of acute liver failure and 
further developed into a bio-artificial liver system facilitating metabolic support (157, 
158). To enhance wound healing and skin repair, Cytodex 3 has also been used to 
culture primary keratinocytes and develop a multilayered and keratinised epithelium in 
a full thickness wound healing model (153). However Cytodex 3 microcarriers are not 
biodegradable in vivo and hence can induce an inflammatory reaction. Consequently in 
2002 the research group Stark et al. generated biodegradable PLGA microcarriers which 
were surface modified to contain a layer of gelatin and recombinant human epidermal 
growth factor (159). At 14 days post-transplantation, a new stratified epithelium was 
detected in the full-thickness wound healing model using this novel PLGA microcarrier. 
Human nasal chondrocytes have been expanded on CultiSpher-G (macroporous gelatin-
based) microcarriers to generate cartilage. After implantation into nude mice, collagen 
expression was higher in the chondrocytes-laden microcarriers than in cells cultured in 
2D T flasks (146). Furthermore, chondrocytes have also been expanded on gelatin and 
PLGA microcarriers (148). PLGA microcarriers have also been used in mouse models 
by Kang et al. (2005) to demonstrate articular cartilage repair (160). Previously the use 
of microcarriers was confined to generation of therapeutic proteins, however the use of 
microcarriers to deliver therapeutic cells to the site of damage or diseased tissues (2001) 
has demonstrated the feasibility of utilising microcarriers in regenerative medicine. 
1.7.5 Microcarrier based expansion of MSCs  
There has been a growing trend in the use of microcarriers for stem cell 
expansion (161-163). MSC based clinical therapies require large MSC quantities (as 
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discussed in Section 1.6), as typical intravenous treatment dose uses 5 x10
6
 cells/kg 
body weight. Therefore a reproducible, scalable method to yield un-differentiated 
homogeneous MSC populations is required. Several strategies are available to deliver 
cells expanded on microcarriers, e.g. harvested cells can be injected into the body, 
transferred to a scaffold for tissue engineering purposes; or the microcarrier-cell 
construct can be injected directly to repair damaged or diseased tissues such as, brain, 
bone, cartilage, liver or skin. Previously, growth and expansion studies of embryonic 
stem cells (ESC) on microcarriers have shown that both human and murine ESCs 
maintain their pluripotency with Cytodex
TM
 and trimethyl ammonium-coated 
polystyrene carriers (164). However, until relatively recently few studies have indicated 
the success of a microcarrier based system for MSC expansion. 
Pioneering work by Wu et al. in 2003, demonstrated human MSCs attaching, 
proliferating and differentiating on macroporous microcarriers in spinner flasks (165). 
Expansion over 7 days gave a 10-fold increase in viable cells. Also lactate production 
from glucose consumption was lower in spinner culture (indicating better cell health) 
than in static culture. Most importantly, MSCs cultured on microcarriers were still 
multipotent after 12 days in culture. Other studies performed by Marc et al. in 2011 
compared the culture of porcine derived BM-MSCs on three different commercially 
available Cytodex (1,2 and 3) microcarrier types (166). Cytodex 1 showed the highest 
level of attachment, the cells remained multipotent and also demonstrated cell migration 
from one microcarrier to another in ‘bead to bead transfer’. Other experiments 
performed by Schop et al. (2008) have shown that using goat derived MSCs cultured on 
microcarriers, the addition of 30% fresh medium containing virgin microcarriers every 3 
days allowed a more homogenous cell distribution of cells across the  microcarriers due 
to bead to bead transfer (113). In addition, cell proliferation increased whilst the 
production of lactate from glucose decreased. The transfer of cells from colonised beads 
to fresh beads facilitates an extendable culture surface, potentially lengthening in vitro 
culture times. However cell multipotency and ‘stemness’ have not been fully 
characterised on microcarrier expanded MSCs.  
Injectable microcarriers may act as tissue engineering scaffolds allowing for the 
precise placement of cells within a site of injury, in addition to enhancing the function 
of injected cells. Adipose derived stem cells have been successfully expanded and 
differentiated ex vivo into adipocytes and osteoblasts in 2011 by Santos et al. on 
Cultispher-G microcarriers (138). Similarly Yang et al. in 2007 compared apoptosis of 
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BM-MSCs directly injected into subcutaneous tissue to BM-MSC laden Cultispher-G 
microcarriers. It was found in short term conditions that apoptosis was significantly 
reduced in cell-microcarrier constructs. Long term effects demonstrated in vivo that 
there was an induction of de novo trabecular bone formation (167).  
Proof of principle studies have demonstrated the successful expansion of MSCs 
on microcarrier supports in spinner flask bioreactors, whilst maintaining important 
multipotent characteristics. Furthermore, bioreactor techniques have been established 
including proliferation of cells on microcarriers via bead to bead transfer (113). 
However, microcarrier properties need to be optimised to generate a clinically useful 
expanded MSC population as several experiments have demonstrated the genomic and 
behavioural changes of these cells in response to culture substrates (168).  
1.7.6 Issues with microgravity 
Bioreactors such as roller bottles or spinner flask can induce a microgravity 
environment, (the bioreactor subjects the suspended cells to a continual state of free fall, 
hence, simulating microgravity). This microgravity environment can alter the 
differentiation of cultured MSCs on plastic microcarriers, inhibiting osteoblastic 
lineages and inducing adipogenic differentiation (169).  This has been attributed to 
RhoA and cytoskeletal disruption (170). This models the reduction in bone mass 
experienced by humans after a prolonged time in space, and also suggests that a 
bioreactor system whereby cultured MSCs on microcarriers experience microgravity, 
cannot sustain the differentiation potential of MSCs within the appropriate level of 
control. 
1.8 Biomaterials 
Cell adhesion is substrate dependant (171, 172) and there are optimum surfaces 
for cell growth (173, 174), which vary between cell types (61, 173, 175).  A key aim in 
biomaterials research is to provide cells with adhesive substrata that convey cues similar 
to those received in vivo (176). In mimicking the native environment in which the cells 
develop, differentiate and function, the development of microcarrier surfaces for animal 
cell culture has advanced to include characteristics from the extracellular matrix (ECM). 
These may be mechanical, chemical and/or topographical stimuli (177-179). 
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In vivo, cells growing within soft tissues reside within an ECM, a hydrogel 
scaffold comprised of cross-linked proteins and polysaccharides. The ECM provides 
mechanical and chemical cues which influence cell behaviour and differentiation. To 
generate homogenous populations of stem cells for cell therapies and pharmaceuticals it 
is important to determine the factors within the stem cell niche which tightly regulate 
stem cell self-renewal and differentiation. Furthermore, to develop therapeutic 
applications of MSCs, instructive biomaterials are required that can provide key 
regulatory signals and exert control over MSC behaviour and phenotype. Directed 
biomaterials will need to be designed to expand homogenous multi-potent and 
differentiated stem cells populations ex vivo.  
Most scaffolds are generated from polymers, (both natural and synthetic), metals 
or ceramics. Metals and ceramics are restricted to models of very hard tissues such as 
bone. However, polymers can be manipulated to mimic the physical properties of the 
ECM of all tissues from the mechanically weak cornea to harder tissues such as 
cartilage and can be fabricated into porous, fibrous or solid scaffolds (180). Polymers 
were first suggested for use in biomedical applications in 1960 (181), and can be made 
from natural materials, e.g. collagen, gelatin, hyaluronan, fibrin and alginate, or from 
synthetic chemicals such as Poly(ethylene oxide), Poly(acrylic acid), Poly(vinyl 
alcohol) and biodegradable poly lactic glycolic acid (PLGA). 
1.9  Natural Polymers 
Collagen comprises 30% of total body protein, is highly conserved and forms a 
thermally and ionically reversible hydrogel under certain conditions. There are several 
different collagen isoforms, which have been widely investigated and have been shown 
to promote ESC and MSC attachment, growth and differentiation (182, 183). In 
addition, gelatin (denatured collagen) has been widely used in scaffolds and 
microcarriers (184). MSCs cultured in collagen-based matrices can degrade and re-
assemble the underlying matrix structure using matrix metalloproteinases (MMPs) 
(185). In addition, the cultured cells were able to differentiate into 
spherical chondrocytes and synthesise several cartilage specific proteins (146). 
Collagen-based hydrogels have comparatively large pores allowing for efficient 
diffusion of nutrients and waste and have weak mechanical properties which can be 
improved with chemical crosslinking reagents, e.g. glutaraldehyde (186, 187). 
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Fibrin is a key mediator in blood clotting and normal wound healing processes 
and hence has been used as a biomaterial (alone and in combination with other 
materials) to differentiate stem cells (180). In 2005 Lee et al. demonstrated that both 
ADSCs and BM-MSCs differentiate into several mesodermal lineages on 2D fibrin 
scaffolds and within 3D fibrin-agarose scaffolds. Furthermore BM-MSCs performed 
chondrogenesis and osteogenesis more effectively than 2D culture (188).  
Silk protein has high mechanical strength and is elastic with high tensile strength 
due to strong hydrogen bonding when compared to other biomaterials such as collagen 
(180). Silk proteins make good candidate materials to model bone, cartilage and 
ligament tissue as they have slow degradation kinetics in vivo (189). In 2006 Kaplan et 
al. compared hMSC differentiation to chondrocytes on silk biomaterials and found 
chondrogenesis was more effective and extensive on silk scaffolds when compared to 
collagen (190).  
Matrigel, marketed by BD Biosciences, is a soluble protein blend of basement 
membrane proteins isolated from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells. 
It is gelatinous and contains several ECM components including laminin, collagen IV, 
and heparin sulphate  proteoglycans and entactin, as well as several unknown 
components (191). Matrigel has been successfully used as a model system providing a 
3D environment to culture a variety of cell types to study cell morphology, biochemical 
function, cell migration and invasion, and gene expression (192). Matrigel has also been 
used to maintain an undifferentiated stem cell state, for example hESCs have been 
cultured in mouse fibroblast conditioned medium in a feeder-free system (193). 
Furthermore, Matrigel has been used to study differentiation. For example, ESC-derived 
neural precursors cells cultured on Matrigel were capable of differentiating into neurons 
(194). However, several factors limit the use of Matrigel in large scale or high 
throughput experiments. Firstly, Matrigel is expensive relative to traditional cell culture 
methods or other biomaterials. Secondly, Matrigel is a thermally responsive hydrogel 
and begins gelation above 4
o
C, which can generate technical challenges in handling and 
can form matrices with heterogeneous properties. In addition, due to its source Matrigel 
can pose a risk of possible pathogen transmission and immunogenicity (195). Batch-to-
batch inconsistencies and the inability to experimentally vary both the composition and 
compliance of Matrigel have led to researchers seeking synthetic ECM equivalents 
which can generate a 3D environment with in vivo-like properties.  
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In addition to proteins, polysaccharides are essential in maintaining the structure 
of the ECM. Common polysaccharides utilised to culture stem cells include 
agarose, alginate, and chitosan. Agarose is derived from seaweed, and forms a thermally 
responsive, biodegradable, porous, hydrophilic hydrogel (180). However as a 
biomaterial substrate it lacks adhesion cues, and therefore has limited utility in cell 
culture processes. In addition, humans lack the necessary enzymes to degrade agarose 
hydrogels, hence it is unsuitable for injectable MSC delivery. Agarose gels have been 
exploited to analyse hMSC chondrogenesis under compression loading by Bader et al. 
in 2006 (196). For example, BM-MSCs seeded in agarose constructs were shown to 
change cell morphology under chondrogenic conditions into a spherical shape and under 
hydrostatic pressure undergo chondrogenesis.  
Alginate is an anionic polysaccharide which forms cross-linked networks via 
ionic interactions to yield flexible gels mimicking soft tissues such as brain and liver 
(197).  It is widely used as a biomaterial as it evades immune and inflammatory 
responses. Alginate scaffolds have been shown to support attachment of ADSCs and 
BM-MSCs and in addition support chondrogenic differentiation (198). Alginate 
hydrogels contain interconnected pores which can generate a 3D microenvironment for 
cell culture. In addition alginate gels have been used to make porous microspheres, in 
which many cell types have been encapsulated and supported (199). GEM, a 
commercially available microcarrier contains a porous highly negatively charged 
alginate core, with optional extracellular matrix coating. The microcarrier also contains 
magnetic particles for ease of manipulation (200). Cell recovery from alginate 
microcapsules is simple as the matrix can be dispersed using divalent cation chelators 
such as citrate. This property makes alginate hydrogel processing more flexible and 
increases its potential uses in regenerative medicine.   
Chitosan is a biodegradable linear polysaccharide which can vary according to 
the degree of deacetylation. Chitosan-based biomaterials are both biocompatible and 
nontoxic and display cationic behaviour. In addition they are versatile in their ability to 
form hydrogels, films, fibres, 3D porous structures and microcarriers. They are 
therefore useful for developing wound dressings, space filling implants and scaffolds 
for stem cell applications (201). Chitosan can be modified via covalent bonding due to 
its primary amino groups and blended with other polymers to add strength. In addition, 
it has tunable mechanical properties, for example high molecular weight chitosans 
produce relatively tough scaffolds used for modelling bone (202). In its protonated 
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state, it is also capable of ionic interactions and thus can be used to enhance adhesion of 
stem cells.  Chitosan has been used to generate smooth microcarriers to culture both 
human and mouse fibroblasts (201). Chitosan is composed of glucosamine and N-
acetylglucosamine, which shares a structural similarity to glycosaminoglycan (GAG) 
and its analogs, a major component of ECM found in cartilage. Therefore chitosan 
coated PLLA microcarriers have been used by Gao et al. in 2008 to study 
chondrogenesis, where chondrocytes were able to attach and maintain their phenotype 
in vitro, creating a potential cell delivery vehicle for cartilage repair (203). In 2009 Kim 
et al. generated porous chitosan microcarriers by electrospraying techniques (discussed 
in Section 1.12.2) and demonstrated that hMSCs were able to attach and proliferate 
within the pores of the chitosan beads and be maintained in spinner flask culture for up 
to 21 days (204).  
Natural polymers most closely resemble the tissues they are meant to replace 
and they are nearly always biocompatible and biodegradable. However, biologically 
derived materials also have several disadvantages, they require isolation, purification 
and processing which can be expensive and exacting (205). They may elicit undesirable 
immune responses and pose an increased risk of endotoxin contamination (206).   In 
addition, they demonstrate restricted versatility (207); though natural hydrogels based 
on ECM components such as alginate (198), hyaluronic acid and collagen (187) have 
been well studied and used successfully for stem cell culture, natural scaffolds lack the 
capacity for tailoring the mechanical and degradation properties required to study a 
range of tissue environments. 
1.10 Synthetic polymer scaffolds for cell adhesion 
A wide variety of biomaterials based on synthetic polymers have been 
developed for cell culture applications, due to their ease of handling, processing and 
purification (83).  Synthetic hydrogels can be generated from a variety of polymers 
using different gelation techniques, resulting in gels with a wide range of mechanical 
properties, chemical compositions and overall shape (83). Additionally, controlling 
molecular weight and cross-link density parameters permits greater control of material 
properties (205). Hydrogels are hydrophilic polymeric networks that can absorb water 
without dissolving, and can be made from natural or synthetic materials (207). They are 
attractive materials for the production of tissue engineering scaffolds because they 
possess characteristics similar to the ECM in many tissues including chemical and 
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structural similarities. They provide an aqueous environment for cells; they are highly 
porous to allow for nutrient transport, readily modifiable and are generally 
biocompatible (208). Hydrogels are typically processed under mild conditions. Due to 
their compatibility with in vivo tissues, hydrogels have provided the primary scaffold 
material for several varied applications including drug and growth factor delivery, 
artificial tissue replacements in tissue engineering processes amongst many others 
(209).  
Polyethylene glycol dimethacrylate (PEGDMA) hydrogels have proven to be 
excellent biocompatible substrates (210). PEGDMA is hydrophilic, easily manipulated, 
highly wettable and resistant to non-specific protein adsorption (211). It is now widely 
used in tissue engineering as a preferred cell culture substrate (212-214), and can be 
processed simply, forming hydrogels via chemically initiated or UV-initiated free 
radical photo-polymerization (215).  The resulting hydrogel has a high water content 
(216), and possesses mechanical properties similar to those of soft tissues, such as a 
high elastic modulus (resulting in greater compressibility) making it ideally suited to 
study MSC adhesion and controlled differentiation (215). Synthetic hydrogels generated 
from polymers such as poly(ethylene glycol) are bioinert systems, and can provide a 
scaffold to anchorage dependant cells, but lack directed cues causing adhered cells to 
alter their cellular functions, often leading to apoptosis (217, 218). Recently, the 
modification of biomaterials has been expanded to include functionalised polymers with 
ECM-derived bioactive factors, which has been widely shown to increase cell viability 
and direct cell function (205, 206). Biomaterials can provide not only a structural and 
mechanical support but can also interact with cells and alter their biological functions. 
Various biological signals, such as ECM proteins, have been incorporated into 
biomaterials, either as a surface modification or tethered throughout the bulk of the 
matrix to alter cell adhesion spreading, proliferation and matrix production (217).  
1.11 Influence of bioactive-functionalised materials on cell growth 
Integrating proteins isolated from the ECM such as laminin, collagen and 
fibronectin onto artificial polymer surfaces can be problematic (214, 219). Isolation, 
purification and immunogenicity can be costly and generate undesirable responses (as 
discussed in Section 1.9). Such proteins contain several different cell recognition and 
adhesion motifs which are responsible for binding cell surface integrin receptors (220, 
221). ECM deposition onto materials with variable surface properties such as charge, 
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wettability (222) and topography can influence protein orientation and conformation 
(223, 224), potentially sterically hindering cell-protein interaction (225).   A more 
controllable solution is to present cell recognition motifs as small, immobilised 
peptides. Originally demonstrated by Hern and Hubbell, incorporating ECM-derived 
peptide sequences into PEGDMA hydrogels creates a synthetic material with cell-
adhesive and/or proteolytically cleavable properties (226). They can be used to 
functionalise materials in a defined, concentration dependant manner (227). 
Incorporating defined, synthetic peptides can therefore be used to target and select for a 
particular cell type (228, 229).  Linear peptides can be susceptible to enzymatic 
degradation and have a relatively short half-life, cyclic peptides however exhibit 
excellent long term stability (228).  
The most commonly used bioactive peptide for the functionalisation of surfaces 
is the Arg-Gly-Asp (RGD) sequence (229). RGD is a conserved peptide sequence found 
in several core proteins of the ECM, including collagen, fibronectin and laminin. 
Peptides containing this core sequence have been shown to bind 12 of the known 24 
integrins (230) and have a vital role in cell adhesion, in addition to influencing many 
other cellular functions including embryogenesis and cell differentiation (231). 
Previously, a range of peptides has been used to functionalise various biomaterials that 
are derived from conserved ECM peptide sequences. For example, a commonly used 
peptide derived from fibronectin is arginine–glutamic acid–aspartic acid–valine 
(REDV), and peptides derived from laminin are tyrosine–isoleucine–glycine–serine–
arginine (YIGSR) and isoleucine–lysine–valine–alanine–valine (IKVAV) (207).  
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Figure 3: Bioactive peptides for improved MSC-biomaterial interactions 
Other agents that mediate cell adhesion include growth factors and adhesion 
molecules. It is possible to incorporate growth factors or growth factor derived peptides 
into hydrogels by chemically tethering them to the polymer backbone as demonstrated 
using ECM components (207). Such hydrogel modifications provide an opportunity to 
regulate the function of interacting cells. In 2001, West et al. cultured smooth muscle 
cells in PEG hydrogels containing the tethered peptides RGDV and transforming 
growth factor β (TGFβ) active fragment, and found enhanced cellular functions, in 
particular increased ECM production (232). TGFβ has a significant role in regulating 
ECM production, by presenting the growth factor in this manner it was able to interact 
with cellular receptors constitutively  without being internalized (233). 
1.11.1 Hydrogel polymerisation methods 
Hydrogels are cross-linked, hydrophilic swollen polymer networks which can 
retain large quantities of water (215). Hydrogels can be used for biomedical applications 
to encapsulate cells and bioactive peptide or protein therapeutics (199, 234).  Hydrogels 
based on the synthetic oligomer PEG can be crosslinked either chemically or physically. 
Chemical crosslinking gelation results in ionic or covalent bonds between polymer 
chains (235). This method of gelation can result in hydrogels with greater mechanical 
stability, however, chemicals and conditions, (temperature, pH, initiators, catalysts or 
UV) required for polymerisation are often cytotoxic and result in undesirable reactions 
Peptide sequence ECM/Molecular source Function Ref. 
RGD Fibronectin, vitronectin, 
laminin, collagen , osteopontin and 
thrombospondin  
Promotes hMSC adhesion, spreading, migration 
and proliferation 
(233-235) 
Regulates hMSC differentiation 
IKVAV, YIGSR Laminin Enhances hMSC adhesion and viability (236, 237) 
KIPKASSVPTELSAISTLYL Bone morphogenetic protein-2 (BMP-2) Promotes MSC differentiation and mineralization  (238) 
GPQGIWGQ, LGPA Collagen type I (MMP substrate)  Cell -mediated proteolytic degradation (239, 240) 
QPQGLAK Collagen type II (MMP-13 substrate)  Cell -mediated proteolytic degradation (241) 
VRN, YKNR Fibrinogen (plasmin substrate)  Cell -mediated proteolytic degradation (242, 243) 
Y(GPO)7 Collagen type I Collagen retention (244) 
Promotes hMSC differentiation 
(GPO)4GFOGER(GPO)4GCG Collagen type I Collagen -integrin β1 interactions  unpublished 
data 
Promotes hMSC differentiation 
KLER Decorin Collagen type II retention and organization (245) 
Promotes hMSC differentiation 
AKA3KA Elastin Enhances gel elasticity (246) 
K-βAla-FAKLAARLYRKA Anti-thrombin III Heparin binding  (242, 243) 
E6 Osteonectin Hydroxyapatite binding  (247) 
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and can generate a hydrogel which is not biocompatible, limiting its uses (83). Physical 
crosslinking of hydrogels occurs under relatively mild conditions by either ionic 
interactions, hydrogen bonding or hydrophobic interactions or by molecular 
entanglement and/or weak secondary forces such as Van der Waals interactions. 
However they are mechanically weaker than chemically crosslinked hydrogels. 
Covalently-crosslinked PEGDMA hydrogels are commonly used as scaffolds for tissue 
engineering and regenerative medicine applications, where tunable mechanical strength 
and stability are required. Hence chemical crosslinking is often favoured.  
 
PEG dimethacrylate can be polymerised using radical mediated chain growth 
mechanism in the presence of appropriate radical generating initiators and conditions 
(236). This is the most commonly used method of generating PEG based hydrogels for 
tissue engineering purposes. This method can generate stable hydrogels under 
physiologically relevant conditions and within a relatively short time period (minutes).  
In redox initiated polymerisation, radicals are formed by a pair of redox active chemical 
initiators, typically a persulfate with N,N,N’,N’ -tetramethyl ethylenediamine (TEMED) 
(236). However, recent advancements (2009) utilising PEG based hydrogels for stem 
cells encapsulation have used UV photo-polymerisation which gives faster crosslinking  
and spatial and temporal control over gel formation (as radical production can be 
restricted to a focused light source) (237). In addition several UV photo-initiators have 
been widely studied in cell encapsulation demonstrating biocompatibility (238). 
Photopolymerisable PEG hydrogels have been extensively studied including by Liu et 
al. (2009) for the biomaterial culture of both ESCs and MSCs and have proved to be a 
useful platform in the study of stem cell differentiation (83, 239). A drawback of radical 
initiated chain growth polymerisation is that macro-monomer crosslinking can be low. 
Changes in UV exposure time or pH can increase macromer crosslinking; however this 
can be incompatible if attempting to encapsulate cells during polymerisation.   
 
Incorporation of bioactive peptides into PEG polymers to direct cellular function 
requires new polymerisation techniques (229). There are several established techniques 
to tether bioactive peptide to PEG hydrogels. The most common approach covalently 
links target peptides to a monoacrylated PEG monomer through an N-
hydroxysuccinimidyl group (226). This is an extensively studied method of peptide 
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incorporation and is similar to traditional techniques of coupling proteins to PEG. This 
system requires a pre-synthesis reaction off resin using expensive reagents, which is 
time consuming and produces a variable product yield (240). In addition it involves an 
unstable NHS ester intermediate.  
 
An alternative technique, termed ‘click chemistry’, utilizes free thiol groups on 
cysteine containing peptides to tether bioactive sequences into unsaturated alkene or 
acrylate groups during photo-polymerisation (241). Step growth thiol-acrylate 
polymerisation occurs in the presence of a photoinitator, generating peptide 
functionalized PEG hydrogels (242). The system comprises mixed-mode 
polymerisation, the reaction mechanism consists of two competing reactions; that of the 
acrylate homopolymerization and the thiol acrylate step growth reaction (Figure 4) 
(243). Described by Anseth et al. in 2008, this method provides a robust, cost-efficient, 
and cytocompatible reaction scheme for the incorporation of peptide sequences into 
PEG hydrogels for 3D cell culture and the direction of cellular function (244, 245). The 
reaction produces a high yield with fast kinetics that can occur in mild, solventless 
conditions or in water. This has been shown to be a very successful modification of 
PEG hydrogels with approximately 95% incorporation of a target bioactive peptide 
(240). 
Figure 4: Preparation of cell-adhesive PEG hydrogels by thiol-acrylate photo-polymerisation  
Thiol-acrylate photo-polymerisation of PEGDA with monothiol-containing cell adhesive peptide 
(PEPTIDE-SH) (Adapted from (246)). 
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1.11.2 Mechanical cues 
MSCs reside within a niche where they are surrounded by ECM which presents 
an array of complex biophysical and biochemical signals. During normal periods of 
regeneration adult stem cells are thought to egress and travel away from their niche to 
other tissues where they can engraft and differentiate (247). During migration, cells will 
experience a diverse variety of tissue or matrix microenvironments.  MSCs are known 
to differentiate into a wide range of cell types from neurons to osteoblasts, each of 
which typically reside in very different physical microenvironments. One physical cue 
is the surrounding elasticity or stiffness of the ECM, which can influence cell 
morphology and function (248). When a cell exerts a force that deforms the surrounding 
ECM it feels a level of resistance, this can be measured by the elastic constant, E, of the 
matrix or microenvironment. The compressibility of the culture substrate can drive 
differentiation or maintain stem cell phenotype in adult stem cells (249). 
MSCs interpret their surrounding substrate elasticity and transduce information 
into changes in morphology and differentiation potential (249). To ‘feel or sense’ the 
matrix and respond, cells must first pull against the matrix. Following this, an 
intracellular mechano transducer(s) must generate a signal proportional to the force 
required to deform the matrix (250). The actin cytoskeleton is linked to focal adhesion 
groups at the cell surface, which provide the site for attachment to the ECM via cell 
surface receptors termed integrins and allow force to be transmitted from the 
extracellular elastic matrix to the cytoskeleton inside the cell (251).  At focal adhesion 
sites, a number of proteins form an intracellular complex at the plasma membrane, 
which is known to interact with well characterised signalling molecules, and are the 
sites for mechano-transduction (252). Studies by Chen et al. in 2004 have shown 
proteins that contribute to actin cytoskeletal motors, (such as non-muscle myosin II 
isoforms), act as mediators modulating contractile forces in the cytoskeleton. These are 
implicated in providing tension in cortical actin structures, which can sense matrix 
elasticity and result in differentiation (253).  Blocking of myosin in MSCs using 
inhibitors blocks differentiation of all lineages on both stiff and compliant substrates. 
Rac and Rho have significant roles in MSC anchorage, contraction and motility, 
interacting with both growth factors and integrins (254). Indirectly inhibiting ROCK, a 
Rho Kinase inhibitor, can deactivate myosin and selectively block compressibility 
directed differentiation of MSCs to osteoblasts on rigid substrates, but not on compliant 
substrates (255).  
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It is known that by varying matrix stiffness, both the intracellular cytoskeleton 
and focal adhesion structure are affected in both naïve MSCs and differentiated cell 
types. It is difficult to identify and isolate how small changes to substrate stiffness 
directly influences cell behaviour from the effects of other physical parameters of 
culture substrates such as topography. However, matrix stiffness at the tissue-level has 
been shown to have very strong influences on naïve MSCs in in vitro cultures, including 
lineage specification and commitment (255). Furthermore, tensional homeostasis 
effects, a mechano-regulatory network that integrates physical and biochemical cues 
between the cells and the tissue microenvironment, can be seen throughout the cell 
(including morphology, transcript profiles, cytoskeletal organization and contraction 
and changes to gene regulatory pathways) (256). 
In vivo, MSCs not only adhere, but contract and crawl within both soft (e.g. 
brain) and hard tissues (e.g. the surface of crosslinked collagen ‘osteoids’ in 
remodelling bone) (255). Several research groups have attempted to analyse the effects 
of matrix stiffness on cell behaviour using a range of synthetic hydrogels. For example, 
Engler et al. in 2006 developed an in vitro model composed of collagen type I coated 
acrylamide gels which were tuned to create a wide range of substrate stiffnesses. The 
research group demonstrated that multipotent MSCs will commit to a specific lineage 
when cultured on gel substrates with stiffnesses comparable to their counterpart tissues 
in vitro. For example, MSCs differentiate into neurons when cultured on physiologically 
relavant soft substrates (0.1-1kPa), into myocytes when cultured on slightly stiffer 
substrates (8-17kPa), and into osteoblasts when cultured on relatively hard surfaces 
such as collagenous bone (25-40kPa (255). In 2009 Stevens et al. demonstrated that 
culturing ESCs on ‘soft’ hydrogel substrates establishes a cellular context to promote 
stem cell self-renewal. ESCs have been shown to upregulate early mesendoderm 
markers on increasingly stiff polydimethylsiloxane substrates, resulting in increased 
levels of osteogenic differentiation (257).  
Further work must be done to evaluate the synergistic effects of soluble signals 
such as growth factors, topography and matrix compressibility on cells cultured on 
biomaterials in vitro. To alter the mechanical properties of an artificial cell culture 
substrate, the following material parameters must be considered: molecular 
composition, water content, elasticity and structure (256). These can affect both the 
intermolecular and intramolecular forces and stress distributions. In vivo tissues and 
cells display viscoelastic behaviour, yet several models fail to represent this property 
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and more work is required to determine the effects of different elastic substrates on cell 
renewal and differentiation. Traditionally, analysis of MSC function is examined on 
cells cultured on plastic or glass, which both have a relatively rigid stiffness, 1GPa and 
70GPa respectively. Whereas in vivo cells typically experience an environment 
approximately 100,000 fold less stiff (less than 100 kPa).  
1.11.3 Topographical and geometrical control over stem cell fate 
Cells exist within a spatial context within the in vivo stem cell niche. The niche 
micro-architecture is known to generate concentration gradients of bioactive factors, can 
modulate cell-matrix and cell-cell adhesion and can establish proximity between 
compartments such as vasculature and the basal membrane (258). Many instances exist 
in vivo including the formation of crypt to villus patterns in the gut, which is able to 
direct stem cell differentiation (259).   
Since cells recognise their environment on a micro or nano-scale, several 
fabrication techniques have been developed to generate artificial microenvironments 
with different topologies and geometries to understand reductively the influence of 
these factors on stem cell fate (260). Initial techniques studied the behaviour of single 
cells adhered to surfaces micropatterned with and without adhesion ligands (261). Initial 
studies revealed primary cells cultured on larger substrates (1500µm
2
) proliferated, 
whereas smaller substrates (500µm
2
) induced apoptosis (262). ADSCs demonstrated 
altered cytoskeletal tension when cultured on substrates with varying geometries, this 
also influenced subsequent differentiation (255, 263).  
Biomaterial scaffolds can be further developed to include topographical cues, for 
example changes in patterns and orientations of biochemical or biophysical features. 
Commonly, within hydrogels pore size and interconnectivity can be controlled, which 
can enable influence over cell proximity and adhesion (264). It can be difficult to isolate 
the effects of topography from chemical cues and hence cell substrate contact area and 
cell shape. These have been decoupled by creating scaffolds containing fibronectin 
adhesive regions with uniform size but varying shape (260). In 2010 Kilian et al. 
showed that by culturing MSCs on small, discrete islands with varying geometry in the 
presence of competing angiogenic and osteogenic differentiation signals, a relationship 
between differentiation and the spatial arrangement of the MSC developed, which was 
found to correspond to cytoskeletal stress mediated by RhoA GTPase signalling (260). 
In particular, cells cultured on convex islands formed a rounded shape inducing 
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adipogenesis. Contrastingly, on more angular shapes, the MSC shape was observed to 
be more spread with increased cytoskeletal tension inducing osteogenesis (260).  
The curvature of spherical particles, such as microcarriers, has been shown by 
Dobler et al. in 2009 to have an effect on cell behaviour (265). The curvature or micro-
topography of microcarriers can be controlled by altering the particle diameter. 
Research has shown microspheres containing a diameter of less than 100 µm have 
limited cell adhesion to their surface. In 2011, Kong et al. investigated the effects of 
curvature on BM-MSCs cultured on RGD modified alginate microspheres with varying 
diameters (in the microscale). A decrease in cell proliferation and osteogenic 
differentiation was observed as microsphere diameters decreased from 3cm to 0.5cm 
independent of RGD concentration (266). This was attributed to increasing shear stress 
experienced by cells cultured on the surface of microcarriers during spinner flask 
culture (as discussed in Section 1.7.2). Kilian et al. (2010) have examined the effects of 
convex substrates on MSC differentiation in static culture, and found cytoskeletal 
changes; in addition to altered lineage commitment in response to differentiation 
induction medium (260). 
A study using melanoma cells on varying convex and concave adhesive islands 
demonstrated that adherent cells respond to convex features by promoting the assembly 
of lamellipodia, and concave features resulted in the assembly of stress filaments (267). 
The use of small molecule inhibitors of actomyosin contractility demonstrated that the 
cytoskeleton controls cell polarity according to geometric cues in the surrounding 
extracellular environment. In another study it was proposed that surface curvature could 
mechanically inhibit  the formation bundled microfilaments involved in cell locomotion 
(268). The effect of curvature has also been theoretically modelled, which concurred 
with experimental data showing higher contractile force inhibition as curvature 
increases (265). It has previously been proposed that neurite outgrowth is modulated by 
substrate curvature (269). In addition, the effect of substrate curvature has also been 
observed at the tissue level, whereby tissues grew preferentially on substrates with 
higher curvatures (270).  
Typically the effect of curvature on cell behaviour has been analysed on concave 
shapes, however cells grown on spherical microcarriers would experience a convex 
substrate. Very little research has been conducted in this area, due to a lack of 
convenient reproducible methods to create curved substrates of this type (270, 271).  In 
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order to examine the effects of convex substrates on cell behaviour (as experienced on 
microcarriers), a system would be needed that could generate spherical particles of 
uniform size and properties. Incorporating synthetic peptides into PEGDMA hydrogels 
has become a frequently used technique to generate functionalised biomaterials to study 
cell behaviour. However, to date, this technique has been limited by the methods of 
solid PEGDMA polymer generation. For example, typically PEGDMA hydrogels are 
cast into cylindrical moulds using photolithography, whereby cells can either be 
encapsulated within the hydrogel matrix or cultured in the surface of the gel slab. The 
opportunity to utilise a proprietary microfluidic technique (provided by the industrial 
sponsor in this project Q Chip, and discussed in more detail in section 3.2) to generate 
PEGDMA biofunctionalised microspheres presents an method to utilise this material in 
a new way, as microcarrier system. Furthermore, it allow generates a tool to potentially 
expand stem cell populations. As such, Q Chip took the opportunity to apply for two 
UK patents based on the outcomes of this research. In the first application, the 
generation of a spherical charge neutral PEGDMA microcarrier containing adhesion 
peptides using microfluidics was protected. Additionally, the use of said microcarriers 
to expand stem cell populations was also claimed. The latter patent application can be 
found at the end of this thesis.  
1.12 Preparation methods of hydrogel microspheres 
Polymeric hydrogel microspheres have been used for a wide range of biomedical 
and biotechnology applications including encapsulation of enzymes, drugs and cells 
(272). Delivering protein based vaccines via spherical polymeric particles has been 
demonstrated to enhance the response of the immune system (273). In addition, cell 
encapsulation has been used in clinical applications, for example insulin producing islet 
cells have been encapsulated to treat diabetes (199). This method of cell delivery allows 
immune isolation, potentially removing the need for pharmaceutical/chemical 
immunosuppression. Alginate is the most commonly used matrix when generating 
microspheres for biomedical applications as these can be produced relatively easily 
under gentle conditions. However synthetic polymers such as PEG and poly (vinyl 
alcohol) (PVA) once covalently cross-linked offer many advantages including superior 
chemical and mechanical stability (274).   Despite this, there are limited examples of the 
use of synthetic hydrogels for biomedical purposes and encapsulation. A key limiting 
factor has been that the production of microspheres from synthetic hydrogels typically 
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requires harsh conditions such as high temperatures, non-physiological pH or organic 
solvents, which are incompatible with labile enzymes, protein therapeutics, or cells (as 
discussed in Section 1.11.1 (275)). UV photo-polymerisation has been widely used for 
biomedical applications and cell encapsulation as it occurs quickly at physiological 
temperature and pH and allows spatial and temporal control over gelation (276).  The 
most common techniques to generate polymeric microspheres include emulsion 
polymerization and suspension polymerization. However these methods often require 
tedious removal of surfactants or stabilisers required to stabilise the discrete polymer 
droplets prior to and during polymerisation. In addition hydrogel properties, particularly 
swelling behaviour is influenced by their dimensions and interface and using these 
common manufacturing methods (above), it is impossible to generate hydrophilic 
microspheres with uniform size and shape. 
1.12.1 Emulsion method 
Fabrication of hydrogel microspheres requires a two-step process, droplet 
generation and an appropriate gelation reaction (277). Droplet formation methods 
include emulsion methods, air jet (278), jet-cutter (279) and vibration jet break up 
(280). Of these the emulsion method is compatible with UV photo-polymerisation. To 
generate microspheres using hydrophilic polymers the most widely used method is 
suspension polymerisation using water-in-oil (w/o) emulsions. This method requires 
two immiscible phases, an aqueous polymer phase which is dispersed in a continuous 
organic phase (which can contain oil-soluble surfactants) (281). Within the aqueous 
phase, synthetic monomers containing photopolymerisable groups are suspended as 
droplets in an immiscible fluid, intensively stirred or sonicated and are subsequently 
exposed to a UV source for crosslinking. The resulting emulsified droplets in the 
continuous phase can be solidified by the addition of water soluble cross-linker, using 
heat for physical crosslinking. To ensure the formation of stable droplets and to prevent 
coagulation after mixing, surfactants or emulsifiers can be added (282). To separate the 
resulting solidified microspheres from the organic phase, which can contain oils, 
chemicals or surfactants, the microspheres are washed using either a solvent, detergent 
or water (283). This has been demonstrated recently by Olabisi et al. (2010) using an 
aqueous phase containing PEG diacrylate macromer, photoinitiator and fibroblasts, 
which was emulsified in mineral oil using a vortex and photopolymerised (284). 
Mechanical emulsion techniques generate droplets, and subsequently microspheres, 
with a large size distribution, a major drawback as it is wasteful. Furthermore, key 
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obstacles with this technique are unreacted monomer and organic solvents, which can 
become incorporated in the final microspheres and can be undesirable for some 
applications. The combined drawbacks of the technique mean that the use in biomedical 
applications is limited.  Microsieve technology has been generated to overcome the 
emulsion problem of polydispersity. By dispersing a fluid into another immiscible fluid 
through a sieve with pores or a uniform size, droplets that are monodisperse and 
reproducible are generated which can be polymerised (285). However, this technique 
still requires a toxic bulk solvent phase. 
1.12.2 Electrospray  
An alternative method known as submerged electrospray can be used to create a 
controlled emulsion. Also known as electrostatic atomisation or electrohydrodynamic 
atomisation, this technique uses a high voltage to break surface tension of the fluid 
meniscus resulting in the atomization of the liquid into fine droplets (286). Typically 
electrospray occurs in air or vacuum, however it has also been demonstrated in 
insulating liquids, known as a ‘submerged electrospray’.  In 2012 Martens et al. applied 
submerged electrospray for droplet generation by electrospraying poly (vinyl alcohol) 
PVA hydrogel macromer solution into oil. Resulting droplets were UV-
photopolymerised in situ (277). The researchers showed cytocompatibility by 
demonstrating successful encapsulation of fibroblasts with high viability. Previously, 
the electrospray technique was used to generate spherical alginate particles (in air) with 
a tight size distribution. However the submerged electrospray technique demonstrated a 
large polydisperse range of microspheres, comparable to that of mechanical stirred 
emulsion methods (287).  
1.12.3 Microfluidics 
Microfluidics describes the manipulation or processing of small volumes of fluid 
(10
-9
 to 10
-18
 litres) through artificial fluid conducting channels with dimensions of tens 
to hundreds of micrometres. The technology of microfluidics was first applied to 
analysis, offering several advantages over conventional techniques, principally the 
ability to greatly reduce required samples and reagent volumes. In addition to being 
inexpensive, microfluidic systems are capable of carrying out separations and detections 
with high resolution and sensitivity and short analysis times (288). 
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Microfluidics has seen a surge in technology development of the last decade 
mainly due to the many potential applications available. At present the basis of any 
microfluidic system is a method of introducing reagents and samples, a chip, containing 
a series of microchannels (which can be made by several methods and from various 
materials), a method for moving fluids around the system, and various other devices for 
manipulating the behaviour of the ‘on chip’ fluid. When used for analytical purposes 
this technology is often referred to as ‘Lab on a Chip’ (288). Microfluidic devices have 
previously been used as novel biocompatible droplet generation systems, with 
applications including the bioencapsulation of therapeutic protein-expressing cells 
(289).  
Polydispersity is a key factor in manufacturing microcarriers, as cell confluence 
should preferably be reached at the same time point on each carrier. In addition, the 
surface curvature of the particle can alter cellular morphology and behaviour (as 
discussed in section 1.11.3). In response to this, the use of microfluidics is ideally suited 
to the production of microcarriers. Monodisperse linear emulsions can easily be 
produced in a sealed sterile microenvironment, utilizing the phenomenon of segmented 
flow (reviewed in (290). In microfluidic devices, droplets of various sizes and size 
distributions can be generated by varying geometrical sizes and shapes within 
microchannels and junctions (291). The most commonly used configuration for droplet 
formation is a T-junction owing to its ability to form uniform droplets relatively easily 
(292). Droplet formation occurs at the junction where the dispersed phase (containing 
polymer) enters the microchannel which already contains the continuous phase 
(immiscible with the dispersed phase) where they are segmented into discrete droplets 
forming a linear emulsion. Various parameters can control the rate and size of droplet 
formation including the relative flow rate, viscosity, the interfacial tension, in addition 
to channel geometry (293). The size of the droplets can be increased by increasing the 
flow rate of the dispersed phase or by decreasing the flow rate of the continuous phase 
(294). Using microfluidics, the diameter of the produced hydrogel microspheres can be 
accurately controlled, with size distributions of <2% coefficient of variance and well-
defined structure and morphology.  The chemical composition of the dispersed phase 
determines the method of polymerisation of liquid droplets to solid microspheres. 
Several methods of initiation can be used within a microreactor including thermal 
initiation (295), UV-initiation (296), chemical reaction (297), or ionic  cross-linking 
(298). Using microfluidics to produce microcarriers provides a low-waste, high-
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throughput, inexpensive method for microsphere generation. As demonstrated in 2009, 
monodisperse microcarriers made from PEGDMA hydrogels can be photo-polymerized 
in situ, eliminating harsh solvents and lengthy post-processing steps (299). Microfluidic 
reactors offer several advantages over more conventionally used polymerisation 
techniques; by producing monodisperse microspheres with a narrow size distribution 
and uniform shape. In addition, the size of the microspheres can be easily controlled by 
adjusting the flow rate and/or interfacial tension of the liquid inputs.  The method can 
be readily scaled up to increase the production of microspheres and the method can be 
adjusted to generate microspheres from a variety of materials, including hydrogels. 
1.13 Project Aims 
The overall aim of this project was to develop a microfluidic method to generate 
synthetic monodisperse microcarriers containing a range of ECM-derived cues. If 
successful, a further aim was to expand ADSCs in spinner flasks bioreactors, whilst 
maintaining their differentiation potential. This process took part in several stages: 
Aim 1: To develop a novel microfluidics-based production platform to generate 
synthetic monodisperse microcarriers. Further, it was intended to incorporate recent 
progress in synthetic biomaterials to generate a microcarrier with an advanced surface 
for cell attachment and growth. Several microcarrier types were generated with varying 
chemical, mechanical and topographical properties. A microfluidic method for the 
synthesis of highly monodisperse PEGDMA hydrogel microspheres with a range of 
diameters was developed, utilising continuous in situ photo-polymerization. Two 
methods were investigated in an attempt to incorporate a number of cell adhesive 
peptides into the hydrogel matrix. The well-characterised fibronectin derived cell-
adhesive peptide cyclic (RGDfC), and two laminin based peptides, IKVAV and YIGSR 
were assessed as to their ability to support ADSC growth. The affect of modifying the 
microcarrier composition (the polymer content) on the substrates compressive moduli 
was investigated.  
Aim 2: To understand the effect of microcarrier composition, in particular 
chemical and physical cues on ADSC attachment and differentiation. Initial experiments 
assessed cell attachment to a planar hydrogel surface using a number of cell adhesive 
peptides. Cell proliferation on peptide modified microcarriers (at a range of peptide 
concentrations) was assessed over 7 days, and the effect of microcarrier compressibility 
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on cell differentiation was investigated to measure the effects on adhesion and 
adipogenic, osteogenic and chondrogenic differentiation.  
Aim 3: To expand multipotent populations of ADSCs on novel microcarriers 
within spinner flask bioreactors. To maximise ADSC expansion the effect of seeding 
density relative to microcarrier number was investigated. To investigate if the spinner 
flask culture primed ADSCs for differentiation, RT-PCR and was employed. In addition 
ADSCs were driven to differentiate into adipocytes, chondrocytes and osteocytes and 
observed by histochemical staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.0 Materials and Methods  
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2.1 Materials 
Unless otherwise stated, all chemicals were purchased from Sigma, UK.  
2.2 Microcarrier production and analysis  
2.2.1 Microfluidic Manifold Assembly 
The microfluidic device used in all experiments (MicroPlant
TM
) consists of a 
circular stainless steel manifold into which high performance liquid chromatography 
(HPLC) fluid connectors (Anachem, Befordshire, UK) were introduced equatorially. 
Vertical through holes were sealed with nitrile rubber O-rings, (Sealmasters, Cardiff, 
UK), allowing fluid to flow to the top surface of a virgin polytetrafluoroethylene 
(PTFE) disc (100mm diameter x 3mm) located on the manifold. A circular 
polyfluoroalkoxy (PFA) polymer film gasket (250µm thickness; Polyflon, Staffordshire, 
UK) was placed in between the PTFE chip and a borosilicate glass disc cover (100mm 
diameter x 5mm; H Baumbach, Suffolk, UK). A stainless steel clamping piece was 
bolted using screws (RS Components Ltd., Northants, UK) to the fluidic manifold, 
allowing the entire laminated assembly to be compression sealed. (Unless otherwise 
stated all MicroPlant components were produced by Cotton and Brooks, Caerphilly, 
Wales). Fluids were introduced into a microfluidic circuit via 1/16 inch and 1/8 inch 
(inner diameter) Teflon-FEP tubing (Anachem, Befordshire, UK) using syringe drivers 
(KD Scientific – Linton Instrumentation, Norfolk, UK).  
2.2.2 Fabrication and Design of Microfluidic Chips  
Microfluidic channels were machined into polytetrafluoroethylene (PTFE) discs 
(Polyflon, UK) using a Computer Numerical Controlled milling machine (Roland, 
Swansea, UK).  An example of a milled chip is shown in Chapter 3 Figure 11. 
Microfluidic circuit diagrams used to mill each chip are shown in Chapter 3. A range of 
microfluidic circuits were produced with varying channel dimensions, typically in the 
range of 150μm2 – 1000μm2. The width of fluidic input channels were 500μm, opening 
out to 700μm in the sphere forming channel.   
Briefly, channels were designed using computer software (AutoCAD 2009) into 
lines/layers which relate to machined channels on chip, with coloured layers assigned to 
different tool sizes. Blank PTFE chips were initially skimmed on both sides to create a 
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flat surface and to aid sealing. Channels were milled to desired layout/orientation set on 
computer software with a square drill; fluid entry holes were milled with a circular 
microdrill. All chips were produced in collaboration with the engineering department 
within Q Chip. 
2.2.3 Preparation of polymer solutions 
Hydrogel solutions were prepared using a 10-22% (wt.%) solution of PEGDMA 
(Sartomer, Warrington, PA, USA) in H2O with 0.025 wt.% of either photoinitiator 2,2'-
azobis(2-amedinopropane) dihydrochloride (Vazo 56 WSP) (DuPont, US) or 4-(2-
hydroxyethoxy)phenyl-(2-hydroxy-2-propyl)ketone (Irgacure 2959) (BASF, Yorkshire).  
Peptide sequence (3 letter) Acronym Supplier 
cyclic Cys-Arg-Ala-Asp-D-Phe-Cys RADfC 
Cambridge Bioscience, 
UK 
cyclic Arg-Gly-Asp-D-Phe-Cys RGDfC 
Cambridge Bioscience, 
UK 
Cys-Ser-Arg-Ala-Arg-Lys-Gln-Ala-Ala-Ser-Ile-
Lys-Val-Ala-Val-Ser-Ala-Asp-Arg 
IKVAV Sigma Aldrich, UK 
Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg YIGSR Sigma Aldrich, UK 
 
Figure 5: List of cystiene-containing peptides used for the study.  
All peptides were incorporated at 0.1 mM, 0.35mM, 1mM or 2mM. Acryloyl-
PEG-peptide, was incorporated at 1wt%. All resulting solutions were vortexed until 
homogeneous and transferred to a 1mL polycarbonate syringe (BD Biosciences, 
Oxford, UK).  
2.2.4 Incorporation of fluorescent markers into microcarriers  
To test the feasibility of incorporating traceable ligands into the microcarrier 
matrix, fluorescently conjugated antibodies (goat anti-mouse Alexa 405,488,568 
(Invitrogen,UK)) or semiconductor quantum dots (Qdot 625 (Invitrogen, UK)) were 
incorporated into the polymer solution at 1µg/mL (antibodies) or 8nM (Qdots). 
Incorporation was confirmed by widefield fluorescence microscopy. To determine 
whether populations of microcarriers could be distinguished, equal number of 
microcarriers with incorporated Alexa 405,488 and 568 antibodies were mixed, and 
visualised by widefield fluorescence microscopy. 
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2.2.5 In situ Microfluidic Synthesis of Monodisperse Microspheres 
Two immiscible fluids were supplied into microchannels using syringe drivers 
(KD Scientific, Linton Instrumentation, Norfolk, UK). A continuous-phase, high-oleic, 
sunflower oil (carrier fluid), (Statfold seed oils, UK), was injected vertically into the 
microchannel and a functional-phase comprising PEGDMA prepolymer and 
photoinitiator was supplied from a secondary through-hole producing a linear emulsion 
at a vertical T-junction. Segmented polymer droplets were irradiated with an ultraviolet 
source, (365nm UV light at an intensity of ~18 mW/cm
2
), and solidified into 
microspheres. To prevent attachment of gel microspheres during UV polymerization, 
flow rates were altered to increase microsphere spacing. The MicroPlant device was 
placed under a steel UV light guide holder (Cotton and Brooks, Caerphilly, Wales), 
approximately 5.3cm above the surface of the chip. A UV light source (OmniCure 
Series 2000 UV illumination system 100W), (Jenton International Ltd., Hampshire, 
UK), fitted with a liquid light guide was used to irradiate the monomer/initiator 
mixtures. Polymer droplets were exposed to 365nm UV light at an intensity of ~18 
mW/cm
2
. The incident light intensity (%) was manually controlled at the internal 
aperture of the UV light source. Under the experimental condition, 95% UV intensity, 
PEGDMA microspheres could be rapidly solidified in a short exposure time in situ 
(≈175s). Following polymerization, the hydrogel microspheres were collected in glass 
vials. 
2.2.6 Use of surfactants to remove excess oil from microspheres 
Microspheres were collected directly from the MicroPlant for 60 mins, to which 
30mL of 1% Tween 20 (in double distilled cell culture water) was added, inverted 
several times and centrifuged using a Fisher Scientific AcenSpin
TM
 centrifuge (144 x g 
for 3 mins), and the supernatant was removed. This process was repeated a minimum of 
10 times or until all oil had been removed from the microspheres after visual inspection. 
Subsequently, 30mL of ddH2O was added, inverted several times, incubated for 30 mins 
at RT, and centrifuged using a Fisher Scientific AcenSpin
TM
 centrifuge (144 x g for 3 
mins), before removing all liquid. This step was repeated three times and the samples 
were stored in excess water and tested within 24 hours.  
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2.3 Analytical Measurements 
Microsphere radii were measured using a light microscope (Leica Microsystems, 
Heidelberg GmbH) with attached Moticam-2000 camera. Sphere diameters were 
measured using associated software Motic Images Plus 2.0, (Motic, Suffolk, UK). 
Microspheres were measured from a representative sample of each microsphere type. 
The coefficient of variance (CV) was calculated as shown in Equation 2.1. 
   
                  
             
        
2.4 Manufacture of flat gels 
Hydrogel discs were prepared using chip 100962A (Figure 21). The hydrogel 
chip contained a fluid entry and exit point and a large cavity (500µm depth). Hydrogel 
solutions were prepared as described in section 2.1.3 and pumped manually into the 
cavity. The solution was polymerised by exposure to 365nm UV light at an intensity of 
~18 mW/cm2 for 180 seconds. The resulting hydrogel was cut into small discs (8 mm 
diameter x 500µm), washed three times in PBS and incubated in PBS overnight to 
equilibrate. The thickness of each sample was measured using a digital calliper prior to 
experimentation. 
2.5 Microscopy analysis 
For whole well visualisation of 96-well plates, a custom built platform was 
derived comprising of a 2D Olympus stage (Olympus Keymed, Southend-on-Sea, UK) 
mounted on to a 1.3-megapixel CMOS camera driven by photoimpression software 
(Arcsoft, California USA). Microcarrier numbers were counted using the cell counter 
plugin within the Fiji image processing package (www.fiji.sc). 
Brightfield and phase images were taken on a Leica DMIL inverted microscope 
(4x,10x,20x,40x objectives) (Leica Microsystems, Heidelberg GmbH) with an attached 
Moticam-2000 camera driven by Motic image capture software, (Motic, Suffolk, UK). 
Widefield fluorescence microscopy was performed using an inverted IX-71 
frame and objectives (4x,10x,20x,40x,100x)(Olympus Keymed, Southend-on-Sea, UK). 
3D stage, illumination and image capture automation was controlled through simplePCI 
software (Hamamatsu Photonics, Japan) driving an XYZ stage and filter wheel (Prior 
Scientific, Cambridge, UK) and an Orca-AG camera (Hamamatsu Photonics, Japan). 
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Fluorescence light source was an Exfo X-Cite120 (Lumen Dynamics, Ontario, Canada). 
Excitation, emission and dichroic filters were obtained from Chroma Technology 
(Chroma Technology Corporation, USA) and were optimised for the fluorophores in 
use. 
Confocal analysis was performed using Leica SP2 and TCS SPE confocal 
microsopes. For microcarrier/cell analysis and assessment of peptide incorporation, a 
Leica TCS SP2 AOBS spectral confocal laser scanning microscope with 405,488 and 
543 laser lines (Leica Microsystems, Heidelberg GmbH) controlled via a PC running 
Leica Confocal Software (LCS) was used. In all experiments, the laser power was 
minimized in order to avoid photobleaching and laser power was maintained at 40% 
intensity, using a 10x dry objective lens and 2x optical zoom, incorporating both 
fluorescence and bright field transmission scanners. Z-Stacks of optical sections were 
taken through the entire volume of the sphere at 5μm intervals (unless otherwise stated) 
using appropriate excitation and emission settings. Z-Stacks were processed and 
analysed using LCS and presented as 3-D reconstructions that defined the mid-plane of 
the stack at the highest cross sectional diameter of the microsphere. For 
microcarrier/cell analysis, images were taken using a Leica TCS SPE confocal 
microscope with 488,532 and 635 laser lines (Leica Microsystems, Heidelberg GmbH). 
Microcarrier images were visualised using a HC PL Fluotar 10x (NA=0.3) objective 
with an appropriate zoom to capture the entire microcarrier within a 1024x1024 pixel 
scan (typically 2x for a single microcarrier). Z-section resolution was defined through 
the Leica software as ‘optimal’ (2.5 microns) and resulted in around 170-200 sections 
per microcarrier. Individual z-sections were reconstructed within the Fiji image 
processing package (www.fiji.sc), utilising the ‘Z-project’ plugin to create a brightest 
point merge. Depth projections were recoloured using the ‘Temporal-colour code’ 
plugin. 
2.6 Microcarrier characterisation  
2.6.1 Characterisation of Peptide incorporation using Acryloyl-PEG-NHS 
The fibronectin fragment peptides, Gly-Arg-Gly-Asp-Ser (GRGDS), Gly-Arg-
Asp-Gly-Ser (GRDGS) and diamine-RGDS-6-aminohexanoate linker (LC)–biotin, were 
designed and custom synthesised (Peptide synthetics, Hampshire, UK). To determine 
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the efficiency of the conjugation reaction, samples were analysed using a variety of 
methods including Electrospray Mass Spectrometry and MALDI ToF ToF analysis.  
2.6.2 Electrospray Mass Spectrometry Analysis of Acryloyl-PEG-NHS 
Conjugates.  
Electrospray mass spectrometry (ESI) was performed on a Thermo Finnigan 
navigator Thermo Quest LC/MS, single-quadrapole mass spectrometer using the 
positive ion mode, running under Thermo Separation's Xcalibur software. ESI mass 
spectra were recorded on a single quadrupole mass spectrometer fitted with an 
electrospray ion source, the first detector was used for mass detection. Acryloyl-PEG-
NHS, at a concentration of 1mg/cm
3
, dissolved in eluent Acetronitile/Water (1:1, v/v), 
0.3% Formic Acid, and injected via flow injection into the ESI source at a flow rate of 
10µl/min. All solvents used were HPLC grade. The mass spectrometer was calibrated in 
the positive ion mode using Polyethylene Glycol (PEG) (MW 1K). At least three charge 
states were used to determine the reported weights. Data were acquired in the scan 
mode from m/z 400 to 1500 in 5s at a 0.1 step size. Voltages were set at +30V for the 
capillary and adjusted for the sampling cone. The source was heated at 120°C. 
2.6.3  Synthesis and purification of Acryloyl–PEG–Peptide 
The acrylated peptide was synthesized through aminolysis of the N-hydroxy 
succinimide ester of acrylic acid (Acryloyl-PEG-NHS) (Jenkem, USA). N-
hydroxysuccinimidyl-activated esters were used to couple the N-terminal primary amine 
of the peptide to an acrylate moiety, indirectly using a 3,500MW PEG spacer. (Figure 
22). Three alternative methods were employed to produce the PEG-peptide conjugate. 
Method 1: Synthesis of an acrylated peptide Acryloyl–PEG–GRGDS was 
performed following the modified method of Hern and Hubbell (1998) (300). A 
3,500MW PEG (spacer) chain between the peptide and the acrylate moiety was 
produced by reacting the peptide with Acryloyl-PEG-N hydroxysuccinimide. The 
peptide was dissolved to a final aqueous concentration of 1mg/mL in 50mM of sodium 
bicarbonate buffer, pH 8.2. Specifically, two milligrams (1.23mmol) of peptide was 
dissolved in 2mL of 50 mm sodium bicarbonate solution. The 3,500MW Acryloyl–
PEG–NHS was dissolved separately such that the final molar ratio of Acryloyl-PEG-
NHS to peptide was 1:1 Acryloyl–PEG–NHS (9.11 mg, 1.23 mmol) was dissolved in 
400uL of 50mM sodium bicarbonate solution and the resulting solution was added 
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drop-wise to the peptide solution, whilst under continuous stirring. The solution was 
shaken on an orbital shaker for 2h, at room temperature. Dialysis (MWCO 2,000 Da) 
was used to remove unreacted peptide and N-hydroxyl succinimide against deionized 
water for 72h with periodic bath changes. The solution containing the pure product was 
vacuum dried. A low reactant ratio of 1:1 was chosen to minimise the production of 
Acryloyl-PEG-OH, the product of the competing hydrolysis reaction, since this by-
product was not removed from the Acryloyl-PEG-peptide.  
Method 2: Two parameters, the molar ratio of peptide to the succinimide ester 
and the pH conditions, were varied to maximize conversion of the peptide to the desired 
product and minimise side reactions. Reactions were conducted at molar ratios of 1, 1.5, 
and 2 of the peptide to a succinimidyl ester at pH conditions 7.5, 8, 8.5 and 9. Briefly, 
the peptide was resuspended in water and aliquoted into an array format. Acryloyl–
PEG–NHS were dissolved separately in trizma-based basic buffers to produce 4 
samples of pH 7.5, 8, 8.5 and 9 according to manufacturer’s instructions. Stoichiometric 
equivalents of Acryloyl–PEG–NHS samples were added to peptide aliquots 
immediately, in excess buffer to ensure the correct pH for each individual reaction. 
Reactions were conducted in duplicate and divided such that half the samples were 
stored at 25 or 37 degrees.  Purification of samples was performed using dialysis at a 
MW cut off of 1,000Da.  
Method 3: GRGDS peptide was dissolved in anhydrous dimethyl formamide 
(DMF) containing 4M excess of triethylamine (TEA). Acryloyl-PEG-NHS was also 
dissolved in anhydrous DMF and, immediately after, mixed with 1.1M excess of 
peptide. After incubating for 3h at RT, Acryloyl-PEG-GRGDS was precipitated twice in 
cold anhydrous ether and dried under vacuum overnight at room temperature (301). The 
peptide coupling reaction and molecular mass of the product was monitored by matrix-
assisted laser desorption/ionization time-of-flight spectrometry (MALDI ToF ToF). 
2.6.4 MALDI ToF ToF Analysis of Acryloyl-PEG-Peptide conjugates 
1
st
 Analysis 
The MALDI ToF ToF 4800 mass spectrometer (Applied Biosystems) was used 
for analysis of peptide conjugates. One milligram of Acryloyl-PEG-NHS dissolved in 
50mL of 50% Acetonitrile and Trifluoroacetic acid (ACN/TFA), followed by a further 
1:100 dilution. 0.5μL sample of Acryloyl-PEG-peptide (~3 x 10-11moles) was spotted on 
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a 384 well Opti-TOF plate (P/N 1016491, Applied Biosystems) and the air dried spot 
was overlaid with either 0.5 μL of 10 mg/ml α-cyano-4-hydroxycinnamic acid or 
sinapinic acid (donated by Cardiff Biotechnology Services) dissolved in 50% 
acetonitrile, 0.1% trifluoroacetic acid.  
2
nd
 Analysis 
Acryloyl-PEG-peptide conjugate was resuspended in 10mL H2O, diluted 1:100 
with ACN/TFA and 0.5µl was pipetted onto the target. As samples were incompatible 
with α-cyano-4-hydroxycinnamic acid matrix due to high level of Tris salts, dialysis 
was performed. Briefly, 50µl of each taken and dialysed against water using mini-
dialysis kits (MWCO 1000kDa) (Thermo Scientific Ltd., High Wycombe, UK) for 6hrs 
and dried in a SpeedVac, (Thermo Scientific, Ltd., High Wycombe, UK), resuspended 
in 2mL ACN/TFA and spotted 1µL onto the plate. 
3
rd
 Analysis 
Acryloyl-PEG-peptide was dissolved in 1mL of a mixed methanol/water (50:50) 
solvent without cationizing agent. Twenty microlitres of sample was removed, dried in 
a SpeedVac and resuspended in a 1/50 dilution of methanol/water. 0.5µL was hand 
spotted onto the Opti-TOF plate. The MALDI matrix consisted of dihydrobenzoic acid 
(DHB), (donated by Cardiff Biotechnology Services), which was hand spotted onto the 
plate over a target and air dried. In each case, mass spectra were collected in positive 
ion reflector mode with an Nd-YAG laser at 355mn on a MALDI ToF ToF 4800 mass 
spectrometer. The final spectrum was the average of 800 laser shots. Masses were 
calibrated using CalMix 5 (Applied Biosystems, UK).  
2.6.5  Visualising surface bound peptide incorporation 
The surface concentration of bound peptide was determined by confocal 
microscopy. Acrylate-poly(ethylene glycol)-biotinylated peptide (Acryloyl-PEG-
diamine–RGDS-LC-biotin) served as model ligand and was covalently linked to the 
microspheres polymer backbone during microfluidics assisted UV photo-
polymerisation. To assess the presence of PEG-biotin on the particles´ surface, particles 
were incubated with a fluorescent streptavidin conjugate from Anaspec (Cambridge 
Biosciences, Cambridge, UK) and visualized by confocal laser scanning microscopy 
(CLSM). To account for false-positive results due to adsorption of the fluorescent 
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marker, biotin free PEGDM microspheres were treated the same way and compared to 
biotinylated peptide containing microspheres. 
Microsphere suspension (500µL) were produced and washed (as above), placed 
in RNeasy MinElute Spin Column (Qiagen, West Sussex, UK) and centrifuged to 
remove excess fluid. Thirty microlitres of diluted streptavidin (1/50 in H20) was added 
to spin columns and spun immediately at 8,000 x g for 1min to remove fluid. To wash 
excess streptavidin off the microspheres, 600µL of distilled H2O was added to the spin 
column, centrifuged at 8,000 x g, the elutant discarded and repeated 5 times. The 
microspheres where kept in 500uL of H2O to ensure they remained hydrated and 
removed any excess strepavidin by passive diffusion.  
The distribution and localisation of the conjugated peptide distribution was 
visualised by measuring the fluorescent signal from FITC conjugated Streptavidin 
bound biotinylated-peptide on the surface of the microspheres. The labelled 
microspheres were placed on a microscope slide with minimal fluid, and cross-sectional 
images were taken of several microspheres at different depths using an SP2 confocal 
laser scanning microscope.  
2.6.6 Ninhydrin assay 
The ninhydrin assay was used to verify the presence of amine groups within 
peptide modified microcarriers. Microcarrier samples were weighed, dried in a vacuum 
centrifuge at 25
o
C overnight and re-weighed. The dehydrated spheres were digested in 
6N HCl at 100
o
C for 3 hours before being dried in a vacuum centrifuge at 25
o
C for 6 
hours. The resulting digested amino acids were dissolved in equal parts 0.1M sodium 
citrate buffer and ninhydrin solution and heated at 75
o
C for 15 mins. The absorbance of 
the final solution was measured at 570 nm (Fluostar optima, BMG optima, Germany). A 
standard curve was prepared using a solution of a known concentration of Glycine.  
2.6.7 Environmental Scanning Electron Microscopy of microcarriers  
The structure of the hydrogel scaffolds were examined with an FEI (Holland), 
XL30, Field Emission Gun (FEG), Environmental Scanning Electron Microscope 
(ESEM) in "wet" mode. ESEM settings were accelerating voltage 20kV, spot size 4, 
working distance ~9mm. A Peltier stage was used to cool the spheres to ~5°C and 
the vapour pressure adjusted to yield slightly less than 100% humidity in the chamber. 
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A gaseous secondary electron detector (GSD) was used to image microspheres (n=6) in 
their hydrated state (suspended in sterilised water, 25µL, cell culture grade, Sigma, UK) 
(302). 
2.6.8 Mechanical characterisation 
Mechanical testing was performed in unconfined uniaxial compression using a 
Bose ELF 3200 testing system with a 250g load cell (Bose Corporation ElectroForce 
Systems Group, Minnesota, USA). Prior to mechanical testing, the hydrogel discs 
(Section 2.2.8) were swelled overnight in H2O to ensure complete hydration. 
Compression (mm) and load (N) were recorded using Wintest software at a cross speed 
of 10 mm/s and a strain level of 60%. The compressive modulus was obtained as the 
tangent slope of the stress–strain curve. Three specimens were tested for each sample 
type. Samples were strained to 60% and the compressive Young's modulus was 
obtained from the slope of the stress-strain curve.  
                          
 
 
   
      
     
 
Where σ is the stress applied, ε is the corresponding strain, Δ m is the change in 
load applied, g is the force of gravity, L is the length of the scaffold sample, A is the 
cross-sectional area of the scaffold, and ΔL is the change in length during compression. 
2.6.9 Equilibrium water content 
The equilibrium water content (EWC) of scaffolds was calculated according to: 
     
         
  
        
The hydrated mass (Wh) was measured after immersing the scaffolds in water 
for 3 days (n=6) with residual surface water removed by blotting. The dehydrated mass 
(Wd) was measured after drying the samples in a vacuum centrifuge overnight. 
2.6.10 Microcarrier counting 
Microcarriers were produced using microfluidics as detailed in Section 2.2.5. As 
the polymer (dispersed phase) enters the MicroPlant at a constant rate (mL/h), the 
microspheres were segmented and exited the MicroPlant at a constant rate. Based on the 
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polymer flow rate and average microsphere diameter, the frequency of microsphere 
production can be calculated using the following equations: 
                         
 
            
     
    
 
 
                                                  
  
                         
                       
 
 
Accordingly, the average microsphere diameter was 461µm, with a polymer 
flow rate of 0.65mL/hr. This provided a frequency of 3.52 Hz, and therefore, within one 
60 mins batch 12,671 microspheres can be generated.  By resuspending microspheres in 
a defined volume (5mL) and aliquoting 250µL per into each well of a 24-well plate, an 
average yield of 506 beads per well should be achieved. However, manually dispensing 
microcarriers via pipetting can result in an uneven microcarrier distribution, therefore 
for viability assays, microscope images of individual wells within a multi-well plate 
were taken and microcarriers were counted using the Cell counter plugin within the FIJI 
image processing package (www.fiji.sc). 
2.7  Cell culture methods 
Routine cell culture work was carried out under a laminar flow (class II) hood. 
Cells were maintained at 37
o
C in a hydrated atmosphere of 5% CO2 and air in 
appropriate medium. Human alveolar epithelial cells (A549) cells (European Collection 
of Cell Cultures) were maintained in Dulbecco’s modified Eagle medium containing 
4500mg/L glucose and 110mg/L pyruvate supplemented with 10% heat inactivated 
foetal bovine serum (FBS). Penicillin (10,000 units per mL) and streptomycin (10,000 
µg per mL) were also added to the medium. All medium was stored at 4
o
C until use. 
2.7.1 Sub-culturing of A549 cells 
The cell line A549 was routinely passaged at 60-80% confluence, using 0.02% 
Trypsin/0.05% EDTA in PBS. Typically a cell seeding density of 750 x 10
3
 in a T75 
flask required sub-culturing every four days. Culture medium was removed and cells 
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rinsed twice with pre-warmed PBS (10mL). Attached cells were removed by adding 
Trypsin/EDTA (5mL) to a T75 culture flask. Cells were incubated for 5 mins at 37
o
C to 
allow detachment of cells into a single-cell suspension. After incubation, enzymatic 
action was terminated through the addition of serum-containing medium (10mL). Total 
cell suspension was centrifuged at 900 x g for 5 mins. The supernatant was removed 
and the cell pellet resuspended in 1mL of complete medium by gentle pipetting to 
remove any cell clumps, before splitting approximately 1:8 into new T-75 flasks before 
in a final volume 15mL. 
2.7.2 Culture of ADSCs 
StemPro® Human-Derived Stem Cells (ADSC) obtained from Invitrogen 
(Invitrogen, UK) were cultured in DMEM (low glucose) containing Glutamax 
supplemented with 10% Mesenchymal stem cell qualified FBS, 75 µg/mL Gentamicin 
and 37.5 ng/mL Amphotericin. ADSC were seeded at 5,000 cells/cm
2
 and incubated at 
37°C, 5% CO2. The medium was changed approximately 24 hours post seeding and 
subsequently every three. Cells were harvested once they reached ~70% confluence 
(approx. 5 days), using Accutase (Invitrogen). Culture medium was removed and cells 
washed once with pre-warmed PBS. Attached cells were removed by adding Accutase 
and incubated for 5 mins at 37
o
C to allow detachment of cells into a single-cell 
suspension. After incubation, enzymatic action was terminated through the addition of 
serum-containing medium. Total cell suspensions were centrifuged at 220 x g for 5 
mins. The supernatant was removed and the cell pellet resuspended in 1mL of complete 
medium by gentle pipetting to generate a single cell suspension. ADSCs were 
cryopreserved at Passage 2, and all experiments were conducted at Passage 4.    
2.7.3 Freezing and thawing cells  
To preserve stocks of cells, harvested cells were diluted to ~1 x 10
6
 cells/mL in 
Synth-a Freeze cooled to 4
o
C, containing 10% DMSO (Invitrogen, UK). Cell 
suspensions (1mL) were aliquoted into cryovials and then frozen to -80
o
C in a container 
filled with isopropanol that was designed to cool at a rate of less than 1
o
C per min. Once 
frozen (overnight), cell vials were transferred into liquid nitrogen and stored until 
required. Recovery of stored cells was achieved by first removing a vial of cells stored 
in liquid nitrogen. These were then warmed rapidly by placing in a 37
o
C water bath 
until all ice crystals were thawed. The warmed cell suspension was then diluted (1:2) in 
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culture medium (1mL) pre-warmed to 37
o
C. Total cell contents were seeded at 5,000 
cells/cm
2
 and incubated at 37°C, 5% CO2. 
2.7.4 Counting total and viable cell numbers of cell cultured on tissue culture 
plastic 
After enzyme disaggregation, cell suspensions were quantified, in terms of total 
and viable intact cell numbers, using a haemocytometer in conjunction with phase 
contrast microscopy. The percentage of viable cells was determined using the dye 
exclusion method ((303); Section 2.7.5). To carry out a total cell count, cells were 
trypsinised, pelleted by centrifugation (220 x g for 5 mins) and resuspended into 
medium, ensuring a unicellular suspension. The haemocytometer and coverslip were 
cleansed (70% ethanol) and the coverslip placed squarely on top of the 
haemocytometer; lightly moistened at the polished surface of the slide before pressing 
the coverslip into position. Cells were redistributed throughout the medium by gentle 
agitation, before a sample (10µL) was loaded into the haemocytometer and counted.  
2.7.5 Trypan blue dye exclusion 
The percentage of viable cells was calculated using the dye exclusion method, 
whereby trypan blue (membrane lipid insoluble) becomes visible upon permeating cells 
that have damaged plasma membranes. An aliquot (10µL) of cell suspension was mixed 
with trypan blue solution (10µL), loaded into the haemocytometer, and the unstained 
(viable) versus stained (non-viable) cells counted. The percentage of viable cells was 
determined according to the following equation: 
                             
                         
                
       
2.8 Differentiation of hADSCs  
2.8.1 Adipogenesis  
For adipogenic differentiation ADSCs were seeded at 1 × 10
4
 cells/mL and 
incubated at 37°C, 5% CO2 for 24 hours in complete medium. The medium was then 
switched to complete StemPro adipogenic differentiation (Invitrogen) for an additional 
14 days with medium changes every 3–4 days, coincident with other analysis. 
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2.8.2 Osteogenesis 
For osteogenesis studies, ADSCs were plated at 5 x 10
3
 cells/cm
2
 complete 
medium which was then switched to complete StemPro osteogenic differentiation 
(Invitrogen) and cultured for 14 days with medium changes every 3–4 days, coincident 
with other analysis. 
2.8.3 Chondrogenesis 
 For chondrogenic differentiation studies, ADSCs were resuspended in complete 
medium to a concentration of 8 × 10
6
 cells/mL. In a 12-well tissue-culture dish, 10µl of 
cell suspension was spotted per well and incubated for two hours at 37°C, 5% C02 and 
90% humidity to form a pellet. After 2 hours StemPro chondrogenic differentiation 
medium was added gently to the wells.  Differentiation media was replaced every three 
to four days. Chondrogenesis was analysed after 14 days.  
2.9 Microcarrier seeding experiments 
Immediately prior to cell seeding, all fluid from the prepared microspheres was 
removed via a micropipette. The microspheres were resuspended in 5mL of cell culture 
medium and gently pipetted to form a homogenous suspension. The suspension was 
aliquoted (250µL) into non-cell adhesive, ultra-low attachment 24-well plates to prevent 
normal cell attachment to tissue culture polystyrene (Corning, UK). Plates containing 
microspheres were placed in the incubator at 37°C, 5% CO2 for a minimum of 4 hour 
prior to seeding to allow equilibration. 
2.9.1 Optimisation of initial cell attachment 
The following conditions were varied during the seeding experiments in order to 
determine the optimum culture conditions that favoured monolayer sphere 
attachment/growth of A549 cells:  
2.9.1.1 Seeding Density 
 A549 cells were seeded onto microcarriers at 100,000, 50,000 and 25,000 cells 
per well. 
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2.9.1.2 Agitation 
 Samples were either static or agitated intermittently for the first 4 hours after 
cell seeding. Samples were agitated intermittently at different time intervals (every 20, 
40 or 60 mins at 40 rpm for 2 mins), on a shaking mini-rocker in a humidified incubator 
at 37
o
C and 5% CO2. 
2.9.1.3 Total Volume of medium  
The total volume of media tested was 3mL and 500µL.  
2.10 Seeding and differentiation of ADSC on microcarriers 
Microcarriers were placed in ultra-low attachment tissue culture plates (Corning, 
UK). Microcarriers in either 6 well or 24 wells were seeded with 40,000 or 10,000 cells 
respectively and cultured in complete medium for 7 days. The medium was then 
switched to either StemPro adipogenic, osteogenic or chondrogenic medium, 
(Invitrogen). Control cultures were maintained with complete media. All cell-laden 
microcarriers were maintained for 7 days for RT-PCR analysis or 14 days for 
histochemical analysis in a humidified incubator at 37
o
C and 5% CO2 with medium 
changes every 3–4 days. Whole wells were imaged to observe differentiated cell laden 
microcarriers distribution using an Oxford Optronix GelCount device (Oxford, UK).   
2.11 Analysis of ADSC attachment to hydrogels  
2.11.1 DAPI nuclear staining to observe ADSC attachment to flat gels 
Hydrogel discs prepared were seeded with 50,000 human ADSCs in ULA plates 
and incubated in DMEM with 10% MSC qualified fetal bovine serum medium for 24 h 
at 37
o
C at 5% humidity. After 48 hours specimens were fixed for 20 mins in 3.7% 
paraformaldehyde (PFA) in PBS. After washing with PBS, the discs were immersed in 
4’,6’ diamidino-2-phenylindole dihydrochloride (DAPI) solution (1:10000) and 
optionally Concanavalin A (both Sigma) (1:100) for 10 mins. The disks were washed 
three times in PBS inverted into an imaging chamber containing PBS and observed 
using widefield fluorescence microscopy.  
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2.12 Analysis of cell-laden microcarriers 
2.12.1 SEM analysis 
Microcarriers were analysed using scanning electron microscopy (SEM) to 
assess ADSC distribution and morphology. To prepare SEM samples, scaffolds were 
mounted on 0.5” carbon-coated aluminium specimen stubs (Agar Scientific) and gold-
palladium (90:10) coated with a sputter-coater in a Biorad (K) vapor deposition unit, at 
15 mA for 60 s. SEM (Zeiss SMT S360 Scanning Electron Microscope) was operated at 
a working distance of 15 mm and an accelerating voltage of 20 kV. 
2.12.2 Cell growth measured by PrestoBlue viability assay 
The proliferation of ADSCs on microcarriers was measured using the Prestoblue 
viability assay (Invitrogen, UK). ADSCs (10,000) were seeded onto approximately 100 
microcarriers containing different cysteine containing peptides in ultra-low attachment 
96 well plates (total volume 90µL). Alternatively, 90µL microcarrier samples were 
removed from spinner flasks placed into ultra-low attachment 96 well plates. Ten 
microliters of Prestoblue reagent was added to each well, mixed and incubated for 24 
hours at 37
o
C in a CO2 incubator. The supermatent (90µL) was removed and transferred 
to a black walled, clear bottomed 96 well plate. The fluorescence of each sample was 
measured using a Fluostar Optima microplate reader (BMG Labtech Gmbh, Ortenberg, 
Germany) by fluorescence detection at excitation and emission wavelength of 540–570 
and 580–610nm, respectively.  
2.12.3   Immunocytochemistry 
F-actin was detected in ADSCs cultured on microcarriers after 7 days either in 
static or spinner flask culture (samples transferred to a 12 well plate prior to analysis) 
using TRITC conjugated phalloidin (Sigma, UK). After removing ~85% of the media, 
the cell-laden microcarriers were washed twice with PBS by (by exchanging ~85% of 
the supernatant) and fixed for 20 mins in 3.7% paraformaldehyde in PBS. After 
aspirating the paraformaldehyde (PFA), 30mM Glycine was added and incubated for 5 
mins at RT. The microcarriers were then immersed in 0.1% Triton X-100 for 5 mins, 
followed by a further washing step in PBS and blocked with 3% bovine serum albumin 
(BSA) for 30 mins at RT. After this procedure, in parallel the cell constructs were 
stained with either, anti-tubulin (1:1000)(Labvision corporation, California USA) or 
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phalloidin-TRITC (1:500) for 1 hour or 10 mins respectively at RT. The microcarriers 
were then washed in PBS a further 3 times for 5 mins each. Anti-tubulin samples were 
treated with Alexa 488-labeled anti-mouse secondary antibody (1:400) (Invitrogen, UK) 
at RT for 1 hour and washed in PBS a further 3 times for 5 mins each. Cells were 
counterstained with DAPI (1:10000) to visualise nuclei, the constructs were then 
washed in PBS a further 3 times for 5 mins each. The cell constructs were washed and 
viewed using an SP2  laser scanning confocal microscope.  
2.12.4 LIVE/DEAD® viability/cytotoxicity kit 
The viability/cytotoxicity kit (Sigma, UK Product number 04511) supplied 
prepared solutions of Calcein-AM and Propidium Iodide (PI). The assay solution was 
prepared according to manufacturers’ instructions by combining Calcein-AM solution 
(10µL) and Propidium Iodide (PI) solutions (5µL) with PBS (5mL). As serum contains 
esterases, which can interfere with the analytical method, culture medium was removed 
from the wells and microcarriers were gently washed three times in PBS (1mL). To 
prevent any excess shear force removing bound cells, washing steps only removed 
~85% of the supernatant (via gentle pipetting). In the final washing step PBS was 
replaced with 300µL of assay solution. The samples were incubated at 37
o
C for 15 
mins. Calcein generated from Calcein-AM by esterases in a viable cell emitted strong 
green fluorescence (excitation: 490nm, emission: 515nm). PI solutions emitted a strong 
red fluorescence (excitation: 535nm, emission: 617nm)). Both Calcein and PI-DNA 
could be excited at 490nm, and therefore, simultaneous monitoring of viable and dead 
cells was possible using fluorescence microscopy. With 570nm excitation, only dead 
cells could be observed.  
2.12.5 RNA extraction and RT-PCR analysis of gene expression 
Total RNA was extracted from cells directly from the microcarrier unless 
otherwise stated using an RNeasy Mini Kit (Qiagen, Crawley, UK) following the 
supplier's instructions. Cell-laden microcarriers were harvested at different time points 
according to the experimental design. ADSCs cultured on microcarriers with a range of 
compressive moduli were harvested at day 5, and 14 days after being placed in 
differentiation induction media. In addition cells were harvested from spinner flasks at 
either day 7 or Day 14. The samples at all time points were lysed in supplied lysis 
buffer. The lysate was homogenized with QIAshredder spin column (Qiagen, Crawley, 
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UK). The homogenised lysate together with 700µl of 70% ethanol was then transferred 
to RNeasy spin column for purification. Samples were treated with DNase to remove 
genomic contaminants. RNA was extracted according to the kit instructions. Total RNA 
concentration and quality was assessed using a NanoDrop 1000 spectrophotometer 
(NanoDrop Technologies, Labtech, Ringmer, UK). RNA samples were reverse-
transcribed to cDNA using Promega cDNA synthesis kit (BioRad, UK) following the 
supplier's instructions. The real-time RT-PCR reactions were conducted and monitored 
with a Mastercycler® ep Realplex (Eppendorf, Cambridge, UK). TaqMan® Gene 
Expression assay kits (Applied Biosystems, UK) were used for transcript levels of genes 
(Figure 6). One µl of cDNA from each sample was mixed with 0.5µl of the assays-on-
demand kit, 8.5 µl of RNase/DNase free water, and 10 µl of 
2× TaqMan® Universal PCR Master Mix (Applied Biosystems, UK). Final data were 
analysed by Mastercycler® ep realplex software (Eppendorf, Cambridge, UK). The Ct 
value for each sample was defined as the cycle number at which the fluorescence 
intensity reached a certain threshold where amplification of each target gene was within 
the linear region of the reaction amplification curves. Relative expression level for each 
target gene was normalized by the Ct value of TaqMan® endogenous gene B2M using 
an identical procedure (2
-ΔΔ
Ct formula) (304). Each biological replicate was run in 
triplicate on and no Reverse transcriptase and no template controls (NTC) were run in 
parallel for each primer/probe set to ensure no contamination. Each sample was 
analysed in triplicate. B2M primers were used as an internal control. The samples were 
then subjected to an initial 50°C for 2 mins to optimise UDG enzyme activity and 
cycling conditions of: 95
o
C (10 mins), 50 cycles of 95
o
C (15 s) and 60
o
C (1 mins).   
 60 
 
 
Figure 6: List of TaqMan® Gene Expression assay kits used for RT-PCR 
Analysis of gene expression was performed using the Mastercycler® ep Realplex software (Eppendorf, 
Cambridge, UK).  Content of cDNA samples was normalized and expression of each specific gene was 
calculated using the formulae 2
− (ΔCt)
 and was compared to the value obtained for MSC at J0. 
Chondrogenic pellets were incubated with 1mL of collagenase type II at 2mg/ml 
in PBS for 1 hour in a humidified incubator at 37
o
C, 5% CO2. Subsequently, the entire 
volume containing disassociated pellets (without microcarriers) was transferred to 
microcentrifuge tubes, vortexed and centrifuged at 300 x g for 5 mins at room 
temperature. The supernatant was removed via pipette and replaced by lysis buffer.  
Softer microcarriers such as those generated from 12% PEGDMA are not 
compatible with Qiagen supplied lysis buffer. Hence cells are enzymatically removed 
from 12% microcarriers using Trypsin, transferred to microcentrifuge tubes and 
centrifuged at 300 x g for 5 mins, the supernatant was removed and replaced by lysis 
buffer.  
2.12.6 Analysis of cell phenotype by flow cytometry 
Flow cytometry analysis was performed in order to characterise the 
multipotency ADSCs prior to microcarrier seeding. At least 50,000 cells were harvested 
via Accutase (to preserve cell surface markers), counted and resuspended in Block 
solution (5% Goat serum in PBS) for 15 mins at RT to yield 0.5 x 10
6 
cells/mL. 
Suspensions were incubated with primary antibodies (diluted 1:200) against human: 
CD34, CD44, CD45, CD90, CD105 (all AbCam, Cambridge, UK) and CD29-FITC 
Gene name Gene Symbol Gene Aliases Locus position 
        Aggrecan ACAN AGC1, AGCAN, CSPG1, 
CSPGCP, MSK16, SEDK 
NM_001135.3 
5'-nucleotidase, 
ecto (CD73) 
NT5E CD73, E5NT, NT, NT5, 
NTE, RP11-321N4.1, eN, 
eNT 
NM_002526.3 
Beta-2-
microglobulin 
 
B2M CDABP0092 NM_004048.2 
Fatty acid binding 
protein 4, 
adipocyte 
FABP4 A-FABP, AFABP, ALBP, 
aP2 
 
 
NM_001442.2 
Regulator of cell 
cycle 
RGCC C13orf15, KIAA0564, 
MGC87338, RGC-32, 
RGC32, bA157L14.2 
NM_014059.2 
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(Chemicon, UK) at 4
o
C for 30 mins. Cells were collected via centrifugation (200 x g for 
5 mins) and then washed 3 times with PBS. Non-specific background staining was 
determined by staining cells with corresponding isotype control antibodies mouse 
IGG2A, mouse IGG1 and rabbit IGG in parallel. Bound primary antibodies were then 
detected by incubating cells with corresponding Alexa 488 conjugated anti-mouse or 
anti-rabbit secondary antibody (diluted 1:100) and incubated at 4
o
C for further 30 min. 
Cells were pelleted via centrifugation (200 x g for 5 mins) and then washed 3 times with 
PBS to remove unbound antibodies. Stained cells were then analysed using a BD FACS 
Canto instrument equipped with FACS Diva software (BD Biosciences, UK). A 
minimum of 10,000 cells were counted in each sample. All experimental data were 
analysed offline using FlowJo software (Tree Star, Inc., USA), and the mean fluorescent 
intensity for each sample was used to determine the relative expression of each of the 
CD markers. 
2.13 Histological analysis and immunostaining studies 
2.13.1 Adipogenesis 
Adipocytes on tissue culture plastic or adipogenic-microcarrier constructs were 
washed with PBS and fixed in 3.7% PFA for 1 hour at RT. The cells were then rinsed 
with distilled H2O and incubated in 60% isopropanol for 5 mins. Samples were stained 
with double-filtered Oil Red O stain for 5 mins. To prepare the staining solution, a 
saturated isopropanol-Oil Red O solution was mixed with dH2O (ratio of 3:2). Excess 
stain was removed and washed several times with distilled H2O. Alternatively 
adipogenic samples were fixed in 3.7% paraformaldehyde for 20 mins and washed with 
PBS to remove residual formaldehyde. Paraformaldehyde-fixed samples were incubated 
in LipidTOX™ Red neutral lipid stain (1:2000) for 30 mins at room temperature. In the 
final 10 mins, Reddot-1 nuclear stain (Biotium inc, California, USA) was added 
(1:200). Samples were washed three times in PBS and fluorescent cells were imaged 
using confocal microscopy. 
2.13.2 Osteogenesis 
Control cells and osteocytes were washed with PBS and ice cold 70% ethanol 
for 1 hour at RT. The ethanol was removed and washed twice for 10 mins each with 
distilled water and stained with Alizarin red solution and incubated for 30 mins. Excess 
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stain was washed with distilled H2O. Images of stained cells were taken using a 
brightfield microscope. 
2.13.3 Chondrogenesis 
Differentiation of ADSCs into chondrocytes was achieved using two distinct 
methods. The first method followed the gold standard of MSC chondrogenic 
differentiation using tissue culture plastic, whereby ADSCs are cultured at a high 
density as pellets, also known as micromass culture (outlined in section 2.8.3). 
Alternatively, ADSCs cultured on microcarriers were transferred to chondrogenic 
induction media (as outlined in section 2.10) whereby cells mass migrated from 
monolayer culture on the surface of the spheres to high density pellets (mostly 
associated to multiple microcarriers) spontaneously.    
To assess chondrogenic pellets maintained in chondrogenic medium using 
histological stains (generated from either method  2.8.3 or 2.10), the samples were fixed 
with 3.7% paraformaldehyde for 15 mins and washed three times with PBS and stained 
with 1% (w/v) alcian blue in HCl (pH 1.0)  for 30 mins at RT. Excess stain was 
removed using 0.1N HCl.  
To assess ECM production, microcarrier associated chondrogenic pellets 
(generated using method 2.10) were fixed in 10% neutral buffered Formalin overnight 
at 4
o
C and washed in PBS. The pellets were the dehydrated using cold (4
o
C) industrial 
methylated spirit (IMS) at 70% 90% 100% (v/v%) for 30 mins each, followed by two 
incubations of 100% RT IMS for 30 mins each. The samples were placed in xylene for 
30 mins and then embedded in paraffin wax for 30 mins using a Leica EG1150H 
Embedding Centre, the blocks were then placed on a Leica EG1140C cold plate to 
allow the wax to harden rapidly. Sections were cut at a thickness of 5μm using a Leica 
RM2235 rotary microtome, floated on warm water and mounted on Polysine 
microscope slides. The sections were dried overnight at 45
o
C. The slides were stained 
with Toluidine Blue to visualise glycosaminoglycan (GAG) content or heamatoxylin & 
eosin (H&E) for structural analysis. The images were photographed using a brightfield 
microscope. Immunohistochemistry was used to detect collagen type I and II, in 
chondrogenic cell-microcarriers. Sections were deparaffinised in xylene and 
permeabilised using 0.01% Tween for 5 mins each. Sections were washed in Tris-
acetate 6.5 pH for 2 mins and pre-digested for 2 hours at 37
o
C in 0.25 U/mL of 
chondroitinase A/B/C and hyaluronidase (2U/mL). The sections were subsequently 
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washed in PBS for 5 mins and blocked with 5% normal goat serum in PBS for 20 mins 
at RT. Sections were incubated overnight at 4
o
C in collagen type I and II primary 
antibodies in parallel at 11µg/mL and 10µg/mL respectively. The sections were then 
washed with PBS 3 times at 5 mins intervals. The slides were then incubated in the 
relevant FITC conjugated anti-mouse or anti-rabbit secondary antibodies (1:100 
dilutions in PBS) (Invitrogen, UK) for 1 hour at RT. After washing with PBS 3 times at 
5 mins intervals, the slides were mounted in Vectashield containing DAPI (Vector, 
UK). The images were observed using a widefield fluorescent microscope. 
2.14 Cleaning spinner flask glassware 
To remove organic matter, cell debris and protein from the spinner flasks, the 
insides were brushed using distilled water, sigmaclean and a large pipe cleaner and then 
rinsed. Flasks were filled with 1M NaOH solution at RT for 2 hours before being rinsed 
with distilled water. The spinner flask was then filled with 1M phosphoric acid, rinsed 
with distilled water and dried in a 90
o
C oven for 1 hour.  Spinner flasks were then 
treated with Sigmacote to siliconise the glassware (and reduce cell binding to the glass 
surface), air dried and rinsed several times with distilled water. The flasks were then 
dried at 90
o
C for 30 mins before being sterilised in an autoclave at 121
o
C for 15 mins. 
Clean sterile flasks were subsequently dried in a 90
o
C oven for 1 hour prior to use.  
2.15 ADSC expansion in spinner flasks 
Approximately 12,300 microcarriers containing 1mM cRGDfC were generated 
in one microfluidic 60 minute run, washed to remove all oil and placed in spinner flasks 
containing 30mL of  DMEM (low glucose) (containing Glutamax supplemented with 
10% Mesenchymal stem cell qualified FBS, 75 µg/mL Gentamicin and 37.5 ng/mL 
Amphotericin), and incubated at 37°C, 5% CO2 for 8 hours to equilibrate the 
microcarriers.  
2.15.1 Seeding experiment 1 
500,000 ADSCs were seeded into the spinner flasks and cultured under 
intermittent stirring (18-21rpm 1 min every 45 mins) for 7 days. After 24 hours the 
medium was increased to 100mL.  Partial media changes (50%) were performed every 
three days. Samples were removed daily for microscopic and viability analysis. After 7 
days the microcarriers were removed and either transferred to ultra low attachment 
 64 
 
wells containing differentiation media or processed for RNA extraction. Microcarriers 
containing differentiated cells were analysed using lineage specific histochemical stains. 
2.15.2 Seeding experiment 2 
Approximately 215,000, 114,000, 38,000 or 12,000 ADSCs (counted using the 
dye exclusion method described in section 2.7.4) were seeded into spinner flasks and 
cultured under intermittent stirring (60rpm 1 min every 45 mins) for 14 days. After 24 
hours the medium was increased to 100mL.  Partial media changes (50%) were 
performed every two days. Samples were removed daily for microscopic and viability 
analysis. After 7 days the microcarriers were removed, washed twice in PBS and either 
transferred to ultra low attachment wells containing differentiation media or processed 
for RNA extraction. Microcarriers containing differentiated cells were analysed using 
lineage specific histochemical stains.  
After 14 days all cells were enzymatically removed from the microcarriers (as 
described in Section 2.16). The number of viable cells was counted (as described in 
Section 2.17), and the specific growth rate and the doubling time of the MSCs can be 
calculated, using the following equations: 
                      
             
  
 
 
Where Xf = final cell density, Xi = initial cell density.  
   
   
 
 
Where td represents the generation time (h) and μ is the specific growth rate (h−1). 
2.16 Enzymatic detachment of cells from microcarriers 
The culture medium was partially removed (~85%) and microcarriers rinsed 
twice with pre-warmed PBS. Attached cells were removed by adding TrypLE express 
(500µL) to each well. Cells were incubated for 5 mins at 37
o
C to allow detachment of 
cells into a single-cell suspension. After incubation, enzymatic action was terminated 
through the addition of serum-containing medium (3mL). The total supernatant was 
removed and centrifuged at 220 x g for 5 mins. The cell pellet was resuspended in 1mL 
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of complete medium by gentle pipetting to dissociate any cell clumps. Cell viability was 
determined using the exclusion dye method (Section 2.4.6).  
2.17 Measurement of anti Il-8 using ELISA  
A 96-well plate (Corning) was coated with a goat anti-human IgG-Fc polyclonal 
antibody (100 μL/well, 10 μg/mL; Bethyl Laboratories) in 0.1 M sodium hydrogen 
carbonate buffer. After overnight incubation at room temperature, the plate was washed 
three times with phosphate-buffered saline (PBS) containing 0.05% (v/v) Tween 20 
(PBS-T). Unbound active sites were blocked with 300 μL of 1% (v/v) bovine serum 
albumin (BSA)/PBS per well for 1 h. The plate was washed with PBS-T and reference 
samples of human IGG or supernatant samples were taken from CHO cell laden 
microcarrier cultures were added to the plate. The plate was incubated for 2 h at room 
temperature. After being washed in PBS-T washing solution, the plates were incubated 
at room temperature for 1 h with 100 μL of horseradish peroxidase-conjugated goat 
anti-human IgG-Fc polyclonal antibody solution (1 μg/ mL; Bethyl Laboratories) in 1% 
(v/v) BSA/PBS. Following washing of the plates in PBS-T washing solution three 
times, 100 μL of 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) or ABTS 
(Thermo Scientific Ltd., High Wycombe, UK). The samples were transferred to a new 
plate and absorbance was measured at 405 nm using a microplate reader (Fluostar 
optima, BMG optima, Germany). 
 
 
 
 
 
 
 
 
 
 
 
3.0 Generating a microfluidic 
platform for the synthesis of 
microspheres with tunable 
properties 
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3.1 Introduction  
In vivo, cells integrate physical and biochemical cues from the surrounding 
environment and ECM. This is a complex process whereby each cell receives a unique 
combination of external stimuli, which synergistically defines a variety of cellular 
processes including cell morphology, cytoskeletal organization, differentiation and gene 
regulatory pathways (256). Classified into three broad areas; cells recognise and receive 
input from mechanical, chemical and topographical stimuli (177-179).  
The versatility in PEG chemistry and the biocompatibility of synthetic 
PEGDMA hydrogels have prompted the development of hydrogel systems for directing 
cellular functions and regenerative medicine applications (305). PEGDMA hydrogels 
can be readily processed using UV photo-polymerisation and are of particular interest as 
they provide a bio-inert platform which can be used to systematically investigate the 
effects of mechanical and chemical factors on cellular processes (240). PEG hydrogels 
can be modified to incorporate covalent coupling of  functional groups, such as bio-
adhesive peptides, and to generate relatively stable gel structures with tunable 
mechanical properties such as swelling ratio, permeability and elasticity (306).  
The primary objective of this chapter was to establish a novel microfluidics-
based platform for the production of synthetic microcarriers. A microfluidic method for 
the synthesis of highly monodisperse PEGDMA hydrogel microspheres was developed 
herein using continuous droplet formation and in situ UV photo-polymerisation. The 
production method developed can be tuned to generate PEGDMA microspheres with a 
wide range of target diameters, and hence surface topographies, each with an extremely 
narrow size distribution (299).  
A key factor in the development of normal cellular structure and function is the 
signal(s) received though chemical interactions at the cell surface. In vivo, interactions 
between integrin receptors on the surface of mammalian cells and ligands present within 
the extracellular matrix (ECM) regulate a diverse range of cellular functions, including 
adhesion, growth, differentiation, and motility (307). PEGDMA has previously been co-
polymerised with functional motifs, such as ECM-derived cell adhesive peptides, to 
interact with cells and to render the otherwise inert PEG hydrogels bioactive (308). 
Modification of PEG hydrogels to include specific peptide sequences can be achieved 
through several different methods. This chapter describes the incorporation of ECM-
derived peptides into PEGDMA microspheres using two methods: a) By covalently 
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linking peptides to a monoacrylated PEG monomer through an N-hydroxysuccinimidyl 
group (309) b) By directly reacting cysteine-containing peptide sequences into 
hydrogels through Michael-type addition (240).  
When developing biomaterials, scaffolds should provide mechanical support for 
cells as well as transmit mechanical stimuli (310). To probe the mechanical properties 
that can influence cell fate, a variety of PEGDMA hydrogel microspheres with a wide 
range of mechanical properties, including compressive modulus and mesh size, were 
generated and characterised. Surface topography was assessed using environmental 
scanning electron microscopy (ESEM).   
The objective was to design and optimise a robust microfluidic method to 
synthesise monodisperse microspheres reproducibly, capable of presenting ECM-like 
stimuli to adhered cells. The optimisation of polymer content generated a range of 
microcarriers with different sizes, synthetic peptide modifications and compressive 
moduli. Presenting these factors in a spatially defined and controlled manner, the 
bioinert PEGDMA hydrogel microspheres developed herein provide a platform 
whereby chemical, mechanical and topographical parameters can be individually 
assessed based on cell responses.  
3.2 Emulsion formation in Microfluidic devices 
Microfabricated devices consist of microchannels arranged in specific, user-
defined geometries to exploit specific microfluidic phenomena. Such arrangements are 
termed fluidic circuits. The most commonly used microfabrication method to generate 
fluidic circuits is soft lithography of polydimethylsiloxane (PDMS) due, in part, to its 
relatively low cost and standardized technique. Typically, such devices are permanently 
sealed, with external connections through which fluids are introduced.  
For this study, a novel microfluidics-based device, termed MicroPlant
TM
, was 
used. The system developed by Q Chip (Cardiff, UK), was designed to enable rapid 
evaluation of microfluidic circuits and junctions. To produce fluidic circuits in PDMS is 
laborious and requires a minimum of 8 hours (311). The system developed by Q Chip 
employs a single milling operation to produce microchannels, which is much quicker 
and easier, (typically circuits can be produced within 60 minutes). Therefore, using the 
MicroPlant
TM
 allowed ideas to be rapidly converted to testable circuits. In addition, 
design iterations to the fluidic circuit were quick and easy to investigate.  
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Unlike traditionally fabricated microfluidic devices, MicroPlants
TM
 are not 
permanently sealed. This allows the device to be assembled and disassembled rapidly. 
In addition, any blockage of channels (which can occur rapidly after commencement of 
an experiment) can be easily rectified. This is particularly useful in cases of accidental 
experimental failure (e.g., channel blockage due to unwanted polymer cross-linking), 
allowing rapid recovery during testing and optimisation of conditions, which would be 
impossible in permanently sealed devices.  
Microfluidic circuits are machined into hydrophobic and rigid 
polytetrafluoroethylene (PTFE) discs ‘chips’. Fluidic circuits consist of microchannels, 
which are rectangular in cross-section. A computer Numerical Controlled (CNC) 
milling machine is used to create the microchannels in the PTFE surface. 
Microchannels, by definition, must be less than 1mm in at least one dimension, and can 
be made any size, to a minimum of 100µm, which represents the limit of the 
micromilling method. 
The finished PTFE chip containing the desired milled microfluidic circuit is 
placed onto a 316 stainless steel fluid distribution manifold, into which high 
performance liquid chromatography fluid connectors are introduced vertically. To 
provide a top surface to the fluidic channel, a hydrophobic gasket (PFA film, 250µm 
thick) is placed onto the surface of the chip. In addition, a transparent borosilicate disc 
is placed over the chip (and gasket), thus allowing observation of fluid flows in 
microchannels. Disposable sterile syringes containing the required fluids are connected 
to the base of the microfluidic device via narrow bore tubing. Fluids (pumped using 
syringe drivers) enter the fluid distribution manifold via vertical through-holes (sealed 
with nitrile rubber O-rings) and flow to the top of a chip into the microchannels through 
entry holes. Finally, a stainless steel clamping piece is bolted to the fluidic manifold, 
allowing the entire laminated assembly to be compression sealed. The device is 
illustrated schematically in Figure 9. 
To form droplets (and therefore a linear emulsion) in a microfluidic circuit, the 
inherent physical properties of immiscible liquids are exploited. In a microfluidic 
circuit, a linear microemulsion can be formed when immiscible fluids flow together into 
a microfluidic junction. The simplest of these is the T-junction, illustrated in Figure 7A. 
Fluid flowing in one channel is sheared by a second immiscible phase, flowing into the 
cross-channel (312). Co-flowing streams can be used to generate emulsions, these can 
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take the form of cross-junctions and flow focusing junctions (Figure 7B and C (313)).  
Conventionally, when forming an emulsion the fluid which forms droplets is termed the 
disperse phase (Fluid α in Figure 7), and the immiscible fluid is termed the continuous 
phase (Fluid β in Figure 7).  
Figure 7 Schematic representation of microfluidic junctions. 
Emulsion formation at (A) T-junction, (B) Cross-junction or (C) Flow focusing junction 
 
Channel properties, such as contact angle, surface energy and hydrophobicity, 
influence the ability of a given liquid to form droplets. Aqueous PEGDMA solutions are 
repelled from the hydrophobic PTFE chip surface used in the MicroPlant
TM
. A fluid 
which is immiscible with an aqueous PEGDMA solution is required to form a linear 
emulsion. The nature of a linear emulsion is dependent on the surface tensions (and 
interfacial tension) of the component fluids, as well as the energies of the microchannel 
surfaces. The particular characteristics of a linear emulsion, e.g. droplet size, size 
variance, and droplet production frequency are strongly dependent upon fluid flow rate 
and microchannel architecture. As the interfacial surface tension is constant for a given 
pair of fluids at a given temperature, variations in relative flow rates are used to produce 
different flow patterns. 
At slow fluid flow rates, plug formation occurs, rather than spherical droplet 
formation (Figure 8B). A plug is defined as a droplet large enough to fill the cross-
sectional of a channel (in addition to a thin layer of continuous phase, preventing it from 
contacting the channel walls) with its length in the direction of fluid flow greater than 
its width (314). Upon passing into a channel with a greater cross-sectional area, liquid 
plugs form spheres due to the surface tension forces. 
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By increasing the continuous fluid flow rate, droplet formation is favoured 
(Figure 8A). The dispersed phase is forced to break into droplets by the increased 
pressure and viscous forces exerted by the continuous phase. However, if the 
continuous phase flow rate is increased further, the disperse phase is pulled into a stable 
neck formation with droplets pinched off near the tip (Figure 8C). In this flow pattern, 
although droplets are very small, (much smaller than the channel diameter), satellite 
droplets are often produced leading to a large observed droplet polydispersity (315). In 
all experiments, flow rates were empirically determined to bring about stable 
segmentation, as opposed to plug or unstable droplet formation. 
Previously the MicroPlant has been employed to generated polymeric 
microspheres for small peptide therapeutics and PCR reagents. In addition, it has been 
used to encapsulate dopamine expressing cells.  
 
Figure 8 Flow patterns produced in a microfluidic cross-junction. 
(A) Droplet formation, (B) Plug formation and (C) stable neck formation. 
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Figure 9 The microfluidic evaluation platform (MicroPlant
TM
) used in microfluidic experiments. 
Expanded schematic showing the components of the microfluidic device. The MicroPlant assembly 
consists of a circular 316 stainless steel base containing several fluid entry points.. 
  
PTFE Disc 
PFA Gasket 
Glass Disc 
Manifold Base 
Manifold Clamping 
piece 
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3.3 Results 
3.4 Generation of Monodisperse PEGDMA Microspheres in a 
MicroPlant. 
The MicroPlant, (depicted in Figure 9) was used to synthesise PEGDMA 
hydrogel microspheres (both unmodified and peptide-containing).  A continuous phase 
(high-oleic acid sunflower oil; Statfold seed oils, UK) was brought into contact with a 
dispersed phase, (an aqueous solution of PEGDMA macromer, photoinitator (and 
peptide conjugate where applicable)), at a T-junction.  These immiscible phases formed 
a linear emulsion at the microfluidic junction by a process called segmented flow. The 
dispersed phase droplet size could be controlled by varying the relative flow rates of the 
two immiscible fluids. By increasing the flow rate of the continuous phase, 
segmentation can occur more rapidly, producing droplets more frequently. If the 
discontinuous polymer rate remains the same at the inlet, increasing the continuous 
phase will have an inversely proportional effect on microsphere size. In order to 
produce discrete droplets of approximately 500µm diameter, PTFE chip design, and 
fluid flow rates were tested and optimised. UV-induced photo-polymerisation was used 
to irreversibly crosslink the PEGDMA containing dispersed phase droplets, producing 
solid PEGDMA hydrogel microspheres.  
3.5 PTFE Chip design 
In an effort to produce UV photopolymerised PEGDMA microcarriers of 
approximately 500µm diameter, PTFE chips containing several different microchannel 
designs and junctions were fabricated and tested. 
3.5.1 Chip 100073A 
Initially, a smaller evaluation MicroPlant (a miniaturised version of the 
MicroPlant described in section 3.1), was employed to trial dispersed phase 
segmentation and determine the ultimate method that would be used to produce the 
spheres. Using chip 100073A (labeled according to an internal referencing system), the 
polymer was segmented at a flow-focusing junction by two equivalent inputs of 
immiscible continuous phase (Figure 10) (288). The polymer droplets generated 
continued into the microchannel spiral (the ‘UV curing zone’), designed to increase the 
time the droplets were retained within the chip, increasing UV exposure and hence 
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photo-polymerisation time. Chip 100073A provided valuable information regarding in 
situ curing rates and optimum channel sizes to produce microspheres of 500µm 
diameter. However, improvement was required on two points. Firstly, the top mounted 
UV light source illuminated the entire surface of the chip, including the whole 
microchannel circuit, crosslinking the polymer at the fluidic junction prior to 
segmentation. Future designs would require the polymer entry point to be shielded from 
UV light. Secondly, the microchannel, and hence, ‘on-chip’ retention time was too short 
to allow complete photo-polymerisation of polymer droplets. Again, subsequent designs 
featured longer channels for increased residual exposure. Experimental data gathered 
from the evaluation MicroPlant, elucidated suitable channel dimensions and these 
remained consistent in all channel designs hereafter. The fluidic input channels were of 
cross-sectional dimension 500μm2, opening out to 700μm2 into a spiral UV-curing zone.    
 
 
Figure 10 PTFE chip 10073A. 
An evaluation chip, the polymer is segmented at a flow-focussing junction by two immiscible carrier 
flows. Carrier fluid entry points are indicated by green arrows. Functional fluid (polymer) entry holes are 
indicated by black arrows.  Red arrows indicate points anchored to the manifold. Fluid exit holes are 
indicated by a purple arrow.  A dark blue arrow indicates the spiral UV curing zone, designed to increase 
UV retention time. 
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Figure 11 Size comparisons of evaluation and full size PTFE chip designs. 
Diameters: 1 penny = 12mm, evaluation MicroPlant chip = 50mm, and MicroPlant chip = 100mm. 
3.5.2 Chip 100660A 
In order to allow the microchannel to be lengthened and increase on-chip 
retention time, all subsequent chips were designed for use on the larger MicroPlant, 
which holds significantly larger chips than those on the evaluation MicroPlant (for a 
comparison of chip sizes see Figure 11). The junction used to segment the dispersed 
phase was changed from a flow-focusing junction to a T junction in Chip no. 100660A 
(Figure 12) by introducing the dispersed phase into the microchannel using a vertical 
though-hole (as described in section 3.2) (Figure 13). The polymer solution was 
segmented immediately as it entered the channel, and using a mask, the entry hole was 
shielded from UV exposure. Post-polymerisation, extra fluid channels were added, 
providing the potential to add further reagents to the microspheres post-curing. 
However, it was observed that this chip was suboptimal as the UV curing zone 
contained a tight exit from the spiral, which caused microspheres to slow down. This 
allowed partially photo-polymerised polymer droplets to contact one another forming 
large hydrogel aggregates (as shown in Figure 14), or alternatively deposit partially 
crosslinked polymer residue on the microchannel walls, both of which resulted in the 
channel becoming blocked. 
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Figure 12 PTFE chip 100660A 
A full sized chip, the flow-focussing junction has been replaced by a vertical junction to prevent 
polymerization prior to segmentation. Carrier fluid entry points are indicated by green arrows. Functional 
fluid (polymer) entry holes are indicated by black arrows. Red arrows indicate points anchored to the 
manifold. Fluid exit holes are indicated by a purple arrow. A dark blue arrow indicates the spiral UV 
curing zone, designed to increase UV retention time. 
 
 
 
 
Figure 13 Cartoon schematic of a microchannel and droplet formation at a T-Junction.  
A) The PTFE microchannel consisted of a continuous phase input (red arrow) followed by disperse phase 
inlet at a T-junction (blue arrow). The fluidic input channels were of cross-sectional dimension 500μm2, 
opening out to 700μm2 into a spiral UV-curing zone.  B) The continuous phase represented by a pink 
arrow was brought into contact perpendicularly with the PEGDMA solution (shown here in blue), at a 
fluidic T-junction to produce a segmented flow stream.  
 
A B
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Figure 14 Covalently cross linked microspheres 
The microspheres in this image have contacted one another prior to complete polymerisation. The result 
is the microspheres attach to form a solidified ‘string’ of beads. 
3.5.3 Chip 100670A 
Chip 100670A (Figure 15) was engineered to contain the same T junction as 
chip 100660A, however the length of the curing zone was further increased. The 
microchannel was designed to allow the spheres to exit the surface of the chip from the 
center of the spiral to overcome the tight turn used in 100660A. Previously, the 
microspheres had to travel through a small piece of PTFE tubing, (approximately 3cm 
in length) before falling into a collection vessel. This caused back pressure in the 
channel as the spheres tended to stall before the exiting the chip. To increase the 
efficiency with which the polymerised microspheres exited the MicroPlant, a section of 
the steel manifold (below the exit junction on the PTFE chip) was milled out. However, 
the exit hole was preceded by a tight turn in the microchannel spiral, which also resulted 
in the channel becoming blocked. 
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Figure 15 PTFE chip 100670A 
The curing zone has been enlarged for longer UV exposure. Carrier fluid entry points are indicated by 
green arrows. Functional fluid (polymer) entry holes are indicated by black arrows. Red arrows indicate 
points anchored to the manifold. Fluid exit holes are indicated by a purple arrow. A dark blue arrow 
indicates the spiral UV curing zone, designed to increase UV retention time. 
 
3.5.4 Design and Manufacture of a UV light-guide holder 
To produce microspheres with reproducible, monodisperse characteristics 
including chemical crosslinking, uniform UV exposure was required during in situ 
photo-polymerisation. Previously, the positioning of both the MicroPlant and UV light-
guide was implemented using a clamp stand. The distance, angle and position of the UV 
light-guide relative to the surface of the PTFE microchannels introduced several 
variables into microsphere production. Most importantly, it was difficult to reproduce 
both the distance of the UV light source in relation to the chip, and to illuminate the 
entire curing zone equally. Hence, amendments to the steel manifold were designed and 
implemented with the assistance from engineers at Q Chip. Firstly, the manifold base 
was adapted to include a permanent stage. Three metal supports of 15cm length were 
inserted into the manifold base to form a tripod stand. 
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Figure 16 AutoCad-2008 generated blueprint of UV light-guide holder, designed to fit a 316 
manifold. 
(A) Cross sectional view: The UV light-guide is held in place by a stepped section with two nylon screw 
entry holes to hold the light-guide in place. The cone portion has been designed to have a curvature of 
72°, matching the angle of incidence of the UV light source. (B) An overview, the ‘hat’ contains a hole in 
the steel cone to allow visualization of microspheres in situ. 
Secondly, a UV light-guide holder was designed to provide an optimal 
illumination height for polymer curing. As shown in Figure 16, the UV light-guide 
could be placed into the custom designed steel unit and held in place by nylon screws. 
The light-guide holder was designed to fit on top of the assembled MicroPlant. This 
enabled control over the distance between the UV source and the chip, and uniform chip 
illumination. This also ensured the entire surface of the chip was illuminated, and 
created an enclosed system, thus providing a shield between the UV light and the user 
during microcarrier production. The light-guide holder was designed to have an 
incidence angle at 72
o
 degrees matching the angle of incidence of the UV light source. 
To aid in quality control during microsphere production, a hole was milled into the 
holder to allow the visualization of microsphere production. The final MicroPlant 
assembly is shown in Figure 17.  
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Figure 17 Photograph of the final assembled MicroPlant after modifications 
Experimental assembly comprising two syringe drivers pumping fluid into the MicroPlant though narrow 
bore capillary tubing. 
3.5.5 Chip 100718A 
The final chip layout, 100718A (Figure 15), was designed and produced after 
the UV light-guide holder was engineered (Section 3.5). Consequently, the UV curing 
zone was centralised on the chip to achieve even and maximum exposure to the UV 
source. From experimental data, the time taken for complete photo-polymerisation to 
occur was determined to be 180 seconds and the total length of the microchannel was 
shortened accordingly. In addition, the tight turn prior to the exit hole found in chip 
100670A was removed to increase the stability and ease of microsphere exit from the 
microchannel. The size distribution of the microspheres, along with their coefficient of 
variance were calculated from measured values from product microspheres ( 
 
Figure 20). Using chip 100718A, monodisperse microspheres with a diameter of 
approximately 461µm were manufactured reproducibly. The evolution of microchannel 
designs are summarised in Figure 19. 
Syringe 
Driver
‘Top Hat’
Polymer 
filled 
syringe 
Oil filled 
syringe 
UV light 
guide
Microsphere 
collection
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Figure 18 PTFE chip 100718A 
The final chip design, the curing zone was centralised and the sharp bend near the exit has been removed. 
Carrier fluid entry points are indicated by green arrows. Functional fluid (polymer) entry holes are 
indicated by black arrows. Red arrows indicate points anchored to the manifold. Fluid exit holes are 
indicated by a purple arrow.  A dark blue arrow indicates the spiral UV curing zone, designed to increase 
UV retention time. 
3.5.6 Chips 101019A and 101020A 
To produce alternatively sized microspheres Chips 101019A and 101020A were 
designed and tested. The microchannel layout remained identical to 100718A, however 
the dimensions of the channel and the entry and exit holes were increased and decreased 
accordingly, and resulted in microcarriers with an average diameter of 261.3µm and 
950.7µm. Frequency distribution graphs of the resulting microspheres are shown in  
 
Figure 20. 
101019A 101020A 
300µm Continuous phase entry hole 700µm Continuous phase entry hole 
100µm Dispersed phase through hole 350µm Dispersed phase through hole 
300µm channel opening to 500um 1000µm channel opening to 1300µm 
700µm exit hole 1300µm exit hole 
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Figure 19 Evolution of microchannel design. 
Multiple channel designs were generated, milled and tested. Carrier fluid entry points are indicated by 
green arrows. Functional fluid (polymer) entry holes are indicated by black arrows. Red arrows indicate 
points anchored to the manifold. Fluid exit holes are indicated by a purple arrow.  A dark blue arrow 
indicates the spiral UV curing zone, designed to increase UV retention time. (Scale bar 300µm)  
  
Chip design
Example of 
resulting 
microspheres
Key alterations to chip design
No microspheres 
produced
• Evaluation MicroPlant (50mm chips)
• Polymer cured prior to segmentation 
(at green asterisk) due to top mounted 
UV illumination source
• UV curing spiral (indicated by blue 
arrow) too short (and hence ‘on chip’ 
retention time) for complete 
polymerisation
• Larger MicroPlant (100mm chips) 
employed to allow a larger UV curing 
spiral and longer ‘on chip’ retention 
times.
• The segmentation junction (black 
arrow) was changed to a T Junction and 
shielded using a mask.
• Spiral design contained a tight turn 
causing microcarriers to contact one 
another co-polymerising prior to exiting 
the chip.
• The exit hole (indicated by the purple 
arrow) was moved to the centre of the 
spiral.
• The length of the curing zone was 
increased to allow complete 
polymerisation prior to exiting the chip
• A tight turn at the end of the spiral 
resulted in spheres blocking the channel 
and co-polymerising 
• The tight turn prior to he exit hole was 
removed to allow for fully polymerised 
discrete microcarrier to be consistently 
produced.
• UV curing zone centralised to allow for 
even UV exposure.
*
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Figure 20 Size distribution of generated microcarriers 
(A)Frequency distribution graph displaying the mean microsphere diameter of microfluidic generated 
microspheres was 261.3µm, 460.6µm and 950.7µm with a CV of 2.91%, 2.86% and 2.00% respectively 
(n = 40). (B) Compound light microscope image of solid PEGDMA microspheres demonstrating uniform 
size and shape.  
3.5.7 Chip 100962A 
To study hydrogel compressibility and to assess cell attachment after various peptide 
modifications, flat PEGDMA hydrogels discs with a depth of 500µm were required. 
Chip 100962A was generated to contain a large uniform chamber with a depth of 
500µm, containing fluid entry and exit holes (Figure 21). Polymer solutions were 
manually syringe driven into the chip cavity and exposed to UV for 180 seconds. The 
MicroPlant was then disassembled and the flat gel slab removed and using a circular 
cutter, (diameter 8mm) hydrogel discs were generated.  
 
Figure 21 PTFE Chip 100962A 
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A large uniform chamber allows the production of flat PEGDMA gels of 500µm depth. 
3.6 Optimised Flow rates Table and MicroPlant Assembly 
To produce stable segmented flow within the microchannels, the flow rates of 
the polymer and continuous phases required optimisation and fine-tuning. A main 
obstacle to successful microsphere production was caused by partially polymerised 
microspheres contacting each other in the microchannel during long ‘on-chip’ retention 
times, particularly in the UV curing zone. Ideally the microspheres should remain 
separate until they have exited the MicroPlant. If contact occurred prior to complete 
photo-polymerisation, the microcarriers could become crosslinked to one another 
resulting in semi-polymerised multimers of beads, which typically block flow within the 
channel (Figure 14). To prevent this, the continuous phase fluid flow-rate was increased 
to enlarge the spacing between polymer droplets, helping to maintain discrete structures 
until fully solidified. 
3.7 Incorporation of cell adhesive peptides using an Acryloyl-PEG-
NHS linker. 
Calculating the efficiency of the conjugation reaction was essential to determine 
the final concentration of peptide incorporated into the microsphere. The well 
characterised fibronectin-derived peptide sequence, GRGDS was selected for 
incorporation into PEGDMA microspheres. Previous research has demonstrated that 
GRGDS enhances cell binding and proliferation of multiple cell types to PEG hydrogels  
(316, 317). To incorporate the adhesive peptide GRGDS into PEGDMA hydrogel 
microspheres, peptides were first conjugated to a monoacrylated PEG macromer with a 
carboxylic end group activated by N-hydroxysuccinimide (NHS) to give acryloyl-PEG-
NHS. GRGDS was conjugated to PEG via the reaction between N-hydroxysuccinimide 
and primary amines within the peptide, forming acryloyl-PEG-GRGDS (as shown in 
Figure 22). The success of this conjugation was assessed by Electrospray mass 
spectrometry and MALDI ToF ToF mass spectrometry.   
 
Figure 22 Incorporation of cell adhesive peptides using an Acryloyl-PEG-NHS linker. 
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3.8 Electrospray Mass Spectroscopy of Acryl-PEG-peptide 
Conjugates 
The molecular weight of the acryloyl-PEG-NHS was measured before and after 
the conjugation reaction.  The molecular mass of the precursor molecule, Acryloyl-
PEG-NHS was 3711gmol
-1
. After cleavage of the NHS moiety and incorporation of 
GRGDS peptide (490.06gmol
-1
), the expected molecular weight of the polymer-peptide 
conjugate was 4084gmol
-1
 (Figure 23).  
Electrospray Mass spectrometry (ESI) was employed to assess the yield of 
acryloyl-PEG-GRGDS produced from the above conjugation reaction. Initially the 
compatibility of ESI to analyse Acryloyl-PEG-NHS was assessed. The resulting spectra 
generated an array of signals (Figure 23), but did not provide defined peaks. The 
technique demonstrated the poly-dispersity of the repeating PEG units, which contains 
an average molecular mass of 3400. A lack of separate peaks confirmed that ESI was 
not suitable to analyse the conjugation reaction as it is not possible to track a single 
mass/charge ratio shift effectively.  
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Figure 23 Spectrum of Acryl-PEG-NHS generated using Mass Spectrometry 
A) Full scan showing a cluster of peaks with a large range of mass/charge ratios (m/z). (B) Sub section of 
full scan of Acryl-PEG-NHS around the mean. 
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3.9  MALDI ToF ToF Analysis of GRGDS Peptide Conjugate. 
To analyse the conjugate Acryloyl-PEG-GRGDS, MALDI ToF ToF was performed.  As 
shown in Figure 26, the detected mass of the reaction product was shifted by 
approximately 382±3Da (relative to starting material), corresponding to the molecular 
mass of the peptide gained after successful conjugation. Both the starting material and 
product MALDI ToF ToF mass spectra showed complex multiplets with a repeating 
Mw difference of 44Da, which corresponded to repeating ethylene glycol units. Several 
optimisation steps were required to successfully form and detect Acryloyl-PEG-
GRGDS, detailed below. 
First attempts at MALDI ToF ToF analysis aimed to determine whether a clear 
spectrum could be obtained from the PEG sample. Using sinapic acid as a matrix, this 
could not be achieved. However the sample was compatible with the α-cyano-4-
hydroxycinnamic acid matrix (Figure 24A). The maximum peak at 3720.98gmol
-1
 
corresponds to the average size of the acryloyl-PEG-NHS macromer.  
The conjugated samples were analysed following a method outlined by Hern and 
Hubbell (300). In Figure 24C, the green spectrum represents the control sample, 
Acryloyl-PEG-NHS. Overlaid onto this spectrum is the conjugate sample, prepared by 
reacting the control sample with GRGDS peptide in a 1:1 ratio (Section 2.6.4 Method 
1). The spectrum showed the conjugate contained a slight shift in mass/charge ratio. 
However, the shift was not consistent with the calculated shift in mass/charge ratio 
expected after the addition of peptide (4408.87Da). Figure 24B shows that despite 
dialysis, a large amount of unreacted peptide remained in the sample, shown by a large 
red peak at the left hand side of the spectrum. 
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Figure 24 MALDI ToF ToF Spectra of Acryloyl-PEG-(3500)-NHS 
(A) Demonstrating a classic polydisperse PEG spectra. All peaks indicate the intensity of each sample 
mass and are labeled with their mass/charge ratio and signal intensity. MALDI ToF ToF spectrum of 
Acryloyl-PEG-NHS (green), overlaid with the ‘conjugate’ sample (red). (B) The spectra shows a large 
red peak at a low mass/charge ratio. This is partly attributed to the presence of unreacted peptide in the 
sample. (C) A subsection of the spectra displayed in Figure 20B demonstrating the closely overlapping 
peaks which indicates a lack of peptide conjugation. 
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It was hypothesised that the rate of reaction would increase under higher pH 
conditions. A series of controlled reactions varying both the stochiometric ratio of 
peptide to Acryloyl-PEG-NHS, and the pH of reaction was performed (Section 2.6.4 
Method 2). An array of basic pH conditions was employed, however, the TRIS buffer 
used was incompatible with the α-cyano-4-hydroxycinnamic acid matrix causing an 
intractable yellow by-product to form and degrading the treated matrix. Subsequently, 
the signal intensity was low due to poor loading of the sample onto the plate reader. 
Higher concentrations of Acryloyl-PEG-peptide resulted in a gel being formed upon 
drying which proved incompatible with the MALDI ToF ToF technique, as the laser 
required a flat surface to take an accurate mass measurement. The samples were further 
dialysed at a 1KDa MWCO to remove excess TRIS salts. However this shown to be 
insufficient to remove the entire TRIS base, which was still present in relatively high 
quantities at higher pH conditions. Consequently, only data for reactions performed at 
pH 7.5 were recorded. The data gathered at pH 7.5 are shown in Figure 25. The spectra 
for both the control and experimental samples (at pH 7.5) (both 1:1 and 1:1.5 ratios) 
were found to be identical.  However, the spectrum produced at a PEG to peptide ratio 
of 1:2, showed additional peaks. The conjugate showed two overlapping peaks, one that 
corresponded to the MW of the control, Acryloyl-PEG-NHS, and one that corresponded 
to the calculated molecular mass shift expected for the conjugate Acryloyl-PEG-
GRGDS. However, this technique failed to provide a quantitative measure of 
conjugation; therefore it was not possible to determine what percentage of the sample 
contained the successfully conjugated peptide. 
The final experiment, outlined by Bencherif et al. 2009, and as used here, 
included dihydrobenzoic acid (DHB) as the matrix (301). This provided a conjugate 
spectrum that had a clear mass shift in relation to the control sample. The molecular 
mass of the precursor molecule, Acryloyl-PEG-NHS is 3711gmol-1. The reaction 
occurs via substitution of the NHS moiety, which is replaced by a peptide GRDGS of 
490.07 gmol-1 resulting in a molecular mass shift of 4084 (±13gmol
-
1) (Figure 26). 
Overlapping graphs of the control and experimental samples showed a clear shift in the 
entirety of the spectrum corresponding to and centered around the molecular mass of the 
conjugate, this was unseen in previous experiments (Figure 24, Figure 25).    
 90 
 
 
Figure 25 MALDI ToF ToF spectra for samples reacted at pH 7.5. 
(A) The spectra shows a characteristic pattern equivalent to the range of masses found in Acryl-PEG-
NHS. The  highest peak intensity matches the average molecular mass of Acryloyl-PEG-NHS stated of 
approximately 3711. (B) Acryloyl-PEG-GRGDS conjugate (Section 2.6.4 Method 2). Close inspection 
reveals two conjugate peaks, one that corresponds to the MW of Acryl-PEG-NHS, and the other to the 
MW of the conjugate. 
 
Figure 26 Comparison of Acryloyl-PEG-NHS and Acryloyl-PEG-GRGDS MALDI-ToF spectra. 
Acryloyl-PEG-NHS spectrum (average MW 3711gmol-1(*)) prior to conjugation is shown in red. 
Acryloyl-PEG-GRGDS (average MW 4084gmol-1(**)) spectrum has shifted post-conjugation, shown in 
green, indicating successful conjugation of GRGDS.    
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3.10 Confocal Analysis of Peptide Distribution 
Confocal microscopy was employed to visualise the presence of biotinylated 
peptide residues on the surface of PEGDMA hydrogel microspheres. PEGDMA 
microspheres were bulk modified to contain a biotinylated peptide (throughout the 
sphere volume) using acryloyl-PEG-RGDS-6-aminohexanoate linker (LC) – biotin, 
(formed through the conjugation of diamine-RGDS-6-aminohexanoate linker (LC) – 
biotin with acryloyl-PEG-NHS) (custom synthesised by Peptide Synthetics UK). After 
extensive washing steps, the resulting microspheres were treated with fluorescently  
labeled (HyLyte Fluor) Streptavidin and the level of incorporation was assessed using 
confocal microcopy.  
Streptavidin is capable of diffusing non-specifically into PEGDMA hydrogel 
microspheres, hindering analysis by generating false positive results in control and 
peptide modified microspheres. Therefore, the staining method was optimised to 
minimise the exposure of streptavidin to the microspheres (detailed in Section 2.6.5. 
After streptavidin treatment, the microspheres were washed extensively to remove 
unbound streptavidin. Biotin was conjugated to the matrix throughout the microsphere. 
However, due to the method in which microspheres were exposed to streptavidin, 
positive staining (indicating the presence of biotinylated peptide) was detected at the 
microsphere surface only.  Figure 27B depicts the presence of biotinylated peptide at the 
microsphere surface following streptavidin treatment and was compared to PEGDMA 
microspheres without peptide modification. Cross-sectional images (Figure 27) 
demonstrated that at the same laser intensity, biotinylated microspheres exhibited higher 
fluorescence when compared to peptide-free control microspheres. This was further 
demonstrated by fluorescence intensity plots (Figure 27C and D) 
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Figure 27 Confocal microscopy images of streptavidin-treated PEGDMA microspheres. 
(A) Compiled image, (100 Z-stacks), showing streptavidin fluorescence of PEGDMA microsphere 
containing Acryloyl-PEG-LC-biotin. (B) Cross-sectional image of a biotinylated-peptide containing 
microsphere. No fluorescence was visualized in biotin-free microspheres (not shown). Fluorescence 
intensity plots of PEGDMA hydrogel microspheres. (C) Two biotin-free PEGDMA microspheres 
demonstrating the nominal fluorescent signal detected in cross-sectional (Z stack) images. (D) Two 
PEGDMA microspheres containing biotinylated-peptides demonstrating a high fluorescent signal isolated 
to the microsphere circumferences (the peak separation was equal to the diameter of a single bead). 
.  
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3.11 Incorporation of peptides using thiol-acrylate “click” chemistry  
Incorporation of peptides using intermediate PEG linkers requires a pre-
conjugation reaction. This necessitates time consuming and costly characterisation as it 
is essential to determine the concentration of peptide which is subsequently conjugated 
into the microspheres. In 2008, Salinas et al. showed successful incorporation of 
cysteine-containing peptides into PEGDMA hydrogels via click chemistry using photo-
polymerisation (Shown in Figure 4) (240). Utilising thiol-acrylate mixed mode photo-
polymerisations, peptides can be incorporated using a robust cytocompatible method. 
Previously, the fibronectin analogue GRGDS, which is capable of binding the αVβ3 
integrin, has been incorporated into the microspheres by NHS coupling chemistry. To 
generate microspheres with similar chemical characteristics as those used in preliminary 
cell attachment studies, the peptide cyclic RGDfC was employed as it also binds the 
integrin αVβ3. Two further laminin–based peptides were tested, 
CSRARKQAASIKVAVSADR, containing the IKVAV motif and CDPGYIGSR 
containing the YIGSR motif. To determine whether cell attachment was peptide 
specific, PEGDMA microspheres containing the nonsense peptide cyclic RADfC, and 
unmodified PEGDMA microspheres were generated and tested in parallel (Chapter 4).  
3.11.1 Ninhydrin assay 
The Ninhydrin assay was used to assess the efficiency of peptide incorporation 
using thiol-acrylate photo-polymerisation. Peptide modified microspheres underwent 
aminolysis, and the free amino acids were detected using the Ninhydrin reagent. All 
peptides demonstrated a concentration-dependent increase in peptide content per mass 
of microspheres, as measured by absorbance (Figure 28).  
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Figure 28 Ninhydrin assay to demonstrate relative peptide incorporation via click chemistry.  
Relative peptide concentration was measured using a Ninhydrin assay which was normalized to a mass of 
dried microspheres.  
 
3.12 Morphology and Surface Topography of Microspheres 
Environmental scanning electron microscopy (ESEM) experiments were 
performed to study the morphology of PEGDMA hydrogel microspheres.  Unmodified 
and peptide-modified (cRGDfC) samples were imaged at ~99% humidity to prevent 
shrinkage / surface deformation.  The consistent surface-smoothness and surface-
uniformity of PEGMDA hydrogels synthesised using microfluidics was apparent 
(Figure 29). Samples containing the cRGDfC peptide conjugate showed no meaningful 
difference in surface properties, when compared with unmodified microspheres on the 
macro-scale. 
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Figure 29 Environmental microscopy image of monodisperse PEGDMA microspheres 
(A)  Peptide-free microspheres. (B) cRGDfC-containing microspheres. There were no appreciable 
differences in surface characteristics between peptide-free and peptide-containing microspheres. ESEM 
conditions: wet mode, 7.0 Torr of H2O vapor, and gaseous secondary electron (GSE) image. 
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3.13 Compression analysis of PEG hydrogels 
To determine the mechanical properties of the microfluidic produced 
microspheres compression testing was employed. To simplify calculations and 
handling, PEGDMA discs were generated which were comprised of the same chemical 
composition as microspheres (as described in Section 3.5.7). Several hydrogels discs 
containing a range of PEGDMA concentrations, 14, 16, 18, 20 and 22 w/v%, were 
prepared and allowed to swell overnight in PBS, before being mechanically tested using 
uniaxial unconfined compression (Bose Electroforce EF3200). The compressive 
modulus was calculated as the linear portion of the stress-strain curve (shown in Figure 
30). As expected, increases in hydrogel modulus were associated with increased 
PEGDMA concentration, and the compressive moduli ranged from 69.0 ± 13.3 to 273.9 
± 15.7 kPa for 14 w/v% and 22 w/v% respectively.  
Hydrogels containing 10 and 12 w/v% were also generated; however, 10 w/v% 
hydrogels were mechanically too weak to be moved after polymerisation without 
breaking. In addition, 12 w/v% hydrogel discs were functional as cell culture substrates, 
though they were too weak to be compression tested and disintegrated after force was 
applied and before effective measurements could be taken within our experimental 
setup. However, the compressive moduli was extrapolated from the linear relationship 
between PEGDMA concentration and compressibility, and calculated to be 8.14kPa. 
Incorporating thiol-containing peptides inhibits complete crosslinking of the 
PEGDMA hydrogel by taking up methacrylate end groups. To determine the effects of 
peptide incorporation on the mechanical properties of the modified hydrogels, 1mM 
cysteine was incorporated, (the highest concentration of peptide added into the 
microspheres) and the resulting hydrogels were compression tested in parallel with 
PEGDMA hydrogels. The stress strain curves showed no difference in compressive 
properties (Figure 30).  
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Figure 30 Compression analysis of PEGDMA hydrogels  
Change in compressive moduli resulting from a change in PEGDMA concentration. Hydrated hydrogel 
discs were tested using uniaxial compression (n=3). Compressive moduli were taken from the linear 
portion of a stress strain graph.  No changes were observed on hydrogel compressibility when 1mM 
cysteine was incorporated. 
 
 
 
 
Figure 31 Swelling ratio analysis of PEGDMA hydrogels. 
Changes in equilibrium swelling ratio and degree of swelling as a result of changing PEGDMA 
concentration (n=3).   
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3.14 Swelling ratio analysis 
The degree of equilibrium swelling of a polymeric hydrogel is known to be 
inversely proportional to its mechanical strength (or G‘). The amount of water a gel can 
take-up is represented by the swelling ratio, (Q). To determine the effects of PEGDMA 
concentration on the degree of equilibrium swelling, hydrogel discs were swollen in 
excess PBS for 3 days, weighed, dehydrated and then re-weighed. From the results in 
Figure 31, the degree of swelling is an inverse function of PEGDMA concentration, 
with equilibrium swelling ratios ranging from 14.2 to 6 for 14 w/v% and 22 w/v% 
hydrogels respectively. 
3.15 Discussion 
PEG based hydrogels containing synthetic ECM analogs have been proven to be 
suitable for cell culture (318-321) due, in large part to their inherent biocompatibility 
and the fact that they provide a blank slate upon which key functionalities of native 
ECM can be conferred (300, 322). To date, PEG hydrogels have been widely explored 
as substrates for cell culture to compare the effects of varying mechanical and chemical 
stimuli (306, 323, 324). To facilitate cell adhesion, Hern and Hubbell reported the use 
of monoacrylated RGD peptides with and without a PEG spacer, copolymerized with 
PEGDA (300).  This method has been extensively studied and has been shown to 
stimulate cell adhesion, spreading and growth on the otherwise non-adhesive PEG 
hydrogel surface (308, 325-329).  Altering the mechanical properties of the polymerised 
hydrogel has been demonstrated to change the level to which cells can bind and to alter 
the phenotype of adhered cells (210). This chapter describes a novel application for bio-
adhesive PEGDMA hydrogels in the production of neutrally-charged microcarriers.  
Recently, a variety of microspheres has been developed for biomedical applications, 
such as drug delivery (330), cell microcarriers (331), and tissue-engineering scaffolds 
(332-334). Microfluidics is an established technology for the production of hydrogel 
microspheres (299, 335). A key feature of microfluidic generated microspheres is high 
inter/intra-batch uniformity, in addition to strict control over microsphere size. 
According to  
 
Figure 20 and size distributions and coefficients were variance (CV) of  were 
261.3µm, 460.6µm, 950.7µm and 2.91%, 2.86% and 2.00% respectively, demonstrating 
the resulting microspheres were highly monodisperse.  The US National Institute of 
Standards and Technology (NIST) defines “monodispersity” as a narrow size 
distribution having a CV < 5% (336, 337).  
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Yeh et al. have previously demonstrated the synthesis of non-biocompatible 
hydrogel microspheres (due to a cytotoxic continuous phase), based on ethylene glycol 
dimethacrylate, using a polydimethylsiloxane microfluidic device (338).  Using UV-
initiated cross-linking, solid microspheres were produced on-chip.  However, the 
product microspheres were non-uniform and polydisperse (~10% C.V), due to unstable 
segmented flow conditions.  Yeh et al. also demonstrated that the properties of hydrogel 
microspheres could be subtly changed by varying the fluid flow conditions and 
architecture of the microfluidic device (338).  Further, changes in microsphere size and 
composition can vary the cross-link density of the hydrogel, altering the material’s 
mechanical properties.  In the present study, the intended purpose of the PEGDMA 
microspheres is to support cell cultures, hence, their size distribution should be narrow 
such that cell confluency is attained at a uniform rate.  
Generation of PEGDMA hydrogel microspheres using on-chip photo-
polymerisation has recently been demonstrated by Choi et al. (2009), using hexadecane 
as a continuous phase to produce PEGDMA droplets at a flow-focussing junction (299). 
As we intend to use our microspheres as cell adhesive substrates, hexadecane was 
avoided as it is cytotoxic.  Instead, high oleic acid sunflower oil (previously shown to be 
non-cytotoxic) (335) was used as the continuous phase. In addition, the harsh solvents 
used in spray-drying and double-emulsion techniques for microsphere generation could 
be avoided by using the UV-assisted polymerization method described here.  This is 
advantageous as the deleterious effects of solvents upon adhered cells could be 
precluded. Complete polymerization is required to prevent coagulation of microspheres, 
an undesirable property for microcarriers. The MicroPlant system allowed variable UV 
exposure in situ by altering the PEGDMA droplet flow rate and therefore retention time 
in the microchannel.  
Microspheres produced using the microfluidic method outlined in this chapter 
have consistent topographies with uniformity across their surface. Surface homogeneity 
is an important factor in designing microcarriers to ensure adherent cells experience 
identical surface binding conditions. This is particularly important as changes in surface 
texture have been shown to influence the adhesiveness of materials and affect cell 
morphology (210). There were no observed changes in surface properties (by ESEM) 
between control and peptide containing microspheres, suggesting peptide incorporation 
has no effect on surface topography. Inter/intra-batch surface uniformity allows 
systematic investigation into the effects of incorporating ECM analogues and varying 
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compressibility (i.e. chemical and mechanical cues) on adherent cell morphology and 
behaviour.  
Microcarriers also provide a curved surface for cell attachment and growth, 
which is a simple yet often overlooked feature. Research has shown microspheres 
containing a diameter of less than 100 µm have limited cell adhesion to their surface. In 
2011, Kong et al. investigated the effects of curvature on BM-MSCs cultured on RGD 
modified alginate microspheres. A decrease in cell proliferation and osteogenic 
differentiation was observed as microsphere diameters decreased from 3cm to 0.5cm 
independent of RGD concentration. This was attributed to increasing shear stress 
experienced during bioreactor culture. Kilian et al. (2010) have examined the effects of 
convex substrates on MSC differentiation in static culture, and found cytoskeletal 
changes; in addition to altered lineage commitment in response to differentiation 
induction media. Varying the size of the microcarriers would provide an opportunity to 
assess cellular responses to micro-topography. As proof of principle, a range of 
microspheres was generated containing average diameters of 278µm. 483µm and 
986µm.  
Several groups have demonstrated the use of Acryloyl-PEG-NHS to attach a 
variety of synthetic ECM analogs, such as laminin, (325), elastin, (325) collagen 
derived sequences (339) and growth factors (340). MALDI ToF ToF was employed to 
analyse the extent of conjugation of the fibronectin peptide fragment, GRGDS to 
Acryloyl-PEG-NHS. The MALDI ToF ToF technique generated semi-quantitative data 
for this peptide-polymer construct. After determining successful conjugation of GRGDS 
to the PEG-NHS monomer, the conjugate was incorporated into PEGDMA hydrogels 
using microfluidic assisted photo-polymerisation.  This provided a cell-adhesive 
element to the normally bio-inert material.  This technique can be applied to other ECM 
derived peptides (with a suitable nucleophilic terminus) and incorporated into 
PEGDMA microspheres. 
It is predicted that cells bind to the surface of the hydrogel microcarrier by 
interacting with incorporated peptides, hence, the distribution of these peptides across 
the surface is of critical importance. In previous work, Hern and Hubbell (300) estimate 
that peptides located within 10nm of the hydrogel surface are ‘available’, i.e. ‘able to 
bind to cell surface integrins’ (341). Consequently, a proof-of-concept experiment was 
performed to detect the accessibility and location of peptides on the surface of our 
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PEGMDA microcarriers. The biotinylated peptide (RGDS-LC-Biotin) was used to 
provide a binding motif for a fluorescent streptavidin reporter. A spacer group (PEG 
Mw 3500gmol
-1
) (previously optimized by Shin et al.) was incorporated in the hydrogel 
in accordance with previous literature. After treatment with Streptavidin-HiLyte Fluor 
647 solution, CLSM allowed the model peptide to be visualized and fluorescence was 
detected at the outermost circumference of the microcarrier. Confocal analysis 
demonstrated photo-polymerising monoacrylated GRGDS into PEGDMA hydrogel 
microcarriers allowed the RGD ligand to be presented at the hydrogel surface. 
Incorporation of peptides using an intermediate monoacrylated PEG-NHS 
monomer requires a pre-conjugation reaction. Characterisation of peptide conjugation 
was both time consuming and costly. After determining the optimum reaction 
conditions and characterisation method, the results were very difficult to reproduce. 
After consulting with peptide conjugation specialists, who also could not produce the 
results described herein using the same starting materials, it was decided that we would 
employ a simpler “click” chemistry method which bypassed the use of an acrylate 
linkage. Researchers have demonstrated cysteine-containing peptides can be 
incorporated into PEGDMA hydrogels via click chemistry using  thiol-acrylate photo-
polymerisation (240). This method has been shown to be robust and reproducible (245). 
Anseth and co-workers have demonstrated, using acrylate-thiol chemistry, high 
quantities (>95%) of thiol-containing RGD peptide incorporation into PEG hydrogels 
(342). In this study peptide incorporation in microspheres was successfully 
demonstrated; however an exact concentration of peptide per microsphere has not been 
determined, as the exact quantity of starting microspheres prior to analysis is not 
known. Due to the large quantity of expensive peptide required to generate the 
microspheres for this experiment, it could not be repeated. However, an increase in 
peptide content proportional to starting peptide concentration was shown, and an 
increase in cell attachment to hydrogels in a (starting) peptide concentration dependent 
manner was also evident. Although this gives confidence of successful peptide 
incorporation, future work would characterize the incorporation of peptide into 
microspheres.  
Photo-polymerisable PEGDMA hydrogels have a number of characteristics that 
are desirable for tissue engineering scaffolds. The mechanical properties of these 
hydrogels, namely compressive modulus and ultimate tensile strength, can be tailored 
over a fairly broad range to resemble a variety of soft tissues.  The mechanical 
 102 
 
properties of the hydrogels can be controlled by varying the molecular weight or 
concentration of the polymer. Compressive modulus increases with increasing polymer 
concentration or decreasing polymer molecular weight (343). The mesh size and 
swelling ratio can be similarly controlled (306). Cells are routinely cultured on plastic or 
glass, (1GPa and 70GPa respectively), however the compressibility of soft tissues is 
several orders of magnitude ‘softer’ (approximately 100kPa). Engler et al. demonstrated 
the effects of culturing MSCs on hydrogels with a range of compressive moduli 
between 0.1-40kPa. MSCs committed to a specific lineage, i.e. neurons, when cultured 
on substrates with elastic properties similar to their counterpart tissues in vivo. To probe 
the mechanical properties that can influence cell fate, a variety of PEGDMA hydrogel 
microspheres with a wide range of mechanical properties, including compressive 
modulus and mesh size, were generated and characterised. This was accomplished by 
changing the concentration of the starting PEGDMA macromer, therefore altering the 
crosslink density. The hydrogels generated contained a compressive modulus range 
from 8 kPa to 273 kPa, for 12 to 22 w/v% PEGDMA respectively.  
Incorporation of peptide ligands though acrylate linkage affects the overall 
hydrogel structure. To determine the effects of substrate compressibility on cell 
adhesion and behaviour, it is important that the mechanical and biochemical properties 
i.e. polymer and peptide ligand concentrations can be varied independently. Previous 
studies have shown incorporation of cysteine-containing peptides into PEGDMA 
hydrogels at a ratio 1:4 thiols:acrylate showed no significant difference in mechanical 
properties, including elastic modulus. To confirm this result PEGDMA hydrogels 
containing 1mM cysteine were analysed. No changes in mechanical properties were 
observed.  
3.16 Conclusion 
The microfluidic technique described in this chapter has been demonstrated as a 
simple but efficient tool to generate highly monodisperse PEGDMA hydrogel 
microspheres. Using continuous droplet formation and in situ photo-polymerisation, we 
have synthesized microcarriers with average diameters of 278µm, 483µm and 986µm 
and extremely narrow size distribution. The successful incorporation of the ECM 
peptide analogues using two separate techniques introduced a cell adhesive element to 
otherwise bioinert PEGDMA microcarriers. This technique could also be applied to 
incorporate a wide range of functional peptides. In addition, microspheres were 
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generated with a broad range of mechanical properties including compressive moduli. 
The microfluidic methodology described here has produced a flexible tool to generate 
tuneable, synthetic microcarriers. The microspheres developed in this chapter will be 
assessed for a variety of cell culture applications.  
 
 
 
 
 
 
 
 
 
 
4.0 Investigation into ADSC 
attachment to microcarriers 
with tunable chemical, 
mechanical and topographical 
properties 
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4.1 Introduction  
Recent advances in the field of biomaterials have shown that presenting cues 
derived from the ECM can improve cell growth, intracellular signalling and 
differentiation (217).  Previously, a wealth of research has eluded to possible 
biomaterial compositions that could potentially control MSC fate (189, 271, 306). 
Various parameters have been considered, including chemical compositions, 
biomechanical properties and surface topographies. However, published reports on the 
precise cellular responses to various biomaterials, (such as MSC response to bio-
adhesive peptides) are often conflicting (308, 344, 345). This is largely due to the subtle 
differences in scaffold properties used to probe the effects of ECM derived cues on cell 
growth and behaviour. PEGDMA hydrogels are uncharged and lack any cues that allow 
the directed binding and attachment of cells, providing a “blank” bioinert microcarrier. 
They are tunable, and can be used to systematically investigate the physical and 
chemical factors on cellular processes (241). 
PEGDMA hydrogels have been widely used to assess the effects of 
compressibility and bio-adhesive peptide on MSC fate (241, 261, 308). However, 
typically the studies were performed on cells encapsulated within photopolymerised 
PEG hydrogels, and focussed on assessing one parameter individually. For example, 
Jongpaiboonkit et al. (2009) developed a hydrogel array system for analysing MSC 
adhesion, viability and migration to IKVAV and RGD based peptides encapsulated 
within degradable and non-degradable PEG hydrogels (346). This method generates a 
3D culture system, however cell-cell contacts are lost and topography cannot be 
assessed (345). Cells cultured on microcarriers in monolayer culture experience a 
different microenvironment, and therefore we hypothesised MSC responses to changes 
in these parameters may be different to those previously reported in the literature.  
The overall aim of this project was to develop a synthetic microcarrier capable 
of providing a solid growth support for MSC expansion within a bioreactor. In Chapter 
3 we developed a microcarrier system containing tunable ECM-derived peptide 
sequences, mechanical properties and topographies. Few studies have investigated the 
effects of ECM derived peptides on ADSC attachment. However, it has been reported 
that ADSCs adhere and spread more extensively on IKVAV modified polycaprolactone 
surfaces, as compared to RGD or YIGSR modified surfaces (347). In this chapter we 
optimised ADSC attachment to novel microcarriers by examining various peptide 
ligands at a range of concentrations. This system permitted us to investigate the effects 
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of peptide ligand and compressive modulus on ADSC growth and cell fate, particularly 
examining adipogenesis, osteogenesis and chondrogenesis.  
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4.2 Microcarrier attachment optimisation 
4.2.1 Comparison of cell seeding densities on the rate of initial cell attachment 
To determine the optimum cell inoculum per microcarrier, a range of cell 
seeding densities were tested. Microcarrier density was kept constant at 360 
microcarriers per well (24 well plate) giving an evenly distributed monolayer of 
microcarriers (460µm diameter). It was postulated that higher cell inoculum per 
microcarrier would increase the probability of a binding event and increase the initial 
growth rate kinetics. Therefore three cell seeding densities were investigated, 100,000, 
50,000 and 25,000 cells per well.  
The effects of cell seeding density on cell attachment rates are shown in Figure 
32. The results show that by increasing the cell inoculum in relation to microcarrier 
concentration increased the amount of cell binding. However, the results revealed an 
upper limit on this effect. Large cell aggregates formed with increasing cell 
concentrations, with very few cells bound individually to the microcarrier.  
Microcarriers seeded with 25,000 cells showed a relatively high amount of cell 
adhesion, with few cells unattached in the medium. By increasing the cell concentration 
the level of cell attachment increased proportionally. This demonstrates initial cell 
attachment is dependent on the cell to microcarrier ratio.  
 
Figure 32 Effect of the initial cell seeding density on A549 adhesion to PEGDMA microcarriers. 
A549 cells were seeded into wells containing 360 of PEGDMA microcarriers suspended in cell culture 
medium and agitated at different rates. Cell attachment and growth was imaged 24 hours post seeding. 
Scale bars 240µm.  
 
50,000 cells25,000 cells 100,000 cells
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4.2.2 The effect of total culture volume on the initial rate of cell adhesion to 
microcarriers 
As the microcarriers are neutrally charged initial binding events are reliant on 
the probability that a collision will occur. To increase the probability of cell-
microcarrier contact the volume was incrementally reduced to increase the proximity 
between cells and microcarriers. A qualitative increase in cell attachment was observed 
in the wells (24 well plate) containing 500µL of total medium when compared to cells 
cultures in 3mL of medium. This was observed to be consistent across various 
parameters including different intermittent agitation levels and microcarrier 
compositions (Figure 33). This observation was not made for samples which were 
continuously agitated, where no cell adhesion was observed at either 0.5mL and 3mL 
starting volumes. 
4.2.3 The effect of agitation rates on cell adhesion to microcarriers 
To improve the probability of initial cell attachment, avoid cell clumping and 
increase nutrient transfer throughout the medium the culture was agitated at various 
intervals. To assess the effect of agitation on the initial rate of cell attachment the 
cultures were kept static, or were subjected to intermittent or continuous agitation.  
From Figure 33 it was observed that static conditions permitted cell binding to 
microcarriers. However, the amount of cell attachment appeared less than those 
microcarriers which had undergone intermittent agitation (stirred for 2 minutes at 40rpm 
every 30 or 60 minutes). No qualitative differences were observed between those 
agitated every 30 or 60 minutes.  This affect appears to be mirrored in a repeat 
experiment, shown in Figure 33. Continuous agitation was shown to prevent any 
attachment of cells to microcarriers. 
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Figure 33 Effect of the culture medium volume and agitation rates on cell adhesion to PEGDMA 
microcarriers. 
A549 cells were seeding into wells containing 460 of PEGDMA microcarriers suspended in cell culture 
medium and agitated at different rates. Cell attachment and growth was imaged 24 hours post seeding. 
Scale bars 240µm.  
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4.3 Comparison of photoinitiators  
For effective cell-microcarrier attachment, numerous types of photoinitiator 
have previously been employed to polymerise PEGDMA hydrogels. However, the 
cytocompatibility of the resulting hydrogels can vary between several cell lines (348). 
To determine the biocompatibility of the microcarriers generated in Chapter 3, several 
cell types were seeded onto the microcarriers and attachment was monitored. Initially 
VAZO 56 WSP (VAZO) was utilised as a photoinitiator to generate the microcarriers, 
as it is readily soluble in polymer solutions generated by H2O and PEGDMA, and 
should not be incorporated into the final gel structure of the microsphere. However, 
attachment to the microcarriers was variable, even where the cell type and conditions 
remained constant. This was initially thought to be due to initial attachment conditions, 
i.e. culture agitation, total media volume, cell and microcarrier seeding densities. Cells 
did bind to the microcarriers containing cell adhesive peptides, but were easily prone to 
dissociation upon mechanical agitation (i.e. pipetting), indicating the attachment was 
weak and unstable. As described in Chapter 3, the Ninhydrin assay was employed to 
determine the concentration of incorporated peptides by measuring free amino groups. 
Positive readings were generated for PEGDMA control microspheres which had not 
been modified with a peptide (Figure 34). As amino groups are not present in any of the 
components required to produce PEGDMA microspheres except the VAZO 
photoinitiator, it was postulated that despite extensive washing steps, VAZO remained 
in the hydrogel microspheres, producing a cytotoxic effect, thus rendering the 
microcarriers non-biocompatible. ADSCs adhered to microcarriers with inter and intra 
batch variability. For example, different batches of microcarriers containing the same 
chemistry were prepared in parallel. However, ADSCs formed confluent monolayers on 
some microcarriers and not others.  Hence the photoinitiator Irgacure 2959 was 
employed, which has previously been demonstrated to be cytocompatible in acrylate 
based hydrogels with a variety of mammalian cell types including hMSCs (348). 
Irgacure 2959 generated microcarriers gave reproducible cell attachment and growth, in 
addition the cell-laden microcarriers were stable and remained intact after reasonable 
mechanical agitation, allowing immunostaining to visualise cells. 
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Figure 34 Ninhydrin assay showing varying presence of VAZO photoinitator in microspheres.  
A Ninhydrin assay demonstrated the presence of primary amino acids within PEGDMA microspheres, 
with inter and intra batch variability. ADSC adhesion to RGD-modified microcarriers was variable, and 
often cells would attach to some microcarriers and not others within the same sample.    
 
4.4 Assessment of bio-adhesive peptides for ADSC attachment  
The novel microcarriers are intended for ADSC expansion. To optimise ADSC 
adhesion, three different bio-adhesive peptides were incorporated into the microcarriers 
and cell attachment was assessed. This included fibronectin derived cyclic RGDfC 
(cRGDfC), and two laminin-based peptides; (i) CSRARKQAASIKVAVSADR, which 
contains the IKVAV motif and (ii) CDPGYIGSR, containing the active cell-binding site 
YIGSR. To determine if cell attachment was peptide specific, PEGDMA microspheres 
containing the nonsense peptide cyclic RADfC, and unmodified PEGDMA 
microspheres were generated and tested in parallel.  
4.4.1 Comparison of different peptides incorporated into flat hydrogels on ADSC 
attachment  
To determine the suitability of the chosen peptides for ADSC attachment, 
several different ‘flat’ gels were generated to examine cell attachment to a planar 
surface. A peptide concentration of 0.35mM was employed in concordance with those 
typically reported in hydrogels culture (349). Hydrogels prepared according to Chapter 
3 Section 3.11.1) were placed in non-adhesive wells, seeded with ADSCs and left to 
attach over 7 days and assessed using DAPI staining (Figure 35).  
Unmodified PEGDMA hydrogels have intrinsic bio-inert properties and are well 
known to be non-cell adhesive. However, cell adhesion was observed on PEGDMA 
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gels; though this was limited to a relatively small area of the gel. Flat gels containing 
the nonsense peptide cRADfC also showed cell adhesion to a small fraction of the gel, 
however the cell morphology appeared to have either long thin extensions or to be very 
condensed, i.e. not demonstrating the typical ADSC fibroblastic morphology. A high 
level of cell attachment was observed on cRGDfC gels; however the cells appeared to 
grow in clusters, with a dense centre flanked by spindle like cells growing out from the 
centre, resembling cell colonies. Cell colonies form when seeding low density cultures 
of highly-proliferative, fibroblast-like spindle-shaped cells and are termed colony 
forming unit-fibroblasts (CFU-Fs). These are typically used to isolate MSCs from 
heterogeneous populations of cells. IKVAV modified hydrogels showed on average a 
very high level of attachment however attachment was inconsistent.  In line with 
previous research YIGSR hydrogels demonstrated little to no cell attachment, and any 
attached cells appeared very rounded with minimal spreading (347). 
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Figure 35Attachment of ADSCs onto flat gels containing different adhesion peptides 
(A) Widefield fluorescence imaging of whole gel structure. (Scalebar=5mm), areas containing ADSC 
adhesion are highlighted in yellow. (B) Single widefield fluorescence image of DAPI stained nuclei on 
the flat gels (Scalebar=0.5mm) (C) Brightfield image of representative cell formations on flat gels. 
(Scalebar=100µm) 
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Figure 36 Visualisation of ADSC attachment onto fully hydrated flat gels at different RGD peptide 
concentrations. 
ADSC attachment was assessed by visualising the whole gel system. Cells are stained with Concanavalin 
A (cells surface) and DAPI (nucleus). Images were taken at 10x and stitched into a montage by ImageJ. 
Scalebar=2mm 
B) Four fields of view from the montage demonstrating organisation of cell growth. At 0.35mM cell 
attachment and growth occurs in small colonies, which progressively expands with increasing peptide 
concentration(1mM) and eventually covers the whole gel at 2mM. Scalebar=200µm.  
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1mM
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As 0.35mM cRGDfC supported the formation of ADSC colonies, indicative of 
low cell attachment, the effect of increasing peptide concentration was further explored. 
The following concentrations of peptide were tested, 0.35mM, 1mM, and 2mM. Flat gel 
production was modified to produce uniform discs, to keep the surface area available for 
cell attachment consistent between samples. Peptide modified hydrogel discs were 
seeded with ADSCs and after 48 hours fixed and stained with DAPI and the cell surface 
glycoprotein marker concanavalin A to demonstrate cell morphology (Figure 36).  
Unmodified PEGDMA hydrogels were included as a control and demonstrated little cell 
attachment. In addition, little spreading was observed using the cell membrane marker. 
ADSCs cultured on 0.35mM cRGDfC hydrogel discs formed dense colonies as 
demonstrated previously. Cell attachment to 1mM cRGDfC hydrogels showed no 
distinct colony formation, but a more evenly distributed monolayer of cells which 
resembled the typical morphology of ADSCs observed on tissue culture plastic. 
Hydrogels with 2mM peptide concentration showed confluent monolayers of cells 
covering the entire surface of the hydrogels.  
Qualitatively, it was shown that attachment was highest at 2mM concentration, 
however due to cost implications it was decided that the 1mM concentration should be 
used to modify PEG in future experiments. This decision was based on our desire to test 
a wide range of properties, cell types and differentiation states. Increasing the peptide 
concentration would be a limiting factor in the microcarrier compositions that could be 
assessed.    
4.4.2 cRGDfC supports ADSC attachment to microcarriers  
Substrate curvature, adhesive peptide and peptide concentration may impact 
upon cell attachment, cell motility and division. Therefore, it was hypothesised ADSCs 
may attach differently to microcarriers compared to flat gels, despite having the same 
chemical composition. Therefore to determine the optimum peptide sequence and 
concentration to facilitate ADSC attachment to microcarriers both laminin derived 
peptides, cRGDfC and the nonsense peptide cRADfC were incorporated into 
microcarriers at 3 different peptide concentrations, 0.1mM, 0.35mM and 1mM. 
Representative phase contrast and SEM images taken 7 days after ADSC seeding are 
shown in Figure 37 and  
Figure 38.  
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Figure 37 Brightfield images of ADSC attachment to peptide-modified microcarriers 
ADSC attachment to microcarriers containing a range of peptides at either 0.1mM 0.35Mm or 1mM after 
7 days in static culture. (Scale bar 100µm) 
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Figure 38 Scanning electron microscopy images of ADSC attachment to peptide-modified 
microcarriers 
ADSC attachment to microcarriers containing a range of peptides at either 0.1mM 0.35Mm or 1mM after 
7 days in static culture. 
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Phase contrast images show that initial cell attachment to PEGDMA and 
cRADfC containing microcarriers (at any concentration) was minimal. Cell adhesion to 
cRGDfC showed cell attachment at 0.1mM, however this increased with higher peptide 
concentrations. At 0.35mM, cells appeared to attach to microcarriers with a fibroblastic 
flat morphology. The colonies that had been observed on the 0.35mM cRGDfC 
modified flat gels were not evident on the microcarriers. IKVAV showed peptide 
concentration dependant attachment, however at 1mM the attachment appeared less 
than cRGDfC at the same concentration. As observed with ‘flat gels’, YIGSR showed 
limited attachment and the adhered cells appeared raised on the microcarriers’ surface, 
with few cell-cell contacts. However, attachment was higher than would have been 
predicted from the flat gel experiments (seen in Figure 35).   
As ADSCs are flat and fibroblastic it is difficult to assess the level of attachment 
using phase contrast imaging, hence the ADSC-laden microcarriers were assessed using 
ESEM. However, the images obtained using these techniques were limited as they 
lacked resolution and surface detail, hence SEM was employed to analyse the images ( 
Figure 38). This technique requires the specimen to be visualised under a 
vacuum, which causes hydrogel microcarriers to shrink. This resulted in the overlying 
attached cells becoming wrinkled. In addition the cell surface appears smooth, which is 
an artefact of the technique, in future critical point drying would enable more surface 
detail to be preserved.  However it is still possible to visualise the similar pattern of 
attachment as observed using phase contrast imaging. The cells attached to the 
microcarriers in a peptide concentration manner, and at 1mM a large quantity of ADSCs 
cells were attached to the cRGDfC microcarriers. 
4.5 ADSC proliferation on peptide modified microcarriers 
As peptide concentration can effect cell proliferation and migration, cell 
attachment and growth over 7 days was analysed using a cell viability assay in static 
culture (Figure 35). Cell viability data were normalised to the number of microcarriers 
per well.  
There was a minimal amount of attachment initially to both microcarriers 
modified with cRADfC (at all three concentrations) and PEGDMA control 
microcarriers. Reiterating the results seen by microscopy, cRGDfC modified 
microcarriers appeared to have the highest amount of ADSC attachment. Viability data 
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for cRGDfC containing microcarriers displayed a general trend peaking at Day 5 and 
gradually decreasing by day 7 suggesting near-confluence. From the SEM and phase 
contrast images it appeared on Day 7 that the microcarriers had indeed become 
confluent, possibly restricting further cell growth. IKVAV modified microcarriers 
showed an increase in cell adhesion, directly resulting from an increase in peptide 
concentration. At 0.1mM (IKVAV concentration) ADSC attachment on Day 1 was 
slightly higher than attachment to 0.1mM cRADfC microcarriers and PEGDMA 
controls. However, attachment was lower than to cRGDfC 0.1mM (on Day 1). At an 
IKVAV concentration of 0.35mM, ADSC viability declined after initial attachment on 
day 2, but then steadily increased over 7 days. At 1mM, cell attachment and growth was 
inconsistent over 7 days as can be seen by large error bars, this is most likely due to 
inconsistent binding to the microcarriers, as observed on ‘flat gels’ in section 4.3.1. 
YIGSR modified microcarriers showed an increase in initial attachment on Day 1 in a 
peptide concentration dependant manner but gradually decreased over 7 days. From the 
‘flat gels’ experiments this is likely due to an inability to spread and migrate.  
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4.6 Observation of ADSC cytoskeleton when cultured on 1mM 
cRGDfC microcarriers  
To further probe the influence of the adhesive peptide cRGDfC (at 1mM 
concentration) upon ADSC attachment and spreading, the cytoskeleton organisation 
was examined after 7 days. The actin cytoskeleton was visualised using TRITC 
conjugated phalloidin, which selectively stains F-actin. In addition microtubule 
structures were highlighted using anti-tubulin antibodies, and nuclei were stained using 
DAPI. Representative confocal images of actin and microtubule staining of ADSC 
laden microcarriers are shown in Figure 40.  
Undifferentiated MSCs have a fibroblastic shape and demonstrate mostly long, 
thin parallel stress fibres, extending in the direction of the cell. However, Mao et al. 
demonstrated when stimulated to differentiate into either osteoblasts or chondrocytes, 
cytoskeletal changes occur concurrently with cell shape (350). After osteogenesis the 
cytoskeleton contains robust stress-fibres with more random patterning with a greater 
amount of actin filament crisscrossing and larger stress fibre bundles. Chondrogenic 
differentiation results in a more spread cytoskeleton with additional actin protrusions. 
Studies by Kilian et al. in 2012 have demonstrated when cRGDfC is presented as a 
monolayer for MSC attachment, cells display a higher degree of spreading, more stress 
fibres, and more focal adhesion structures (as compared to cells on monolayers 
presenting the linear form of RGD peptides). In addition, MSCs cultured on cRGDfC 
modified surfaces demonstrated enhanced actomyosin dependant osteogenesis (351). 
After 7 days ADSC spreading was visualised on the high RGD density carriers 
as shown in Figure 40D. Analysis of the phalloidin stained F-actin cytoskeleton 
displayed well defined parallel stress fibres which were mostly stretched along the long 
axis of the cells. A network of stress fibres connected by microfilament vertices in the 
cytoplasm was also visualised. In addition anti-tubulin antibodies showed an organised 
microtubule network extending throughout the cytoplasm to the cell periphery.  
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Figure 40 Analysis of ADSC morphology on the microcarrier. 
(A) Widefield image of Live/Dead cell assay. (B) Maximum intensity projection of cell surface 
(concanavalin A)(green) and DNA (DAPI)(blue). (C) Maximum intensity projection of microtubules 
(anti-tubulin) (green) and DNA (DAPI)(blue). (D) Maximum intensity projection of actin cytoskeleton 
(phalloidin)(red)  and DNA (DAPI)(blue). (E) Depth coded maximum intensity projection highlighting 
the top surface of the bead. (F) Depth coded maximum intensity projection highlighting the bottom 
surface of the same bead. All scale bars are 100µm.  
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4.7 Analysis of ADSC viability in microcarrier culture using a 
LIVE/DEAD assay 
To assess the viability of the culture the LIVE/DEAD assay (Sigma, UK) was 
employed. This technique uses two chemical indicators which once inside the cell 
fluoresce according to cell viability. Calcein-AM stains live cells green and Propodium 
iodide stains dead cells red. The fluorescence was detected using widefield fluorescence 
microscopy. 
The detected fluorescence revealed large populations of live cells bound to 
microcarriers, showing the culture was viable.  Microcarriers containing the cyclic 
(RGDfC) peptide showed a large live cell population bound to the surface. In addition 
cell aggregates can be seen as associated to the microcarrier surface and also joining to 
adjacent microcarriers. The viability of the culture was observed to be very high (Figure 
40A) with no visible dead cells. 
4.8 ADSCs can attach to microcarriers with a wide range of 
compressive moduli. 
To assess the effects of microcarrier compressibility on ADSC attachment and 
multipotency, microcarriers with a compressive modulus of 8kPa, 155kPa and 273kPa 
were generated, containing cRGDfC at a concentration of 1mM. As demonstrated in 
Chapter 3 section 3.13, altering the polymer content alters the mechanical strength of 
the PEGDMA hydrogel. Figure 41 depicts representative microcarriers at each 
compressibility. Softer 8kPa microcarriers appear to be damaged, with parts of the 
microcarrier missing, which occurred during routine preparation, most likely as a result 
of pipetting. In addition, it was observed that the bubble content increased as the 
polymer content increased, reducing the optical transparency of the microcarriers. 
ADSCs were cultured on the microcarriers in static ultra-low attachment plates 
and images were taken at Day 3 and Day 7. ADSCs successfully attached and grew on 
all three microcarrier types. The level of attachment to 273kPa beads appeared similar 
the other microcarriers. However, in addition on Day 3 bridging between the 
microcarriers occurred and numerous cells appeared to make multiple contacts between 
neighbouring microcarriers which increased over the time course. Migration from one 
bead to another had previously been observed in our culture system, however long 
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standing contacts between microcarriers as seen in Figure 42, has previously (to the best 
of our knowledge) not been reported in the literature. 
 
Figure 41 Brightfield and phase contrast images Microcarriers containing varying PEGDMA 
concentrations (w/v%)  
Microcarriers generated using microfluidics containing a range of PEGDMA concentrations (a,d) 12% 
(8kPa) (b,e) 18% (155kPa) (c,f) 22% (273kPa). At 12% (w/v%) PEGDMA microcarriers were easily 
damaged during routine pipetting. As PEGMDA content increases, the optical transparency of the 
microcarriers is reduced. 
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Figure 42 ADSC growth on microcarriers of different compressive moduli. 
Attachment and growth of ADSCs occurs at all mechanical compressibilities tested, but with subtle 
differences within cultures. Most noticeable is the formation of bead bridges formed within 273kPa 
cultures at both 3 and 7 days as cells become attached to more than one bead  
To determine the effect of microcarrier compressibility on cytoskeleton 
formation, a factor known to be related to differentiation capability, TRITC-Phalloidin 
staining of F-actin was employed. As actin microfilaments underlie the cell membrane 
and span the entire cytoplasm, it was postulated that alterations in actin cytoskeleton 
arrangement could occur as a direct result of changes in substrate mechanical strength. 
Diffuse actin staining was observed on soft substrates such as 8kPa microcarriers which 
can be seen in Figure 42. Also, stress fibres became progressively more organised and 
defined on stiffer substrates as seen on both 155kPa and 273kPa microcarriers. 
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Figure 43 RT PCR analysis of ADSCs grown on microcarriers of different compressive moduli. 
ADSCs cultured on microcarriers with a range of compressive moduli were harvested after 5 days to 
assess the levels of lineage specific gene expression. 
Following the 5 days on microcarriers with the compressive moduli of either 8, 
155 or 273 kPa in culture ADSCs, quantitative RT-PCR analysis was used to detect the 
expression of mRNA transcripts associated with lineage specific differentiation (Figure 
43). To determine if microcarrier culture had an effect of priming ADSC differentiation 
to particular lineage, RT-PCR analyses were performed for CD73, a marker for 
multipotency  and three early differentiation genes: RGC32, FABP4, and Aggrecan 
(ACAN), which are early cell markers for osteogenesis, adipogenesis, and 
chondrogenesis, respectively and normalised to multipotent controls cultured in flasks. 
Cell-laden microcarriers cultured all three microcarrier types demonstrated CD73 
expression remained largely unchanged in the cultures (with a fold decrease of 
approximately 0.6), indicating multipotency remained. An increase in the osteogenic 
marker RGC32 showed an upregulation (2.07-fold increase) in expression on 8kPa 
microspheres. A downregulation in gene expression was observed on 273kPa 
microcarriers. The expression of the chondrogenic-specific gene, aggrecan was 
upregulated in all three cultures. The upregulation was most pronounced in 273kPa 
microcarriers (a 1323.37 fold increase), which also showed microcarrier contacts over 5 
days (Figure 42). At 155kPa and 8kPa there was no contacts formed between the 
microcarriers decreased in fold increase in 1052 and 699 respectively. As described in 
Section 4.13, chondrogenesis on novel microcarriers generated herein, is typically 
associated with spontaneous cell aggregation on the microcarrier surface forming a 
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pellet like structure. As can be seen with phase contrast images (Figure 38), this was not 
observed on any microcarriers expanded in culture. Low levels of adipose-specific 
genes, Fatty Acid Binding Protein (FABP4) were detected, with a slight upregulation in 
three of the cultures. However, this was not substantial, as adipogenic induction in 
ADSC-laden microcarriers in static culture generated 45,000 fold increase in FABP4 
gene expression. Furthermore, phalloidin staining demonstrated spread cells well 
defined actin structures, which is not typical of adipocytes, which have a round 
morphology. This indicates the cell population was heterogeneous.  
4.9 ADSC properties on tissue culture plastic 
ADSCs are capable of differentiating into three different cell types (adipocytes, 
chondrocytes and osteocytes), showing a classic tri-lineage potential. Typically ADSCs 
exhibit a fibroblastic phenotype when cultured in monolayers. To assess the 
multipotency of ADSCs using standard culturing techniques (tissue culture plastic), 
ADSCs were cultured in specialised induction media (Figure 44). After 14 days of 
adipogenic induction, ADSCs adopted a differentiated phenotype with accumulated 
lipid droplets within cells, typical of an adipocyte phenotype. Positive staining was 
observed using both Oil-red-O (a lipid specific stain). Under osteogenic induction 
conditions, mineralised calcium deposits were observed (via alizarin red staining) on a 
network-like monolayer. ADSCs cultured under chondrogenic conditions, i.e. high 
density 3D pellet culture, developed a rounded phenotype and cultures were positive for 
alcian blue staining.  
Flow cytometry analysis was performed to characterise ADSC cell surface 
markers (Figure 45).  The ADSC surface markers CD29, CD44, CD90 and CD105 were 
expressed to high levels. In contrast, the expressions of hematopoietic markers (CD45) 
was expressed at low levels <2% compared to isotype controls. 
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Figure 44 Differentiation of ADSCs cultured on conventional tissue culture plastic. 
ADSCs cultured on tissue culture plastic were transferred to differentiation induction medium for 14 
days. Adipogenesis was observed using the lipid stain Oil-red-O to detect the accumulation of lipid 
droplets. Osteogenesis was analysed using Alizarin red S histochemical stain which detects calcium 
secretions. Chondrogenesis in pellet culture was detected using Alcian blue, a histochemical stain for 
sulphated matrix production. All samples were tested alongside a control which was cultured in parallel in 
the absence of differentiation induction media.   
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Figure 45 Flow cytometric analysis of typical surface markers expressed in ADSCs 
ADSCs were stained with positive the surface markers: CD90; CD105; CD44, CD29  and negative for the 
hematopoietic marker CD45. The shaded peak areas show signals from isotype controls (background 
fluorescence), and the white peak areas represent signals from surface marker antibodies on ADSCs. 
FITC-conjugated secondary antibodies were used to detect CD labeling.  
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4.10 ADSCs maintain their multipotency on microcarriers with a 
varied compressive modulus 
To determine the ability of the adhered ADSCs to differentiate into all three cell 
types whilst cultured on microcarriers, ADSCs were seeded onto microcarriers with 
different mechanical properties, allowed to attach and subsequently transferred into the 
appropriate differentiation media for 14 days (with regular media changes). 
Quantitative RT-PCR demonstrated when placed in adipogenic induction 
medium the expression of FABP4 was upregulated on microcarriers with all three 
compressive moduli (compared to multipotent ADSCs cultured on tissue culture plastic) 
(Figure 46). On microcarriers containing compressive moduli of with 8, 155, 273 kPa a 
fold increase gene expression of 147,463, 135,694 and 106,463 was observed 
respectively. This was higher than we analysed using monolayer culture. This was 
corroborated by microscopy (Figure 43), where adipogenesis qualitatively appeared 
higher on 8kPa microcarriers.  
The osteogenic marker RGC32 was upregulated in all differentiation induction 
conditions, on all microcarrier compositions. When cultured in osteogenic induction 
media, the highest level of gene expression was observed on 8kPa microcarriers. In 
addition a very similar level of fold increase in gene expression was observed on 
155kPa and 273 kPa microcarriers. 
Like the osteogenic marker RGC32, the upregulation of the early chondrogenic 
marker aggrecan was observed in all conditions. The highest fold increase in aggrecan 
expression (140 fold increase) was observed on microcarriers with on 273kPa 
microcarriers. CD73 (NT5E) showed a consistent decrease in gene expression in all 
conditions.  
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Figure 46 RT PCR analysis of ADSCs grown on microcarriers of different compressive moduli, 
cultured in differentiation induction medium. 
ADSCs cultured on microcarriers with a range of compressive moduli were cultured for 14 days in 
differentiation induction medium. The levels of lineage specific gene expression was detected using RT-
PCR and compared to multipotent ADSCs cultured on tissue culture plastic to determine fold increases in 
expression.  
4.11 Adipogenesis is supported on microcarriers with a variety of 
compressive moduli.  
After 2 days in culture, the microcarriers were transferred to adipogenic 
differentiation medium in static culture for 14 days. To assess adipogenic 
differentiation, cells were stained with Lipidtox, a neutral lipid stain which selectively 
stains lipid droplets, and analysed using confocal microscopy. As demonstrated by 
whole well imaging (shown in Figure 43), each microcarrier type responded differently 
to adipogenic differentiation. Soft substrates, i.e.  8kPa microcarriers, aggregated to 
form large multi-microcarrier units with very few microcarriers remaining as discrete 
particles (as they were prior to differentiation). As demonstrated by confocal images, 
(Figure 43), Lipidtox stained adipocytes were observed covering the entire surface of 
the 8kPa microcarrier. It was further observed that cell density was very high with the 
interstices (the space between adjoining hexagonally close pack microspheres) between 
microcarriers in the multi-microcarrier units, wherein Lipidtox staining, and hence 
adipogenesis appeared highest.  This effect appeared to be less pronounced on stiffer 
155kPa and 273kPa microcarriers, where the majority of the microcarriers remained 
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discrete with few microcarrier aggregates of typically 5 microcarriers or less. 
Differentiated adipocytes appeared to be confined on the whole to the interstices 
between microcarriers, as indicated by dark masses between microcarriers on the whole 
well images. Overall all microcarrier types supported adipogenesis.  
 
Figure 47 ADSCs cultured in adipogenic induction media on microcarriers containing a range of 
compressive moduli  
ADSCs were cultured in adipogenic induction media for 14 days. Whole well images representing 
microcarrier aggregation (Scale bar 10mm) Confocal images showing Lipidtox which selectively stains 
neutral lipids within lipid droplets. Nuclei (shown here in blue) are labelled using Reddot-1.  (A) A 
representative image of 8kPa microcarriers containing differentiated adipocytes covering its surface. (B 
and C) Concentrated cells found within microcarrier interstices demonstrated a high level of 
adipogenesis. (Scale bar100µm) 
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4.12 Osteogenic differentiation of cells on microcarriers as confirmed 
by Alizarin red S Staining 
To assess the osteogenic differentiation potential of ADSCs cultured on 
microcarriers with a range of compressive moduli, cell-laden microcarriers were 
transferred to osteogenic induction medium 2 days post seeding where they remained 
with regular medium changes for 14 days. Cell morphology was observed by phase-
contrast microscopy and using the Alizarin Red S histochemical stain which can detect 
calcium (by forming an alizarin red S-calcium complex in a chelation process), a marker 
of osteogenic differentiation and extracellular matrix mineralisation.  
Whole-well images showed the distribution of microcarriers within 6 well 
plates. Over 14 days, the medium transitioned from clear to opaque, an indication of 
matrix deposition. As before, the 8kPa microcarriers were fully aggregated into 3 main 
islands. As is evident from the whole-well images, (Figure 48) cells were most dense 
within interstices. The 155kPa microcarriers remained relatively sparse, however 
similarly to 8kPa microcarriers it was observed that the cells were most dense at 
interstices between microcarriers. The 273kPa microcarriers, like the 8kPa microcarriers 
were fully aggregated. Contrastingly, it was difficult to define the 273kPa microcarrier 
edges as cells covered the microcarrier aggregates forming large sheet-like structures 
(Figure 48).     
After 14 days in osteogenic induction medium, cells on all three types of 
microcarrier demonstrated the capacity to form Alizarin Red S positive condensed 
nodules with high calcium content as shown by Figure 48. The nodules became trapped 
within the cell/matrix surrounding the microcarriers. ADSCs cultured on microcarriers 
in non-induction medium formed adherent layers without nodule formation and showed 
no signs of calcium deposition and hence displayed no Alizarin Red S staining. 
Alizarin Red staining on 8kPa microcarriers, showed two types of staining. Cells 
covering the surface of microcarriers, stained bright red, indicating less mineralised 
areas. In addition, dark red to black mineralised nodules were observed between 
microcarrier interstices. Like 8kPa microcarriers, staining on 155kPa microcarriers 
appeared to be focused at interstices between microcarriers where aggregates of cells 
and dark calcium nodules were found. However, unlike 8kPa microcarriers, nodules 
were not confined to interstices, and could also observed at other points on the surface 
of the microcarriers. In addition, a large amount of bright red, less mineralised staining 
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could be seen over the surface of the carriers, however this was inconsistent. In contrast, 
dark red Alizarin red staining on 273kPa microcarriers was localised solely to 
interstices between microcarriers (as shown in Figure 48). Unlike in softer 
microcarriers, no bright red staining was observed on the surface of the spheres and 
extended networks of cells can be observed spanning the 273kPa microcarrier 
aggregates. These observations indicate that ADSCs can differentiate into osteocytes on 
all three types of microcarrier, resulting in the formation of mineralised matrix when 
cultured in osteogenic induction conditions.  
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Figure 48 ADSCs cultured in osteogenic induction media on microcarriers containing a range of 
compressive moduli  
ADSCs were cultured in osteogenic induction media for 14 days. Whole well images representing 
microcarrier aggregation (Scale bar 10mm) Brightfield images showing Alizarin red staining of calcium 
secreted from the cells. Cells cultured on 273kPa microcarriers formed a layer of cells which spanned 
multiple microcarriers. (Scale bar100µm) 
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4.13 Spontaneous cell aggregation in response to chondrogenic 
differentiation medium 
For effective chondrogenic differentiation of MSCs, typically cells are cultured 
as high density micromass cultures, forming a pellet which facilitates cell-cell 
interactions reminiscent of the prechondrogenic condensations during embryonic 
development. When cells are cultured with the combination of 3D culture and 
supplemented medium with growth factors MSCs lose their characteristic fibroblastic 
morphology, become rounded and start to express cartilage specific matrix components.  
To assess the chondrogenic differentiation potential of ADSCs cultured on 
microcarriers with a range of compressive moduli, cell-laden microcarriers were 
transferred to chondrogenic induction medium 2 days post seeding where they remained 
with regular medium changes for 14 days. Prior to chondrogenic induction, cell laden 
microcarriers were discrete structures, with the exception of 273kPa microcarriers, 
which (as described in Section 4.7 contained bridges between microcarriers.  After 14 
days post chondrogenic differentiation, cells displayed a varied behaviour dependent 
upon microcarrier composition. 8kPa microcarriers aggregated within the well and cells 
condensed at interstices between microcarriers. Cells on 155kPa microcarriers 
combined to form small pellets on the edge of a single microcarrier or a small group of 
carriers. The contact between microcarriers remained minimal with and all of the 
microcarriers were dispersed across the majority of the well. The numerous pellets had a 
rounded morphology and were of varied size. The microcarriers the highest compressive 
modulus of 273kPa, aggregated within the well. Over 14 days cells from multiple 
carriers combined to form large rounded pellets. Several pellets contained semi-
transparent centres within which dark masses could be observed. 
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4.14 Production of cartilage-specific extracellular matrix 
After 14 days in culture cell pellets/microcarrier constructs were embedded in 
paraffin wax and sectioned for staining. Histological sections were stained using 
Haematoxylin and Eosin (H&E) to highlight cell nuclei and cytoplasm. H&E staining 
showed that the structure of the cell pellets on 8kPa and 273kPa comprised three 
distinct areas resembling the zonal structure of articular cartilage (Figure 51 and Figure 
53). A ‘superficial-like zone’ at the edge of the pellet consisted of spindle cells highly 
organised and aligned parallel to the surface, a structure resembling the superficial zone 
of in vivo articular cartilage. In a ‘deep-like zone’, obvious morphological differences 
were observed in the three populations, with decreasing cell number and increasing 
ECM content. Decreasing cell number and hence, increasing intercellular space is 
essential to allow ECM accumulation, giving cartilage its unique properties (353). Cell 
morphology of MSCs changed during chondrogenesis from spindle fibroblastic shape to 
more spherical shapes in the centre of the pellet.   In addition H&E staining was partly 
absorbed by the microcarriers indicating their presence. In the 8kPa microcarriers, the 
microcarriers were deformed during the embedding process, however densely 
accumulated cells were observable between microcarriers. A clear superficial zone can 
be visualised with a layer of flattened cells at the edge of the pellet (Figure 51). Cells 
became sparser and rounded towards the centre of the pellet and intercellular space 
increases, which is indicative of a ‘deep zone’. On 155kPa microcarriers small pellets 
had a thin superficial zone, approximately 1 cell layer thick, with small intercellular 
space. Cells in the core formed a swirl like pattern containing mainly enlarged and 
rounded cells. On 273kPa microcarriers, spindle shaped cells parallel to the surface of 
the pellet generated a very prominent edge. In addition a low cell density core with 
rounded cells and large intercellular space indicating matrix deposition.  
In addition, within the ‘deep and middles zones’ there was evidence of columns 
of rounded cells within lacunae (cavities within the cartilage matrix, typically 
containing single cells), were orientated perpendicular to the surface indicative of 
chondrocyte proliferation. Spindle cells were observed on all edges, including the inner 
edge of the pellet. The cellular organisation resembled  certain characteristic features 
present in normal articular cartilage (354).   
Positive metachromatic Toluidine blue staining sulphated proteoglycans 
of chondrogenic pellets provided information on the extent of matrix formation. The 
8kPa and 273kPa microcarriers displayed varying degrees of sulphated proteoglycan 
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accumulation within the pellets. Within 8kPa microcarriers, staining was strongest at the 
surface of the pellets. In 155kPa microcarriers, strong staining was observed throughout 
the pellets indicating the uniform presence of proteoglycans. In all 273kPa pellets, cells 
within the superficial zone displayed strong staining, representative images are shown 
in Figure 52. In addition, unlike the 155kPa microcarriers, a middle zone was observed 
which showed weak toluidine blue staining with large intercellular spaces and few cells. 
In the deep zone, cell density increased with examples of cells contained in lacunae.  
Chondrogenic differentiation of ADSCs in the three conditions was evaluated by 
assessing by the presence and of cartilage-specific extracellular matrix proteins collagen 
types I and II. As MSCs express collagen I whereas chondrocytes primarily express 
collagen II (190, 352).  As observed from the 8kPa microcarriers, the cells formed a 
network which spanned multiple microcarriers as seen in (Figure 47). A more magnified 
view illustrates defined superficial and deep zones (Figure 51). Within the latter few 
cells were observed and within the intercellular spaces positive co-localised staining for 
the presence of collagen types I and II was observed. Smaller rounded pellets present on 
155kPa microcarriers did not produce any detectable levels of Collagen types I and II by 
immunocytochemistry. Type I and II Collagen staining was positive throughout the 
deep zone of the large pellets found on 273kPa microcarriers and faintly present 
towards the mid/superficial zone between cells. However, unlike cells around 8kPa 
microcarriers the deep zone and mid zones of the pellet contained a high density of 
cells, decreasing the possible space for ECM accumulation.  
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Figure 50 Collagen type 1 and II expression in cell aggregates on 8kPa microcarriers 
ADSCs cultured on 8kPa microcarriers were placed in chondrogenic induction medium for 14 days. 
Immunocytochemistry analysis of microcarriers aggregates detected co-localised Collagen type 1 and II 
expression within the cell aggregates indicating chondrogenic differentiation. (500µm) 
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Figure 51 Analysis of ECM production in cell aggregates on 8kPa microcarriers   
H&E staining demonstrated an organised cellular struture. Metachromatic toludine blue staining indicated 
the presence of a sulphated GAG matrix indicating the formation of zonal compartments with different 
ECM properties. Immunocytochemistry demonstrated collagen type I and II colocalised within the area 
between the flat cell layer and the microcarrier denoted ‘middle/deep zones’ (Scale bar 100µm) 
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Figure 52 Analysis of ECM production in cell aggregates on 155kPa microcarriers 
H&E staining demonstrated condensed cells within a pellet. Toludine blue staining indicated the presence 
of a sulphated GAG matrix uniformly across the pellet section. Immunocytochemistry demonstrated no 
collagen type I and II was present within the pellet (Scale bar 100µm) 
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Figure 53 Analysis of ECM production in cell aggregates on 273kPa microcarriers   
H&E staining demonstrated an organised cellular struture. Metachromatic toludine blue staining indicated 
the presence of a sulphated GAG matrix indicating the formation of zonal compartments with different 
ECM properties. Immunocytochemistry demonstrated collagen type I and II colocalised within the 
middle/sleep zone (Scale bar 100µm) 
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4.15 Comparisons with other microcarriers 
Traditionally, microcarriers are used for the expression of therapeutic antibodies 
and proteins. Therefore to assess the ability of the developed microcarriers to sustain 
cell growth and biological function we compared our newly developed microcarriers 
alongside four commonly used commercially available equivalents with a range of 
properties (Appendix 1). Using a CHO cell line expressing a monoclonal antibody, we 
showed comparable levels of cell attachment and antibody production on our novel 
microcarriers. However optimisation is required to be competitive with commercially 
available microcarriers developed for CHO cell culture.  
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4.16 Discussion 
Several synthetic hydrogels have been generated in an attempt to mimic the in 
vivo cell niche.  It has been shown that presenting cues derived from the ECM can 
improve cell growth, intracellular signalling and differentiation (217).  To incorporate 
elements of the ECM hydrogels have been modified to contain chemical, mechanical 
and topographical cues. PEGDMA hydrogels are bio-inert and lack any cell-adhesive 
cues (240). Several peptides have been used to functionalise PEG hydrogels and 
increase MSC attachment (Chapter 1 Figure 3). In addition several key studies have 
investigated the effect of mechanical compressibility in influencing stem cell 
differentiation (189, 271, 306). However there is conflicting reports in the literature 
over the precise factors that influence stem cell growth and behaviour (308, 344, 345).  
This is most likely due to intrinsic material properties influencing cell behaviour. In 
addition, studies have often probed the effect of an individual cue (e.g. peptide ligand) 
on cell attachment. 
Previously the literature largely investigated the effects of biomaterial substrates 
on the culture and differentiation of human BM-MSCs. However, BM-MSCs have been 
shown to possess a different differentiation potential to ADSCs (355). Using the 
bioinert microcarriers developed herein, the chemical and mechanical properties can be 
finely tuned independently of one another to systematically assess the effect of adhesive 
peptide, peptide concentration on ADCS attachment and the effect of compressibility on 
differentiation. To develop microcarriers for ADSC expansion it is important that the 
expanded cells maintain their characteristics including multipotent potential. The effects 
of microcarrier properties on MSC attachment and differentiation were initially assessed 
in static culture. 
4.16.1 Optimisation of cell attachment to microcarriers in static culture 
The initial probability of cell microcarrier binding events is random, and is 
largely dependent on cell proximity to the microcarrier surface. In optimum conditions, 
the ratio of cells to microcarriers should be high enough to permit cell adhesion to all 
microcarriers. 
As the microcarriers are neutrally charged, initial attachment to the microcarrier 
is reliant on cells contacting microcarriers long enough to form an interaction. As 
microcarriers and cells are both in suspension, any decrease in culture volume should 
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increase the probability of cell to microcarrier contact. The result of this investigation 
confirmed this hypothesis, as reducing the culture volume increased cell attachment. 
Initially cells were inoculated with microcarriers containing 3mls of medium, this 
showed total cell adhesion to 5-10 cells per microcarrier. A549 cells typically have a 
‘cobblestone’ appearance. In TCP, A549 epithelial cells do not assume this morphology 
until over 50% confluent, when cell-cell contacts and small colonies are formed. It was 
observed that after several days in culture, the expansion of A549 cells onto 
microspheres in 3mL of medium had not occurred. However, cells cultured in 500µL of 
medium had 1/6
th
 less volume for movement, which was reflected in an increase in cell 
binding, and spreading of cells was observed. There was however a lower limit on this 
effect. Consequently the same microcarriers and cells density cultured in 150µL of 
medium resulted in a meniscus forming inside the well. Attachment to microcarriers at 
the edge of the well was increased. However, several microcarriers remained in the 
centre of the well and dehydrated preventing any cell attachment. For future 
experiments the lower threshold was set at 250µL, which is sufficient to cover the base 
of a well in a 24 well plate, preventing the hydrogel microcarriers drying out. 
4.16.2 Comparison of cell seeding densities on the rate of initial cell attachment 
After inoculation, cells attach to microcarriers in a random fashion and the 
number of adhered cells per microcarrier can be predicted using Poisson distribution 
(356).  In optimum conditions, the ratio of cells to microcarriers should be high enough 
to permit cell adhesion to all microcarriers. It has been suggested that a minimum 
average of around 5-6 cells per microcarrier is optimum for charged microcarriers (356, 
357)and it is predicted that the amount of microcarriers without any cell adhesion would 
be less than 1%. The rate of cell adhesion to uncharged microcarriers would be 
predicted to be slower (358), dependent on cell lines, microcarrier size and composition 
(358), and so the initial seeding densities were determined experimentally for the 
microcarrier system herein. 
From our results it was clear that there is an upper limit to the system. Not all 
cells adhered to the uncharged microcarriers upon initial seeding into the cell culture 
vessel, leaving many cells unattached in the medium. This led to the formation of cell 
aggregates. It is well established that when adherent cells fail to bind to a solid growth 
support they undergo apoptosis (anoikis) (359). If this occurs in microcarrier culture 
toxic metabolites can be released into the culture medium, impeding the growth rate of 
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the culture. Based on our results, an optimum cell seeding density of 2.5 x 10
4
 cells per 
24 well plate was chosen. This gives an approximate ratio of 69 cells per microcarrier, 
much higher than any other reported in the literature.  
4.16.3 Peptide incorporation effect on cell attachment 
Several peptides have previously been used to render hydrogels bio-adhesive for 
MSC adhesion (chapter 1 Figure 3). However there is some controversy within the 
literature regarding the optimum adhesive peptide and peptide concentration required 
for MSC attachment and differentiation.  For example, IKVAV and RGD modified 
surfaces have been shown to promote adhesion and spreading of ADSCs to 
polycaprolactone surfaces (347). Frith et al. (2012), also showed human MSCs bound to 
IKVAV and YIGSR functionalised on polystyrene-block-poly(ethylene oxide)-
copolymer surfaces, however the cells failed to spread and remained rounded (360). 
This possibly represents a species specific difference in adhesion, but could also be due 
to the mechanical or topographical properties of the material which are not detailed in 
the study. 
Adhesive peptide concentration is known to effect cell growth, migration and 
differentiation (344). Yang et al. incorporated RGD at a concentration of 0.025, 1.25 
and 2.5mM into PEG hydrogels and showed an increased in human BM-MSC 
osteogenic differentiation corresponding to increase RGD concentration (308). 
Several peptides (namely cRADfC, cRGDfC, IKVAV, and YIGSR) were 
incorporated into PEGDMA ‘flat’ hydrogels to assess ADSC attachment. Qualitatively, 
cell attachment was highest on IKVAV modified hydrogels, however cell distribution 
was inconsistent across the surface of the hydrogel. PEGDMA, a known non-cell 
adhesive biomaterial, showed some attachment to a small area of the gel. It was 
postulated that this was due to a topographical change in the gel surface, which possibly 
occurred during gel manufacture (handling). The nonsense peptide cRADfC was 
incorporated to assess whether cell attachment to the hydrogels was peptide specific (as 
it is not recognised by cell surface integrins). Very little attachment was observed to 
YIGSR and RADfC gels. This concurred with results by Santiago et al. who 
demonstrated ADSCs could not bind YISGSR functionalised polycaprolactone surfaces. 
ADSC attachment showed the formation of cell colonies on cRGDfC 0.35mM 
hydrogels. To isolate MSCs from biological samples, MSCs are routinely seeded at very 
low cell densities, to produce colonies of highly proliferative cells. Therefore it was 
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hypothesised that initial cell adhesion was low to 0.35mM RGDfC modified hydrogels 
due to the concentration of adhesive RGD ligand.  
To explore the effect of RGDfC concentration on ADSC attachment several flat 
hydrogels were produced containing a range of RGDfC concentrations (0.35, 1 and 
2mM). Flat PEGMDA hydrogels were generated using an optimised technique to try 
and standardise cell surface binding area. In addition the size of the gels was increased 
to make handling easier. This prevented the top of the gel being contacted during 
handling, which could potentially alter the surface topography. As visualised using 
immunocytochemistry, PEGDMA gels showed limited attachment cell spreading. 
ADSC attachment increased as peptide concentration increased from 0.35mM to 2mM. 
Colony-forming units were still observed on 0.35mM cRGDfC hydrogels. However this 
was not observed on 1mM or 2mM hydrogels which showed even attachment. This 
differs from literature reports, for example  Liu et al. (2012) generated a PEG hydrogel 
containing an RGD gradient (0-0.25mM) using microfluidics and observed an RGD 
concentration of 0.107–0.143 mM showed the maximum rat BM-MSCs attachment 
(361). This could show specific differences in adhesion to the RGD peptide.  
The microcarrier topography can influence cell attachment. Therefore all 
peptides (cRADfC, cRGDfC, IKVAV, and YIGSR) were incorporated into 
microcarriers (at three concentrations, 0.1, 0.35 and 1mM). Cell attachment and 
proliferation was monitored over 7 days using the Prestoblue viability assay. 
Attachment to microcarriers containing the cRGDfC peptide was consistently high in all 
three concentrations, with the highest cell attachment and growth was observed on 
(1mM) microcarriers. Contrary to cRGDfC functionalised flat hydrogels, no cell 
colonies were observed on microcarriers at any RGD concentration. Despite showing 
high attachment on flat gels, IKVAV showed a peptide dependent increase in cell 
attachment, however, when incorporated into microcarriers ADSC attachment and 
proliferation (at any concentrations) did not match that of RGDfC. Visualisation of cell 
attachment by SEM and phase contrast microscopy reiterated these This concurs with 
previous research as RGD modified Polyethersulfone (PES) surfaces have shown to 
promote adhesion of ADSCs (362). 
Microcarriers containing the highest level of attachment after 7 days (cRGDfC 
1mM) were analysed further to assess the intracellular cytoskeleton organisation. 
Organised stress fibers and microtubules were observed. In addition, cell viability was 
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visualised using a LIVE/DEAD assay, which showed viable cells attached to the 
microcarrier surface.  
 The 1mM RGDfC microcarrier was selected to probe the influence of 
compressive moduli on cell attachment and differentiation. It was hypothesised that 
peptide concentration and substrate compressibility act synergistically. Ideally, all 
peptides, in particular the IKVAV peptide would also be taken forward. However due to 
cost and time restrictions we focussed on the single peptide that showed the highest 
adhesion and proliferation over seven days in static culture (cRGDfC). Future work 
would attempt to generate an array microfluidic system to produce microcarriers with a 
combination of properties (Discussed further Chapter 6).  
4.16.4 Substrate compressive moduli effects microcarrier aggregation and 
differentiation.  
Effective MSC differentiation has been extensively studied, and to date has 
largely focused on developing optimum medium compositions. Previously instructive 
biomaterials have also been used to direct MSC differentiation, and have found 
differentiation into lineage specific cell differentiation when cells are cultured on 
substrates with similar elastic modulus of tissues in vivo. Seminal research conducted by 
Engler et al. has shown MSCs demonstrated lineage specific differentiation when 
cultured on substrates with similar elastic properties to the native counterpart in vivo. 
For example, MSCs differentiated into neurons, myocytes or osteocytes when cultured 
on neural, (0.1-1kPa), muscle (8-14kPa) and bone (27-40kPa) respectively. 
 In this study ADSCs were cultured on RGDfC (1mM) microcarriers with a 
compressive modulus of either 8kPa, 155kPa or 273kPa. After 5 days in culture, 
ADSCs adhered to all three microcarrier types. As changes in matrix properties are 
modulated by the actin cytoskeleton, phalloidin staining (which selectively binds F 
actin) was performed. A pronounced cytoskeleton and cell spreading was observed on 
all microcarrier types. However, Engler et al. demonstrated an elongated MSC 
phenotype on substrates with a modulus of 11kPa. Differences seen in this study could 
be due to the influence of RGD peptides and/or surface curvature of the microcarriers.  
RT-PCR analysis was performed to demonstrate if the compressive properties of 
the microcarrier primed ADSCs to differentiate into a specific lineage. An upregulation 
of aggrecan, an early chondrogenic differentiation marker was observed on all 
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microcarrier types. The expression increased in concordance with compressive 
modulus, with a 700 and 1323 fold increase in 8kPa and 273 kPa respectively. It has 
been shown that cells can differentiate into lineage specific cells as a direct result of 
changes in matrix elasticity to resemble native counterpart tissues. The compressive 
modulus for articular cartilage has been reported to be 314kPa (363). This could 
potentially explain the increase in aggrecan expression.  
To assess the effect of substrate compressibility on ADSC differentiation, cell-
laden microcarriers were transferred to either adipogenic, osteogenic or chondrogenic 
induction medium in static culture, i.e. the culture was not stirred or agitated. The 
microcarriers generated have a low density, they can settle but are easily placed into 
suspension (a requirement for future bioreactor experiments). Cell-laden microcarriers 
began differentiation culture as discrete spheres, distributed randomly within a tissue 
culture well. Interestingly, after 14 days in differentiation media, microcarriers formed 
large multi-microcarrier aggregates. The extent of aggregation varied between 
microcarriers with different compressive moduli and differentiation induction media, 
despite starting from the same population of microcarriers. For example, 273kPa 
microcarriers remained relatively sparse after adipogenic differentiation and was 
significantly more aggregated in osteogenic and chondrogenic differentiation 
conditions. This appeared to be a microcarrier compressive modulus specific response, 
as opposed to a result of adipogenesis, as 8kPa microcarriers clustered into three islands 
under identical adipogenic culture conditions. A lack of aggregation was observed on 
155kPa microcarriers under any differentiation induction conditions, whereas 
aggregation occurred in every condition on 8kPa microcarriers. It was postulated that 
microcarriers within the incubator may have been disturbed, for example during 
opening and closing of the incubator door, or alternatively during regular medium 
changes. Cell to cell adhesion may have occurred between adjacent settled microcarriers 
as a result of microcarrier collisions, and hence resulting in the microcarriers 
aggregating. 
MSCs can be easily differentiated into adipocytes and therefore hold great 
potential for adipose tissue engineering. However the uses of MSCs are limited due to 
the reduction in adipogenic potential after conventional ex vivo expansion on tissue 
culture plastic. Adipogenesis of cell laden microcarriers in static culture resulted in 
aggregates forming in all microcarrier compositions. Typically cell proliferation is 
restricted after the addition on adipogenic induction media, however high cell densities 
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were observed at interstices within microcarriers. It was postulated this was a sight for 
ECM matrix accumulation, resulting in cell migration. Chen et al. have demonstrated 
that effective MSC adipogenesis was  influenced by high cell densities (254). RT-PCR 
demonstrated the expression of the FABP4 gene (a marker for early adipogenic 
differentiation) was upregulated in the in all cultures. Compared to endogenous 
controls, a 106,000 (8kPa) to 147,000 (273kPa) fold increase in gene expression of 
FABP4 was observed. Immunocytochemistry results reiterated RT-PCR data which 
showed differentiated adipocytes over the entire surface of the 8kPa microcarrier 
surface, whereas adipogenesis was concentrated to interstices in 155kPa and 273kPa 
microcarriers. It is currently impossible to quantify the precise number of cells within a 
population that effectively differentiate from an MSC into an adipocyte. However 
FABP4 expression showed a higher fold increase in gene expression when compared to 
cells cultured in monolayer culture on tissue culture plastic.  
ADSCs cultured on microcarriers with a range of compressive moduli 
underwent osteogenesis as observed from calcium staining using alizarin red. As 
compressive modulus increased, the positive staining was more isolated to interstices 
and areas concentrated in cells Engler et al. showed osteogenic differentiation of MSCs 
was higher on 25-40kPa hydrogels (compared to 8kPa). Osteogenesis was confirmed by 
RT-PCR analysis which demonstrated an upregulation of RGC32 gene expression (an 
osteogenic marker) on cells cultured on all three microcarrier types, the highest fold 
increase was observed on 8kPa microcarriers. Osteogenic media is supposed to limit 
cell proliferation, however after differentiation on 273kPa microcarriers, cells covered 
microcarrier aggregates in a sheet-like appearance, which was not observed on the other 
microcarrier types. Previous studies have shown BM-MSCs encapsulated within 
PEGDA hydrogels showed an increase in osteogenic markers in response to increasing 
RGD concentration from 0 to 2.5mM (308), indicating cRGDfC concentration could 
influence differentiation. Future work would investigate the effect of RGDfC peptide 
concentration on osteogenesis.  
Chondrogenesis does not occur effectively in monolayer culture, as cells require 
a 3D environment for efficient differentiation. The standard method to promote MSC 
chondrogenesis is pellet or micromass culture whereby cells are seeded in droplets 
containing high cell densities (~8x10
6
 cells/mL). Therefore to promote chondrogenesis 
in biomaterials, MSCs are often encapsulated within a hydrogel matrix (345). In a study 
by Toh et al. an increase in chondrogenesis, measured by ECM secretion, of hyaluronic 
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acid based hydrogels was higher on decreasing crosslinking density (increasing in mesh 
size) and decreasing compressive modulus (~6kPa) (364). 
Several tissue engineering strategies are currently being developed to replace 
damaged articular cartilage; as the tissue has limited capacity for self-repair due to 
avascularity and low cellular mitotic activity. Current methods are unable to restore 
native structure of cartilage. Chondral lesions can arise from trauma or disease, and 
often becomes progressively deteriorated  leading to osteoarthritis (365).  
Several studies have demonstrated the generation of cartilage-like tissue using 
MSCs and chondrocytes on cells encapsulated within biomaterials, in particular PEG-
based hydrogels (190, 245).  However, one of the key unresolved challenges in cartilage 
tissue engineering is the inability to generate tissue that replicates the highly organised 
zonal structure of articular cartilage, in particular the spatially distinct regions 
containing varying ECM compositions and mechanical properties. Generating cartilage 
that mimics the zonal spatial organisation of articular cartilage is essential for 
generating a clinically effective transplant for tissue engineering treatments (366).  Four 
zones exist, the superficial, transitional (middle), deep, and calcified zones (Figure 54). 
The ECM contained within these zones is responsible for providing the cartilage with its 
physical properties. For example, hyaline cartilage contains an ECM rich in type II 
collagen and proteoglycans, which aids the material elasticity. Directing a single stem 
cell population to differentiate into different zonal phenotypes within a single 3D 
structure presents a major challenge in cartilage research. The ability to accomplish this 
would be advantageous in providing alternative, native-like cartilage replacements, 
which would eliminate the need for donor tissues. 
ADSCs cultured on microcarriers containing a range of compressive moduli 
could spontaneously migrate to form large multicellular aggregates (or pellets) when 
placed in chondrogenic differentiation media. This effect was moduli specific, as cell 
aggregation varied on microcarriers with different properties. For example, 8kPa 
microcarriers generated large microcarrier aggregates, where cells spontaneously 
migrated from monolayer culture on the microcarrier surface to form a condensed 
network of cells between microcarriers. On 155kPa microcarriers, few microcarrier 
aggregates formed resulting in small cell pellets, as contributing cells were derived from 
a single microcarrier. 273kPa microcarriers also formed multi-microcarrier aggregates, 
however unlike on 8kPa microcarriers, cells from multiple microcarriers migrated to 
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form one large rounded pellet, which was simultaneously anchored to several 
microcarriers. In every condition very few cells were observed on the microcarrier 
surface after chondrogenesis, indicating pellets were comprised of migrated cells rather 
than newly proliferated cells.  
 
Figure 54 Schematic representation of zonal compartments within Articular cartilage  
Articular cartilage is organised into zonal compartments with varying cell architecture and matrix 
properties. A superficial zone comprising of densely compact cells aligned parallel to the cartilage 
surface. A middle zone transitioning to a deep zone as intracellular space increase and is filled with ECM 
matrix. Adapted from (353). 
 
Cells pellets generated on 8kPa and 273kPa microcarriers differentiated into 
structures resembling the superficial, transitional, or deep zones of articular cartilage, as 
observed by H&E staining.  It was postulated that the highly unusual formation of 
multi-cellular pellets from monolayer culture was a result of ECM secretion. PEGDMA 
hydrogels have been shown to be resistant to protein absorption onto its surface. As 
matrix proteins are unable to bind to the microcarrier, they could be deposited onto 
cells, in particular on cells within microcarrier interstices, and hence provide a scaffold 
for cell adhesion. As cells migrate towards the ECM (either by sensing a chemical or 
mechanical gradient) more matrix proteins are secreted, further supporting the structure, 
and resulting in the pellets becoming more architecturally organised. As this is the first 
instance of this being reported in the literature, future work would quantify ECM 
protein secretion from the medium. 
Histology and immunochemistry confirmed the production of cartilage specific 
proteins in 8kPa and 273kPa hydrogel microcarriers. Zonal regions were highlighted by 
Superficial zone
Deep zone
Calcified zone
Middle zone
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toluidine blue staining, which demonstrated spatially distinct areas with varying degrees 
of sulphated glycosaminoglycans. Collagen type I and II was expressed throughout the 
‘middle or deep’ zone within cell aggregated on 8kPa microcarriers. Collagen type I is 
constitutively expressed by multipotent MSCs, however only after cells have undergone 
chondrogenesis do they express Collagen type II (367), indicating pellets formed from 
8kPa and 273kPa microcarriers effectively underwent chondrogenesis. This was 
unexpected as 8kPa microcarriers have a relatively lower compressive modulus than 
that of articular cartilage. However, Park et al. have shown that MSCs had an increased 
expression of collagen type II after chondrogenesis on substrates with 1kPa than 15kPa 
(368).  In addition, chondrogenesis has been shown to be inhibited by RGD when BM-
MSCs were encapsulated with Alginate hydrogels (369).  
RT-PCR confirmed the findings from histology and immunohistochemistry 
analysis and revealed that aggrecan, (an early chondrogenic marker) was upregulated 
(approximately 100 fold) in all microcarrier types, when normalised to multipotent 
controls cultured in monolayer on tissue culture plastic. However, prior to the addition 
of chondrogenic differentiation media, aggrecan expression was upregulated by 1000 
fold increase in expression. This indicates aggrecan was actually downregulated after 
the introduction of chondrogenic differentiation media. This is likely due to aggrecan 
being transiently expressed in MSCs during chondrogenesis, were expression is 
upregulated in the first week and decreases significantly in the second and third week of 
differentiation (370). In addition, Mwale et al. found aggrecan was constitutively 
expressed in human MSCs in monolayer culture prior to chondrogenic differentiation 
(371). In this study this was not observed in ADSCs cultured in monolayer on tissue 
culture plastic. However this could provide an explanation for ADSCs cultured on 
microcarriers.  
Directing the differentiation of a single stem population into spatially organized 
native-like articular cartilage has not yet been reported. Our ability to tailor the culture 
conditions and environmental signals through biomaterial compositions could allow for 
directed differentiation of a single stem cell population into the various zonal 
phenotypes of articular chondrocytes. The resulting chondrocytes should have the 
capability to produce zone-specific ECM and consequently possess spatially varying 
mechanical properties that are similar to native articular cartilage. 
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4.17 Conclusion 
In summary, ADSCs bind and proliferate on RGDfC and IKVAV modified 
microcarriers, and not YIGSR. In addition cells adhered to microcarriers with a range of 
compressive moduli (8, 155 and 273kPa) and were capable of differentiating into 
adipocytes, osteocytes and chondrocytes. RT-PCR and immunohistochemistry data 
showed adipogenesis and osteogenesis was higher on 8kPa microcarriers. Spontaneous 
cell aggregation was observed on microcarriers which showed moduli specific 
differences. Immunocytochemistry showed 8 and 273kPa microcarriers induce 
differentiation of MSCs into chondrocytes that match specific zones of articular 
cartilage which expressed Collagen types I and II. Overall, the microcarriers developed 
herein are capable of sustaining cell adhesion and growth whilst remaining multipotent. 
Further work would attempt to expand ADSCs on RGDfC microcarriers at 155kPa. 
 
 
 
 
 
 
 
 
5.0 ADSC expansion on novel 
microcarriers in spinner flask 
bioreactors 
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5.1 Introduction  
Mesenchymal stem cells are located in several tissues in the body, such as bone 
marrow, fat and muscle, however the populations are largely dormant and present in 
small quantities. To use MSCs for clinical purposes, such as tissue engineering or cell-
based therapies, large cell quantities are required (372).  
Conventionally, MSC expansion is performed in 2D monolayer culture on tissue 
culture treated plastic flasks. However, this format has limited surface area available for 
cell expansion, and hence requires extensive handling for numerous cell passages and 
medium refreshments. This method is both labour intensive and increases susceptibility 
to contaminations. Furthermore, cultures cannot be monitored or controlled, resulting in 
suboptimal culturing conditions and low productivity. Therefore, strategies are required 
to isolate MSCs and expand to (tens of) millions of cells in a controlled, cost-effective, 
and reproducible way. Currently, extensive research is being performed on the 
development of bioreactors as they are highly productive, easily scalable and culture 
conditions can be closely monitored (373). As MSCs are anchorage dependent, to 
maximise expansion in a bioreactor a large surface area is required (373, 374).  
Microcarriers provide a large surface area for cell growth and proliferation, and have 
been extensively studied for the expansion of cells in spinner flasks.  
In a typical bioreactor system, microcarriers are placed in growth medium, after 
which, cells are inoculated and allowed to bind and grow on the surface of the 
microcarriers. The culture is maintained with moderate stirring to keep the microcarriers 
in suspension and to increase nutrient and oxygen transfer throughout the medium, 
providing an easily controllable, homogeneous growth environment (375, 376). Within 
a given bioreactor, the binding affinity of cells to the microcarrier surface will depend 
on the cell line, the microcarrier characteristics (including charge, composition and 
size), the medium composition, and the cell loading per microcarrier (377). The initial 
rate of cell adsorption onto the microcarrier can also be influenced by bioreactor design, 
including the bioreactor material, capacity, inoculum density and rate and type of 
culture agitation. The optimum parameters vary between different cell types and 
bioreactors used. Consequently, the conditions that effect cell attachment, distribution 
on the surface of microcarriers (including growth rate) must be identified and optimised 
for a particular system. 
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Microcarrier culture within spinner flask bioreactors has previously been used to 
expand MSCs (113, 378). Most studies have used charge as the primary means of cell 
attachment to microcarriers. However, charge is undesirable in MSC expansion as cell 
retrieval can be difficult, reducing the final cell yield. In addition, charged microcarriers 
rely on animal serum for cell attachment and positive charges have been shown to effect 
cell spreading and differentiation (379). Few studies have expanded MSCs on charge 
neutral microcarriers within spinner flask bioreactors (like those developed herein) 
where attachment is dependent on integrin interaction. At the time of writing, MSCs 
have not been expanded on a synthetic tunable microcarrier substrate. The aim of this 
work was to test whether the optimised novel synthetic microcarriers were capable of 
supporting ADSC attachment and expansion in a stirred culture system while 
maintaining the characteristic immunophenotype and multipotency differentiation 
potential. To achieve this, the bioreactor design, cell seeding density and stirring regime 
were optimised to increase ADSC expansion.  
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5.2 ADSC expansion on novel microcarriers 
To assess the expansion potential of ADSCs on novel microcarriers (155kPa 
1mM cRGDfC), ADSCs were seeded directly into three spinner flasks at a density of 
5,000 cells/cm
2
 (12,667 microcarriers in 30mLs of medium) and cultured for 7 days. 
The microcarrier culture was stirred intermittently (for 1 minute every 45 minutes) at a 
low rpm (21rpm) for the life span of the culture. Partial media changes (50%) were 
performed every three days. During the cultivation of ADSCs on microcarriers, growth 
was monitored over time in triplicate using a Prestoblue cell viability assay (Figure 55). 
The microcarriers were agitated to create a homogenous solution and removed using a 
pipette from at least two different positions and analysed in triplicate daily. As this 
process potentially yields different quantities of microcarriers cell viability was 
normalised to microcarrier number assessed via microscopy. A cell viability assay was 
preferred to cell counting as this enabled more samples to be analysed, did not require 
cells to be removed from the microcarrier (removing error from inefficient or 
incomplete detachment). In addition, the assay was not affected by any detached dead 
cells (380). 
A general trend of increasing cell proliferation over time was observed in each 
culture, with a temporary decrease in viable cells at 120 hours (Figure 55). As this 
reading was taken before a scheduled partial media change (which took place every 3 
days), a lack of nutrients or an accumulation of toxic metabolites could have potentially 
restricted cell growth.  As the number of viable cells increased in each condition 
(normalised to microcarrier number), standard deviation also increased indicating 
variability within the culture. From bright-field images (Figure 56) it was observed that 
whilst some microcarriers were fully colonised by cells, others had little to no cell 
attachment. In addition, after 7 days cell aggregates had formed within microcarrier 
interstices.  A final cell density could not be accurately established as cells contained 
within interstices could not be fully dissociated from one another.  
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Figure 55 Prestoblue cell viability assay 
Growth of ADSCs on microcarriers was monitored over time in triplicate using a Prestoblue cell viability 
assay. Cell number increase over time was observed in each culture, with a temporary decrease in viable 
cells at 120 hours. 
 
Figure 56 Brightfield microscopy of ADSC bound microcarriers grown in a stirred bioreactor. 
Cell attachment to microcarriers was observed after 1,3, and 7 days. Binding and growth appeared 
inconsistent, with the ADSCs accumulating within microcarriers interstices at day 7 (Scale bar 250µm). 
 
 
Day 1
Day 3
Day 7
Flask 1 Flask 2 Flask 3
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5.3  Morphological analysis 
In stirred suspension microcarrier cultures, the distribution and morphology of 
ADSCs during cell adherence and proliferation was shown by inverted bright field 
microscopy (representative images are shown in Figure 56). Cell attachment to 
microcarriers was observed after 24 hours in culture and cells demonstrated a partially 
rounded morphology. Few unattached cells could be observed in the medium. On day 3, 
cell colonisation of microcarriers increased, and attached cells appeared to have a 
flattened morphology. In addition, cell bridges were observed between adjacent 
microcarriers. After 7 days of cultivation, cells appeared to have reached confluency on 
many microcarriers. However this was inconsistent, as can be seen Figure 56, some 
microcarriers have little to no cell attachment. Microcarriers appeared to have 
aggregated with ADSCs accumulating within microcarriers interstices. The microcarrier 
culture was stirred intermittently for 7 days. However, the impeller speed was not 
sufficient to fully suspend the multi cell-laden microcarrier aggregates, which settled at 
the base of the spinner flask. Following this observation the culture was terminated on 
Day 7. 
To probe the influence of the spinner flask culture upon ADSC attachment and 
spreading, the cytoskeleton organisation was examined after 7 days. The actin 
cytoskeleton was visualised using TRITC conjugated phalloidin, which selectively 
stains F-actin. After 7 days in culture, ADSC spreading was visualised on the 
microcarriers as shown in Figure 57. Analysis of the phalloidin stained F-actin 
cytoskeleton displayed well defined parallel stress fibres which were mostly stretched 
along the long axis of the cells. Phalloidin staining corroborated phase contrast images, 
showing a heterogeneous distribution of cells over the microcarrier population. For 
example, highly populated microcarriers were observed, in addition to ‘unoccupied’ 
microcarriers with no cell attachment. Contrastingly, many cell bridges connecting 
microcarriers could be observed, indicating bead to bead transfer.   
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Figure 57 Visualisation of the actin cytoskeleton of ADSC cells grown on microcarriers in spinner 
flasks 
Analysis of the F-actin cytoskeleton stained with phalloidin displayed well defined parallel stress fibers 
which were mostly stretched along the long axis of the cells. Images have been false coloured to allow 
depth perception of cells. 
  
Flask 1
Flask 2
Flask 3
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5.4 Expression of lineage-specific gene transcripts  
Following the bioreactor expansion of ADSCs, quantitative RT-PCR analysis 
was used to detect the expression of mRNA transcripts associated with lineage specific 
differentiation. To determine whether microcarrier culture had an effect of priming 
ADSC differentiation to a particular lineage, RT-PCR analyses were performed for 
CD73, a marker for multipotency  and three early differentiation genes: RGC32, 
FABP4, and Aggrecan (ACAN), which are early cell markers for osteogenesis, 
adipogenesis, and chondrogenesis, respectively and normalised to multipotent controls 
cultured on tissue culture plastic (Figure 58). Cell-laden microcarriers cultured in 
spinner flasks for 7 days revealed CD73 expression remained largely unchanged in the 
cultures, indicating multipotency remained. The expression of the chondrogenic-specific 
gene, aggrecan was upregulated in all three cultures. The upregulation was most 
pronounced in spinner flask 3 (a 259 fold increase), which also showed the highest total 
cell growth over 7 days.  As discussed in Chapter 4 (Section 4.13), differentiation into 
chondrocytes was associated with a spontaneous aggregation of cells on the 
microcarrier surface to form a pellet like structure. As can be seen with phase contrast 
images (Figure 56), this was not observed on cells cultured on microcarriers after 
spinner flask expansion, where cells formed a monolayer on the sphere surface (with the 
exception of cells found in interstices). Low levels of the adipocyte-specific gene, Fatty 
Acid Binding Protein (FABP4) were detected, with a slight upregulation compared to 
control. However, this was not significant, as adipogenic induction in ADSC-laden 
microcarriers in static culture generated a 136,000 fold increase in FABP4 gene 
expression. Furthermore, phalloidin staining demonstrated spread cells with well-
defined actin structures. This is atypical of adipocytes, which generally have a round 
morphology. In addition, an increase in the osteogenic marker RGC32 showed an 
upregulation with a maximum 4-fold increase in expression in flask 1. This indicates the 
cell population was heterogeneous.  
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Figure 58 RTPCR analysis of ADSCs grown on microcarriers in spinner flasks. 
Cell-laden microcarriers cultured in spinner flasks for 7 days revealed CD73 expression remained largely 
unchanged in the cultures, indicating multipotency remained. The expression of the chondrogenic-specific 
gene, aggrecan was upregulated in all three cultures. 
 
5.5 Effect of cell seeding density on ADSC expansion 
In order to increase ADSC expansion, the bioreactor conditions were optimised. 
In the previous experiment, as cell number increased in each culture, the standard 
deviation also increased. This indicates variability within the culture, in particular 
inconsistent cell seeding on microcarriers. To ensure a homogenous distribution of 
microcarriers and cells, and to prevent cells attaching to the top layer of settled 
microcarriers only, the intermittent stirring speed was increased from 21rpm to 60rpm. 
In addition, it was hypothesised that cell transfer via bead to bead transfer requires the 
microcarriers to contact for a sufficient amount of time as to allow cells to migrate from 
one microcarrier to an adjacent microcarrier. To maximise the probability of 
microcarriers contacting one another, cells and microcarriers were stirred intermittently 
for the entire lifespan of the culture. In addition, medium changes were increased from 
every three days to every two days, to replenish nutrients and remove potentially toxic 
metabolites from the culture. 
 In the first attempt to expand ADSCs on microcarriers, the cell seeding density 
was 5,000 cells/cm
2
, as recommended by the suppliers of ADSCs (Invitrogen). This 
equates to approximately 35 cells per microcarrier. To increase the surface area 
available for expansion, microcarriers were seeded with ADSCs in spinner flasks at four 
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different seeding densities, 2236 cells/cm
2
, 1183 cells/cm
2 
394 cells/cm
2 
and 131 
cells/cm
2 
(17, 9, 3 and 1 cells/microcarrier respectively) and cultured for 14 days. Cell 
number was measured on day 14, and cell viability was measured daily using the 
Prestoblue assay, and normalised to microcarrier number (manually counted by 
microscopy).  
5.6 Analysis of cell proliferation of ADSCs on microcarriers  
In stirred suspension microcarrier culture, cells seeded at the lowest density (131 
cells/cm
2
) demonstrated a small increase in viable cell numbers between 24-120 hours, 
followed by a phase of cell proliferation (120-366 hours) (Figure 59). ADSCs seeded at 
394 cells/cm
2 
also showed low amounts of viable cells until 72 hours, before steadily 
increasing and eventually reaching a maximum value at day 14. Cells seeded at 2236 
cells/cm
2 
generated slightly lower amounts of viable cells after 24 hours than was 
observed than cells seeded at 1183 cells/cm
2
, however the total viable cells seeded at 
2236 cells/cm
2
 was higher after 14 days. Cells seeded at 1183 cells/cm
2 
demonstrated 
growth after 24 hours. Overall, cell number was found to be highest on microcarriers 
seeded with ADSCs at a density of 2236 cells/cm
2
. Over the culture period, viable cell 
numbers per microcarrier increased steadily in all four seeding density conditions. 
However, as viable cell numbers increased, variation in readings also increased. As 
multiple samples were analysed, and viable cell number was normalised to microcarrier 
number this indicated inconsistent colonisation of the microcarriers. The increase in 
viable cell number in stirred microcarrier cultures was also consistent with findings 
made using the inverted bright field images data, which showed an increase of 
colonisation (and inconsistency) of the cells during the cell culture period (Figure 61). 
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Figure 59 Prestoblue analysis of the affect of seeding density on population growth of ADSCs in 
stirred bioreactors. 
Microcarriers were seeded with ADSCs in spinner flasks at four different seeding densities (2236, 1183, 
394 and 131 cells/cm
2
)
 
and cultured for 14 days. Cell viability was measured daily using the Prestoblue 
assay, and normalised to microcarrier number (manually counted by microscopy). 
 
Figure 60 Trypan blue viability assay analysis to determine affect of seeding density on expansion 
capacity of ADSCs in stirred bioreactors. 
Microcarriers were seeded with ADSCs in spinner flasks at four different seeding densities (2236, 1183, 
394 and 131 cells/cm
2
)
 
and cultured for 14 days. Cell number was measured on day 14 using the Trypan 
Blue assay. An inverse relationship between initial seeding density and both doubling time and fold 
increase in expansion is demonstrated. 
 
To determine how many viable cells can be generated through microcarrier 
culture, cells were removed from microcarriers after 14 days in spinner flask culture and 
viable cells were counted using a Trypan blue cell viability assay. The increase in viable 
cells, as shown by the Prestoblue viability assay, was found to correlate to cell number 
(Figure 56). After 14 days of culture, the highest quantity of ADSCs was observed in 
Culture 
conditions  
Initial seeding 
density (105 
cells/mL) Based 
on 30mLs 
Cells 
seeded 
Final cell 
density (105 
cells/mL) 
Final cell 
number (105 
cells/mL) 
Fold 
increase 
Population 
doubling Doubling time 
        
2236 cells/cm2 7177.97 215339 0.73 ± 0.09 73.35 ± 0.09 34.06±0.44 5.09 50.57 ± 0.14 
1183 cells/cm2 3800 114000 0.7 ±0.009 56.07 ±0.009 49.18±0.89 5.62 46.30 ± 0.22 
394 cells/cm2 1266.67 38000 0.3 ± 0.01 31.21 ± 0.01 82.13±3.03 6.36 42.30 ± 0.29 
131 cells/cm2 
 
422.23 
 
12667 
 
0.26 ± 0.08 
 
26.30 ± 0.08 
 
207.65±6.40 
 
7.70 
 
36.34 ± 0.18 
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the culture seeded at the highest cell/microcarrier ratio at 2236 cells/cm
2
, which reached 
a cell density of 0.7 ± 0.09 x 10
5
 cells/mL, but corresponded to the lowest fold increase 
in total cell number of 34.06 ± 0.44. 
 A general trend of decreasing final cell density was observed as 
cell/microcarrier seeding ratio decreased. Contrastingly, the fold increase in expanded 
cells increased. For example, cells seeded at a lower seeding density of 131 cells/cm
2
 
expanded to a density of (0.26±0.08) x 10
5
 cells/mL, resulting in a fold increase of 
207.65 ± 6.40 (Figure 56).  
The doubling time of ADSCs has been shown to vary according to tissue culture 
media. In MesenPro RS (Invitrogen), a proprietary low FBS media, ADSCs have a 
doubling time of 36 ± 4hrs. However, ADSCs cultured in ‘classical’ medium comprised 
of DMEM and 10% FBS (as used in this study) have a doubling time of 54 ± 4hrs. 
During this study the doubling time of ADSCs decreased from approximately 50 hours 
in the highest seeding density to 36 hours in the lowest seeding density.  
5.7   Microscopical analysis 
The distribution and morphology of ADSCs during cell adherence and 
proliferation in the four different culture conditions was shown by inverted bright field 
microscopy (representative images are shown in Figure 61). Cell attachment to 
microcarriers was observed after 24 hours in culture, an even distribution of cells was 
observed on each microcarrier, and cells demonstrated flattened cell morphology. On 
day 7, cell colonisation of microcarriers increased and attached cells continued to have a 
flattened morphology. However, despite an even distribution of cells being observed 
after 24 hours, cell confluency on microcarriers appeared to be inconsistent across all 
conditions. From this two hypotheses were generated i) initial cell attachment was not 
even, and/or cell survival after initial attachment was inconsistent (possibly due to lack 
of cell-cell contact on microcarriers where few cells were attached) ii) the migration of 
cells from one microcarrier to another (bead-to-bead transfer) could only occur if cells 
were in close enough proximity to an adjacent microcarrier. If cell confluency was 
reached on a microcarrier, the ability of cells to transfer to a less confluent microcarrier 
could increase the surface area available for cell expansion. After 14 days of cultivation, 
visual inspection of the culture indicated many microcarriers appeared to have reached 
confluency. As initial cell seeding density increased, confluency appeared greater and 
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more even between the microcarriers. This was more consistent than seen in the 
previous attempt at 5,000 cells/cm
2
, as can be seen Figure 61, where all microcarriers 
had some cell attachment. In addition, very few multi-microcarriers aggregates were 
observed.  
 
Figure 61 Brightfield microscopy of ADSC bound microcarriers grown in a stirred bioreactor from 
a range of seeding densities. 
Cell attachment to microcarriers was observed after 1,7 and 14 days in culture. At early timepoints cell 
binding was observed on each microcarrier, and cells demonstrated flattened cell morphology. Despite an 
even distribution of cells being observed after 24 hours, cell confluency on microcarriers at later 
timepoints appeared to be inconsistent across all conditions 
 
5.8 The effect of different seeding densities on the expression of 
lineage-specific gene transcripts.  
To determine if differences in initial seeding density had an effect of priming 
ADSC differentiation, quantitative RT-PCR was performed to analyse gene expression 
of early differentiation markers (Figure 62). Cell-microcarrier constructs were removed 
from spinner flasks after 14 days and analysed. CD73, (a multipotency marker) 
expression was downregulated consistently (on average a 0.48 ± 0.06 fold decrease) in 
all four conditions compared to multipotent ADSC controls.  
RGC32 (an osteogenesis marker) was upregulated in all four conditions, with 
cells seeded at 394 cells/cm
2 
showing the highest increase (6.8 fold). As seen 
previously, aggrecan gene expression demonstrated a consistent upregulation across all 
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four conditions. Upregulation ranged from 372 to 572 fold, however no apparent 
relationship between expression and seeding density could be identified.  However, this 
is noteworthy, as chondrogenic induction in ADSC-laden microcarriers in static culture 
generated a 1052 fold increase in Aggrecan gene expression.  
 
Figure 62 RT-PCR analysis of ADSCs grown on microcarriers within a stirred bioreactor from a 
range of seeding densities. 
Cell-microcarrier constructs were removed from spinner flasks after 14 days and analysed for a range of 
markers. Although CD73 (multipotency), RGC32 (osteogenesis) and FabP4 (Adipogenesis) remained 
relatively unchanged, there was a large increase in the expression of ACAN (chondrogenesis). 
 
FABP4 expression, an early marker for adipogenic differentiation was 
upregulated in the three highest seeding densities. At the two highest seeding densities, 
FAP4 expression showed an equal fold increase. At a lower initial seeding density of 
394 cells/cm
2
, expression was still upregulated, but with a reduced fold increase. 
Furthermore, FABP4 was downregulated in the flask containing the lowest initial 
seeding density of 131 cells/cm
2
. It has previously been observed that adipogenesis is 
highest on microcarriers where there is a high cell density. As cell density was highest 
on 2236 cells/cm
2
 this could explain the increased expression of early adipogenic genes. 
5.9 Histological analysis 
To assess the multipotency potential of spinner flask expanded ADSCs, cell-
laden microcarriers from both experiments, i.e. after 7 days or after 14 days, were 
transferred to multi-well plates and maintained in adipogenic, chondrogenic, or 
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osteogenic medium for a further 14 days and analysed using histochemical analysis. 
Approximately 30 microcarriers per condition were visualised and approximately 5 
images were taken, microcarriers appeared consistent across all conditions 
(representative images are in Figure 63).  
Cell-laden microcarriers maintained in adipogenic induction medium 
demonstrated adipogenesis as evidenced by positive Oil Red O staining of lipid 
droplets. Microcarriers cultured in the presence of chondrogenic induction medium 
showed that cells formed spontaneous aggregates (similar to those observed in Section 4 
Figure 52), that stained intensely with alcian blue (indicating a sulfated matrix). 
Microcarriers cultured in the presence of osteogenic induction media showed matrix 
mineralization with intense alizarin red staining (Figure 63). 
 
 
Figure 63 Histological analysis of cells driven into differentiation after 7 or 14 days growth on 
microcarriers in a bioreactor. 
To assess the differentiation potential of ADSCs maintained on microcarriers within a bioreactor for 7 
and 14 days, cell-laden microcarriers were placed into chondrogenic, adipogenic or osteogenic 
differentiation media for a further 14 days and stained for differentiation markers. ADSCs still retained 
the potential to differentiate into all three cell types. 
  
Experiment 1 
Day 7
Experiment 2 
Day 14
Alcian Blue Oil Red O Alizarin Red
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5.10 Discussion  
ADSCs are anchorage dependant, and therefore need to be attached to a surface 
for cell growth and expansion. Microcarriers are ideal candidates as they provide a large 
surface area to volume ratio. Several published reports detail the culture and expansion 
of MSCs on microcarriers and have demonstrated the resulting cell populations are 
multipotent, however have no increase in expansion compared to cells grown on 
standard 2D plastic. The published reports vary according to microcarrier composition, 
MSC type (species, source and method of isolation), bioreactor design and culture 
duration, making direct comparisons difficult, (Eibes et al., 2010 (381); Frauenschuh et 
al., 2007 (374); Hewitt et al., 2011 (140); Malda and Frondoza, 2006 (128); Sart et al., 
2009 (378); Schop et al., 2008 (113); Yang et al., 2007 (167)).  
Few of the reported studies used human MSCs, and the processes described 
were not suitable for the manufacture of cell therapeutics due to the reliance on animal 
products, both in the culture medium and microcarrier composition. In the development 
of GMP-compliant expansion protocols to generate cell therapies, Santos et al. (2011) 
made a significant improvement on previously published studies, reporting the 
expansion of human BM-MSCs and ADSCs in a xeno-free microcarrier system, with an 
18-fold and 16-fold expansion respectively in 14 days (138). The microcarriers 
employed were plastic coated with CELLstart™ xeno-free substrate (a proprietary 
formulation, Invitrogen). However, they reported low seeding efficiencies, 23% (BM-
MSCs) and 22% (ADSCs) respectively (and therefore low overall process efficiency).  
In Chapter 4 it was demonstrated that novel synthetic microcarriers can support 
ADSC attachment and proliferation. To generate large quantities of cells, microcarriers 
are cultured within stirred bioreactors, such as spinner flasks, which use an impeller to 
mechanically agitate the culture volume. This creates a homogenous environment, and 
facilitates the transfers of nutrients and diffusion of gases throughout the culture 
volume, ultimately yielding increased cell growth. In addition to increasing cell number, 
microcarrier systems must generate a homogenous population of ADSCs which all 
maintain their original characteristics, including differentiation potential. This is 
important if the expanded cell populations are to be used in clinical therapies. In this 
study, we demonstrated that isolated ADSCs can be expanded on novel synthetic 
microcarriers in stirred suspension cultures to yield viable cells with retained 
multipotent potential.  
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5.10.1 Effect of initial seeding density on ADSC expansion 
Cell seeding density per microcarrier is a critical parameter to optimise cell 
expansion. If the cell to microcarrier ratio is too low this will lead to an extensive lag 
phase (356). Alternatively, if the cell microcarrier ratio is too high the available cell 
surface area is reduced, limiting the amount of expanded cells (382). In optimum 
conditions, the ratio of cells to microcarriers should be high enough to permit cell 
adhesion to all microcarriers. It has been suggested that a minimum average of around 
5-6 cells per microcarrier is optimum for charged microcarriers (356, 357). Using 
Poisson distribution, Frauenshuh et al. (2007) predicted that the amount of (charged) 
microcarriers without any cell adhesion using this seeding density is less than 1% (358). 
This is optimized for charged microcarriers; however, the rate of cell adhesion to 
uncharged microcarriers is slower. On uncharged microcarriers the initial probability of 
cell microcarrier binding events is random, and is largely dependent on cell proximity to 
the microcarrier surface, to form an integrin-peptide ligand attachment.  
Cells seeded at 35 cells per microcarrier formed aggregates between interstices 
after 7 days which were difficult to dissociate, preventing accurate cell counts from 
being taken. Hence, the expansion in the microcarriers couldn’t be quantified. The 
results would suggest an upper limit on cell seeding density per microcarrier. Therefore, 
to assess the effects of cell seeding density on cell expansion, several cell seeding 
densities were tested, 2236 cells/cm
2
, 1183 cells/cm
2 
394 cells/cm
2 
and 131 cells/cm
2 
(17, 9, 3 and 1 cells/microcarrier respectively). In this study, a ratio of 17 cells per bead 
yielded the highest number of cells after 14 days (7.3 million cells) generating a cell 
doubling time of 51 hours, or 5.09 population doublings over 14 days. This is similar to 
the reported doubling rate of ADSCs of approximately 54 hours ± 4 hours, when 
cultured in DMEM and 10% FBS. Alternatively at 1 cell per microcarrier the doubling 
time was significantly reduced to 36.4 hours, indicating 7.7 population doublings over 
14 days. This is similar to the doubling rate reported for ADSCs in a proprietary low 
serum media (MesenPro RS, Invitrogen) of 36 hours ± 4 hours. This correlated to data 
from Kehoe et al. (2012) who also noted an increase in doubling time on microcarriers 
seeded with higher cell densities (111). MSCs expanded ex vivo for clinical therapies 
not only require large lot sizes, but also require the cells to be delivered as quickly as 
possible. The decrease in doubling time observed herein is therefore advantageous for 
MSC expansion. The results presented here were generated using DMEM and 10% 
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MSC-qualified FBS, future work would look at the effect of using different medium 
compositions on cell-doubling rate on microcarriers. 
ADSCs seeded at 1 cell per microcarrier generated a 207 fold increase in cell 
number over 14 days, with fold expansion decreasing as initial seeding density 
increased. However, even the lowest increase (73-fold), is considerably  higher than 
previously reported in the literature for microcarrier based expansion of ADSCs (16- 26 
fold increase in 14 days (138)). 
A limiting factor in MSC expansion in monolayer culture is surface area. As 
shown by Schop et al. one method to expand the culture without passaging the adherent 
cells is the introduction of fresh microcarriers during the culture (378). Cell expansion 
occurs via bead to bead transfer, (the migration of cells from one microcarrier to 
another) increasing the available surface area for MSC culture.  In future experiments 
the upper limit on cell expansion on the microcarriers would be explored, in particular 
the time taken in culture for cell proliferation to plateau due to lack of available surface 
area. In addition the potential to expand the surface area by adding fresh microcarriers 
throughout the culture time would be investigated.  
5.10.2 Effect of stirring regime on initial cell attachment 
Cell culture on microcarriers typically utilises stirred suspension bioreactors, 
such as spinner flasks. Conventionally, cultures are stirred intermittently straight after 
seeding (for the next 4-18hours) to allow cell adhesion, and then switched to continuous 
stirring for cell growth. This provides a homogenous culture environment and allows 
nutrients and oxygen to be transferred throughout the culture. This bioreactor design has 
previously been optimised for microcarriers which rely largely on inherent charge 
potential for cell attachment (115), where cells are electrostatically attracted to the 
microcarrier surface resulting in high initial cell attachment. (121). The primary method 
of cell attachment to the uncharged microcarriers used in this study is via peptide-
integrin interactions. It has been demonstrated that attachment to uncharged 
microcarriers is slower than to charged microcarriers.  
To assess cell morphology and distribution of expanded ADSCs, microcarrier 
samples were removed from the bioreactors daily. For cultures seeded at 5,000 cells/ 
cm
2
 showed cell attachment to be highly variable after 24 hours. In the event of 
unevenly distributed cell attachment across the entire microcarrier population, the 
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cultures were intermittently agitated (1 minute every 45 minutes at 21rpm) for the 
length of the culture, to allow bead-to-bead transfer. It is hypothesised that the 
migration of cells from one microcarrier to another is dependant on the proximity of 
microcarriers. To increase the probability of a cell-laden microcarrier becoming 
adjacent to another microcarrier with space for a cell to attach and grow, the cultures 
were stirred intermittently (as opposed to the conventional continuous stirring).  
Bead-to-bead transfer was observed between the novel microcarriers in samples 
seeded at 5,000 cells/cm
2
 (Figure 56).  After 7 days the attachment appeared to be fully 
confluent on some microcarriers with cell bridges and cell accumulation at interstices 
between microcarriers. This resulted in microcarriers forming large aggregates which 
were too dense to be fully suspended when agitated at 21rpm.  
Cells contained within aggregates experience different culture conditions, 
including oxygen and nutrient transfer. The aim of this study was to generate a 
homogenous population of expanded ADSCs with multipotent potential. The early 
chondrogenic marker aggrecan demonstrated a fold increase in expression in all three 
cultures. Furthermore, the multipotent marker CD73 showed little change in expression 
in all three cultures. This could indicate cells cultured within interstices experience a 
pseudo 3D environment, promoting chondrogenic differentiation. The variation between 
spinner flasks and the remainder of CD73 expression, and increased adipogenic and 
osteogenic markers indicates a heterogeneous cell population. However, there is a lack 
of specific cell surface markers to identify MSC populations. Some markers have been 
proposed to identify MSCs, i.e. STRO-1 and CD105, the most common method is 
plastic adherence and colony formation (49). This method cannot establish the 
percentage of differentiated cells in response to culture conditions. Microarray analysis 
has shown CD73 to be expressed in MSC differentiated chondrocytes  (383) casting 
doubt into the suitability of it as a multipotency marker. To establish the multipotency 
of expanded cells, microcarriers were placed in differentiation medium and the 
differentiated cells were analysed with stains to detect expression of lineage specific 
proteins.  
All microcarriers previously reported for MSC expansion are polydisperse with 
a relatively wide range of diameters. This factor could potentially provide a non-
homogenous culture, as confluency can occur at different rates depending on the 
available surface area of the microcarrier, generating a heterogeneous environment.  
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The microcarriers used in this study were generated using microfluidics and are highly 
monodisperse and hence cell adhesion should be very similar on all microcarriers. 
Variations in attachment are most likely due to problems with bioreactor protocols and 
design, including homogenous distribution of cells and microcarriers during the initial 
attachment phase. When cells were seeded at 5,000 cells/cm
2
, multiple microcarrier 
aggregates were formed with confluent cells. Simultaneously a population of 
microcarriers had little to no cell attachment. To ensure a homogenous distribution of 
microcarriers and cells during the attachment phase of the culture (estimated to be 
approximately 24 hours), and to prevent cells only attaching to the top layer 
microcarriers, the intermittent stirring speed was increased from 21rpm to 60rpm to 
ensure all microcarriers were displaced after agitation. During the culture with different 
cell to microcarrier ratios cell attachment appeared even after 24 hours, however after 7 
days attachment varied between microcarriers. After 14 days the cells appeared to be 
evenly distributed over the microcarriers with few microcarrier aggregates observed. 
The increase in agitation speed can also increase the shear force experienced by a cell 
and increase microcarrier collisions, potentially dislodging newly attached cells if the 
attachment is weak. Previous studies investigating the effect of impeller speed on cell 
expansion have involved continuously stirred cultures using a variety of impeller 
geometries. Hence these data are not directly comparable to the culture system 
described herein. 
The influence of shear effects on MSC differentiation has been linked to 
microcarrier diameter. By decreasing microcarrier diameter from 3m to 0.5mm, Kong et 
al. (2011) observed an increase in osteogenic differentiation in BM-MSCs cultured in 
continuously agitated spinner flasks (266). The effect of shear force on cell attachment 
has not been investigated in this study; however, as the microcarriers are monodisperse 
the relationship between shear force and microcarrier diameter should be identical in all 
cultures. This is unlike most previous studies, where commercially available 
polydisperse microcarriers were used. Future work will optimise the stirring regime to 
maximise cell expansion, whilst maintaining cell phenotype.  
Aggrecan expression is an early chondrogenic differentiation marker and has 
been shown to be upregulated in the first week of ADSC chondrogenic differentiation, 
and its expression is reduced in week 2 and week 3 of differentiation (384). Within both 
7 and 14 day experiments, aggrecan expression was upregulated with no dependence on 
initial seeding density. Despite this result the cell morphology appeared spread and did 
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not form spontaneous aggregates or pellets as shown previously in cell-laden 
microcarriers undergoing chondrogenic differentiation (Figure 56 and Figure 61). The 
cells cultured at different cell seeding densities were shown to still be able to 
differentiate into three lineages by histochemical analysis, demonstrating their 
multipotency. Further work would analyse the expression of several other genes linked 
to chondrogenic differentiation.  
5.10.3 Effect of nutrient depletion and metabolite accumulation on cell growth 
In order to develop a bioreactor system, it is essential to understand the cell 
requirements for optimal cell growth. Cell growth can be inhibited by a lack of 
appropriate nutrients or by an excess of metabolites. To achieve optimal culture 
conditions, the media feeding and refreshing regime is crucial (113). Whilst cells 
proliferate and grow, cells consume nutrients such as glucose and glutamine (in addition 
to other amino acids). Simultaneously cells produce and secrete metabolites, such as 
lactate and ammonia. If the metabolites accumulate in the culture media, at certain 
concentrations they can inhibit cell growth. Schop et al. determined an increase in 
lactate concentration (24mM), inhibits cell growth in human BM-MSCs, which was 
shown to vary between donors (113).  However, their differentiation potential remained 
unchanged. To prevent inhibition of cell growth, the replenishing the media should be 
optimised to prevent depletion of essential nutrients and the accumulation of metabolite 
production. Increase in cell growth correlates to increased nutrient consumption and 
metabolite production, therefore quickly proliferating cells will require more frequent 
media refreshments. 
In the first attempt to expand ADSCs on the novel microcarriers, the feeding 
regime was a partial media change (50%) every three days. ADSCs expanded on 
microcarriers in spinner flasks for 7 days, at a seeing density of 5,000 cells/cm
2
 
demonstrated a notable decrease in the number of viable cells (Figure 55) after 120 
hours in culture. As the number of viable cells was assessed directly before a scheduled 
media refreshment, this could be as a result of nutrient depletion or metabolite 
accumulation in the culture media. Schop et al. demonstrated exponential growth BM-
MSCs on microcarriers using the same feeding regime (partial media change (50%) 
every three days) without generating inhibitory levels of the metabolites lactate and 
ammonia for 9 days. However, after this point the inhibiting concentrations of ammonia 
(2.4mM) became too high and glucose levels were depleted to near 0mM. Santos et al. 
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(2011) cultured ADSCs cultured on plastic microcarriers in xeno-free media over 14 
days and showed that after an optimised daily feeding regime (partial media change 
(25%)), lactate and glucose levels did not inhibit cell growth (138). Glucose 
concentration (both high and low) has been shown to have no effect on BM-MSCs 
grown in tissue culture flasks, including no change in proliferation, differentiation 
potential or trophic factor secretion. This has been confirmed by Sart et al. (2010) and 
Schop et al. (2008) when expanding MSCs on microcarriers (113, 378). This indicates 
lactate and ammonia are metabolites responsible for effecting cell growth and therefore 
should be monitored regularly. Due to cost restraints, nutrient depletion and metabolite 
production was not analysed in our system. Future optimisation of the bioreactor design 
will address this issue. In the second experiment cells were seeded at a significantly 
lower density. To reduce the potential effects of metabolite accumulation the media 
changes were increased to 50% partial media change every two days. From cell viability 
graphs the cells showed linear growth over 14 days.  
5.10.4 Effect of oxygen tension on ADSC growth and differentiation 
An additional parameter that can affect cell growth is oxygen concentration 
throughout the bioreactor. Oxygen tension can affect cell metabolism, for example, an 
increase in glucose metabolism has been shown in cells cultured in hypoxic conditions. 
However, reports on the effects of oxygen concentration on MSC growth rates are 
conflicting.  Schop et al. (2010) compared oxygen concentration (3% ‘hypoxic’ and 
20% ‘normal’) on BM-MSCs cultured on microcarriers in spinner flasks and showed 
oxygen concentration had no effect on the rate of cell growth. Similarly, Wang et al. 
showed hypoxic conditions had no effect on human ADSCs growth when cultured 
within alginate microcarriers in static culture. Contrastingly, BM-MSCs cultured in 
monolayer in tissue culture flasks demonstrated faster growth rates in hypoxic 
conditions (3% O2) compared to 20% O2 (138). In addition, Kehoe et al. (2012) showed 
BM-MSCs cultured on collagen microcarriers had faster growth rates under hypoxic 
conditions (5% O2 compared to 21% O2). However as variations in MSC isolation can 
yield different subpopulations of MSCs with different characteristics, direct 
comparisons can be difficult.  
In addition to cell growth rates, oxygen tension has been shown to affect the 
differentiation potential of BM-MSCs cultured on microcarriers Schop et al.  (2008) 
observed an increase in chondrogenesis in cells expanded under hypoxic (3% O2) 
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conditions. This could be due to a recreation of hypoxic conditions experienced in 
native cartilage stimulating chondrogenic differentiation. Wang et al. also reported 
increased chondrogenesis in ADSCs cultured under hypoxic condition (5% O2), the 
typical oxygen concentration in articular cartilage. However, the authors debated 
whether this was an independent phenomenon or a result of oxygen tension combined 
with matrix effects. For example, ADSCs grown in alginate or agarose retain a spherical 
morphology and show little expression of type I collagen, whereas, fibrin or gelatin 
matrices promote a more fibroblastic morphology and the expression of both type I and 
type II collagen. However, changes in oxygen conditions were not shown to influence 
adipogenesis or osteogenesis on BM-MSC s expanded on microcarriers (113).  
In our study, the spinner flasks were intermittently stirred, therefore diffusion of 
oxygen throughout the culture would be reduced compared to continuously stirred 
cultures described in the literature. An upregulation of the early chondrogenesis marker, 
aggrecan was observed in all seeding densities using quantitative RT-PCR. However no 
obvious morphological changes were observed. As cells require a 3D environment to 
differentiate and express chondrocyte specific genes this was unexpected. In our study 
cells were cultured on microcarriers in intermittent culture conditions. As the 
restrictions of equipment available the spinner flasks did not have an online monitoring 
system to probe the culture and test the oxygen concentration in real time. To increase 
aeration of cultures oxygen sparging has been previously used to by Sart et al. (2010) to 
increase MSC growth rate. 
 
 
 
 
 
 
 
 
 
 
 
6.0 Discussion  
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MSCs are a promising cell source for regenerative medicine to repair or replace 
damaged tissues (1). MSCs are located in several tissues in the body, such as bone 
marrow, fat and muscle, however the populations are largely dormant and are present in 
small quantities (372). To use MSCs for clinical purposes, such as tissue engineering or 
cell-based therapies, strategies are required to isolate MSCs and expand to (tens of) 
millions of cells in a controlled, cost-effective, and reproducible way (372). Therefore, 
methods to rapidly expand MSC populations whilst maintaining cell multipotency and 
viability are currently being developed. Currently, extensive research is being 
performed on the development of bioreactors for efficient expansion of MSCs, as these 
offer several advantages over conventional methods (monolayer culture in tissue culture 
plastic flasks). They are highly productive, easily scalable and culture conditions can be 
closely monitored (373). In particular, the key parameters that affect cell growth can be 
monitored and controlled, such as medium composition and oxygen tension, resulting in 
reproducible cultures. In addition, as it does not require extensive manual handling, the 
risk of contamination is reduced; a factor of paramount importance in developing safe, 
reliable populations of cells for clinical therapies. 
As MSCs are anchorage dependent and so large surface area is required to 
maximise expansion in a bioreactor (373, 374).  Microcarriers provide a large surface 
area for cell growth and proliferation, and have been extensively studied for the 
expansion of cells in spinner flasks (166, 381). To efficiently expand MSCs for clinical 
therapies, an animal free expansion culture systemis required. Animal products must be 
removed from both the culture media and microcarriers. The aim of this thesis was to 
develop an entirely synthetic microcarrier using microfluidics for MSC expansion, free 
of animal-derived components.  
In this study, a microfluidic platform capable of generating monodisperse 
synthetic microcarriers with tunable chemical, topographical and mechanical properties 
has been developed (Chapter 3). Representative PEGDMA microcarriers containing 
bio-adhesive ECM–derived peptides were produced using two different tethering 
chemistries. In addition, microcarriers containing three different compressive moduli 
and diameters were produced. The resulting microcarriers were well characterised. To 
assess the ability of the microcarriers to support ADSC attachment and growth, several 
bio-adhesive peptides (at a range of concentrations) were incorporated into PEDGMA 
microspheres. Over 7 days in static culture, an RGD based peptide cRGDfC at a 
concentration of 1mM was shown to support stable ADSC adhesion and growth. 
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Furthermore, microcarriers with a range of compressive moduli were generated 
(containing the optimised 1mM cRGDfC peptide), to probe the effects of microcarrier 
compressibility on MSC differentiation. Moduli specific differences were observed in 
cell phenotype after osteogenic, adipogenic and chondrogenic induction (Chapter 4). 
Microcarriers with the optimised chemical (1mM cRGDfC) and mechanical (155kPa) 
properties were selected for ADSC expansion. We demonstrated successful expansion 
of viable ADSCs within a spinner flask bioreactor system on novel synthetic 
microcarriers over 14 days (Chapter 5). Cell expansion was optimised by varying the 
cell seeding density. ADSCs showed a 207 fold expansion over 14 days when seeded at 
the lowest seeding density, higher than any reported studies of microcarrier based MSC 
expansion. The study also demonstrated the expanded ADSC population maintained 
multipotent potential, capable of differentiating into adipocytes, osteocytes and 
chondrocytes, essential for use in clinical applications.     
 
6.1 Microfluidic synthesis of PEGDMA hydrogel microspheres with 
tunable chemical, mechanical and topographical characteristics  
The overall aim of this project was to develop a synthetic microcarrier capable 
of providing a solid growth support for MSC expansion within a bioreactor.  Recent 
advances in the field of biomaterials have shown that presenting cues derived from the 
ECM can affect and improve cell growth, intracellular signalling and differentiation 
(217).  Previously, a wealth of research has eluded to possible biomaterial compositions 
that could control MSC fate (189, 271, 306). Various parameters have been considered, 
including chemical compositions, biomechanical properties and surface topographies. 
However, published reports on the precise cellular responses to various biomaterials, 
(such as MSC response to bio-adhesive peptides) are often conflicting (308, 344, 345). 
This is largely due to the subtle differences in scaffold properties used to probe the 
effects of ECM derived cues on cell growth and behaviour.  
In chapter 3, an array system was generated whereby ECM derived cues could 
be tested systematically to ascertain the factors that can regulate MSC growth and 
differentiation. The synthetic polymer, PEGDMA, was selected as it is hydrophilic, easy 
to manipulate (compatible for use with microfluidics), resistant to non-specific protein 
adsorption, biocompatible and non-immunogenic (210). When crosslinked, the resulting 
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hydrogel has high water content and possesses mechanical properties similar to that of 
soft tissue (321). PEGDMA hydrogels are uncharged and lack any cues that allow the 
directed binding and attachment of cells, providing a “blank” bioinert microcarrier. To 
add an adhesive element to the microcarrier, commonly-used ECM derived peptides 
were incorporated to mimic the native microenvironment (241). In addition, the 
polymer content and microcarrier diameter was altered to generate an array of 
microcarriers with a wide range of biochemical and biophysical properties.  
PEGDMA hydrogels have been widely used to assess the effects of 
compressibility, bio-adhesive peptide, and topography on MSC fate (241, 261, 308). 
However, typically the studies were performed on cells encapsulated within the 
photopolymerisable hydrogel, and focussed on assessing one parameter individually. 
For example, Jongpaiboonkit et al. (2009) developed a hydrogel array system for 
analysing adhesion and viability of MSC to IKVAV and RGD based peptides 
encapsulated within degradable and non-degradable PEG hydrogels (346). This method 
generates a 3D culture system, however cell-cell contacts are lost as the cells are 
entrapped within a hydrogel, and surface topography cannot be assessed (345). Cells 
cultured on microcarriers in monolayer culture experience a different 
microenvironment, and therefore it was hypothesised that MSC responses to changes in 
these parameters could behave differently to those previously reported in the literature. 
At the time of writing this study, it is the first time compressibility, bio-adhesive 
peptide, and topography studies have been performed stable in combination, on MSCs 
grown in monolayer culture.  
To generate PEGDMA microcarriers with tunable biochemical and biophysical 
properties a microfluidic platform capable of generating monodisperse microspheres 
was developed. In chapter 3, the optimisation and development of a microfluidic 
method to produce synthetic microcarriers using UV photo-polymerisation is described. 
To achieve this, a range of microfluidic chips, with varying channel designs were 
manufactured and assessed. The resulting method was reproducible and generated 
highly monodisperse microcarriers with uniform characteristics.    
The incorporation of adhesive peptides using “click” chemistry was simple and 
inexpensive. This was a key result as previous methods involved using expensive 
precursor molecules and lengthy characterisation; and gave non-reproducible product 
yields. The only requirement is for a thiol group which can be incorporated into the 
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peptide design via cysteine residues. A fibronectin motif, cyclic peptide cRGDfC, and 
two linear peptides containing the commonly used laminin motifs IKVAV and YIGSR 
were incorporated this way. The cyclic RGD sequence used in this study binds the 
integrin αvβ3, and studies have shown that compared to linear analogues, the cyclic 
form has increased specificity and has up to 240 times enhanced biological activity 
(385). The linear forms of the laminin based peptide IKVAV and YIGSR were used in 
this study as no cyclic forms have currently been reported in the literature.  
Using the method outlined in Chapter 3, further work would incorporate a wider 
range of thiol-bearing peptides into microcarriers to optimise cell attachment. In 2010, 
Corning applied for patent protection for a surface coating for use on tissue culture 
plastic to support adhesion and expansion of BM-MSCs in serum-free media 
(Synthemax, Corning). Technical publications demonstrated BM-MSC expansion was 
~100 fold higher than on conventional tissue culture treated plastic and after multiple 
passages retained high levels of multipotent markers (for Synthemax coatings in 
DMEM and 10% FBS over several passages) (386). The Synthemax surface coating 
contains an acrylated peptide sequence derived from vitronectin, Ac-
KGGPQVTRGDVFTMP, which contains the cell binding motif RGD. By culturing 
BM-MSCs in serum free media (SFM) on this surface they showed approximately a 4-
fold increase in expansion (over 1 passage) compared to normal tissue culture 
conditions, i.e. tissue culture treated plastic classical media (DMEM containing 10% 
FBS).  However, there is no published literature demonstrating the use of this surface to 
culture MSCs. In addition, Synthemax has not been shown to be compatible with MSCs 
isolated from other sources. Future studies would incorporate this peptide sequence, via 
its acrylate functionality and compare it to results obtained from this study. CellStart, a 
similar propriety attachment factor, designed for the use in SFM culture of MSCs has 
recently, (2012) been shown to support the adhesion of BM-MSCs and ADSCs, but not 
placental cord derived MSCs (92). Furthermore, peptide incorporation could be 
expanded to explore the influence of peptides that target non-integrin receptors, and 
hence other signalling pathways, i.e. active fragments of growth factors such as TGF 
beta (known to mediate chondrogenesis in MSCs) (340).  
By altering the PEGDMA (wt %) concentration an array of microcarriers were 
produced with a range of compressive moduli between 8kPa to 231kPa. A linear 
relationship exists between PEGDMA content (wt %) and compressive moduli, 
however there was a limit on the range of compressive moduli that could be produced. 
 184 
 
For example, hydrogels with a compressive modulus less than 8 kPa were very weak 
and not manipulable. Few studies have analysed the effect of compressive modulus on 
MSCs grown in 2D, however, Engler et al. have previously shown a compressible 
modulus of between 0.1-1kPa is required to drive neurogenesis in MSCs (255). To 
improve the range of compressive moduli generated within the microcarrier, different 
molecular weight PEDGMA could be used altering the final cross-linking density of the 
hdyrogel (210, 387).   
 
6.2 Cyclic RGDfC supports MSC attachment and proliferation on 
1mM microcarriers 
To assess the ability of the microcarriers developed in chapter 3 to sustain 
ADSC adhesion and growth, the effect of incorporating several peptides covalently 
linked into the hydrogel was investigated. Peptide modified flat hydrogels were 
produced and showed that ADSCs bound preferentially to cRGDfC hydrogels compared 
to the laminin based sequences. This was unexpected as it had previously been reported 
that ADSCs adhered and spread more extensively on IKVAV modified 
polycaprolactone surfaces, as compared to RGD or YIGSR modified surfaces (347). 
ADSC attachment to RGDfC modified hydrogels at a concentration of 0.35mM resulted 
in the formation of cell colonies, indicating that the cell attachment was low. As the cell 
seeding density per cm
2
 hydrogel surface was relatively high, the effect of increasing 
cRGDfC peptide concentration upon cell attachment was explored, and showed an 
increase in cell attachment coinciding with an increase in peptide concentration. At a 
concentration of 1mM, cells attached uniformly to the surface of the hydrogel. It was 
hypothesised that factors such as topography and peptide ligand density could act 
synergistically to affect MSC fate. Therefore it was decided to test the range of peptides 
and peptide concentrations on microcarriers. From the data gathered it was concluded 
that 1mM RGDfC showed qualitatively the highest level of cell attachment and 
proliferation over 7 days, as seen using a viability assay. Live/dead assays and 
cytoskeleton staining confirmed cell viability data.  
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6.3 Compressive moduli influences MSC differentiation 
To assess the effect of compressibility on cell attachment ADSCs were cultured 
on microcarriers with different mechanical properties for 5 days. To assess the 
multipotency of the attached cells, ADSC-laden microcarriers were transferred directly 
into differentiation induction medium. This result was significant as it demonstrated the 
adhered cells were still multipotent and could undergo osteogenic, chondrogenic and 
adipogenic differentiation on the surface of the microcarriers. This was confirmed using 
RT-PCR analysis and the upregulation of lineage specific gene expression. At the time 
of writing, direct differentiation on microcarrier surfaces has not been shown in the 
literature before. The original aim of this thesis was to generate microcarriers for stem 
cell expansion. However, this result generates an interesting potential function for the 
microcarriers as tissue engineering scaffolds. As the PEGDMA microcarriers are 
irreversibly covalently crosslinked, modifications to the polymer backbone to include a 
biodegradable element would be required. Several research groups have modified 
PEGDMA hydrogels to include a biodegradable element, such as incorporating 
hydrolytically degradable poly(lactic acid) PLA linkages (236) or enzymatically-
sensitive sites which are cleavable by matrix metalloproteinases (MMP) secreted by 
cells (234). These constructs could be placed directly into the tissue requiring repair, 
which offers several advantages over MSC infusion (discussed in Chapter 1).   
An interesting result was observed when stimulating chondrogenesis in ADSCs 
cultured on microcarriers with varying compressive moduli. Cells migrated from 
monolayer culture on the surface of the microcarrier spontaneously to form pellet. In 
addition, it was shown that the pellets had an organised structure which contained 
distinct regions resembling that of articular cartilage. At the time of writing, this is the 
first time this has been reported with on tissue culture plastic or on biomaterials. MSC 
differentiation into chondrocytes, is of particular interest in tissue engineering as it is a 
prerequisite for cartilage regeneration.  
It was originally thought that the only the hardest substrate would be able to 
support chondrogenesis. However, herein the presence of collagen type II in cell pellets 
was demonstrated (using immunocytochemistry) on both the softest 8kPa and the 
hardest 232kPa substrates. Chondrogenesis can be monitored by assessing the 
expression and secretion of collagen isoforms, as MSCs express collagen I whereas 
chondrocytes primarily express collagen II (190, 352). Both isoforms were expressed in 
the hard and soft microcarrier substrates, indicating the presence of MSCs and 
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chondrocytes. The expression of collagen type II is an important result because it is one 
of the major components of the hyaline cartilage and plays a key role in maintaining 
chondrocyte function. This is essential when assessing scaffolds for tissue engineering 
and repair of cartilage defects (352).  
As microcarrier aggregation was higher in the softest and hardest microcarrier 
tested, cell density within the pellets was higher. In 2010, Tang et al. demonstrated that 
cell-cell contacts influenced differentiation of MSCs into adipocytes and osteocytes 
(261). Herein, it is hypothesised the spontaneous migration of cells from monolayers to 
form multi-cellular pellets occurs due to a lack of RGD peptide dependency after 
chondrogenesis. In addition, the secretion of ECM proteins, which are not able to bind 
to the non-protein adhesive PEGDMA microcarrier, could potentially provide a scaffold 
for cells. To assess this further the expression of other genes and collagen isoforms 
could be analysed. 
In chapter 3, the microfluidic production of microcarriers with a range of 
diameters was accomplished. Due to time constraints it was not possible to assess the 
effect of substrate curvature on MSC attachment and differentiation. As spontaneous 
aggregation of MSCs has never been reported during chondrogenesis (in tissue culture 
plastic, in monolayer culture), it was hypothesised that surface curvature, in addition to 
substrate compressibility, influenced pellet formation. Future work would attempt to 
establish the effect of surface curvature on this phenomenon.  
6.4  ADSC expansion on novel microcarriers 
The aim of this study was to assess the feasibility of expanding ADSCs on the 
novel microcarriers developed in Chapter 3. By evaluating the data obtained from 
culturing ADSCs on various microcarriers in static culture (chapter 4), microcarriers 
containing 1mM RGDfC with a compressive modulus of 155kPa were selected as a 
model to test ADSC expansion within spinner flasks. Initial studies demonstrated that 
ADSCs can attach and proliferate on novel microcarriers within spinner flask culture for 
14 days. Importantly, after 14 days of expansion on the novel microcarriers, the adhered 
cells were shown to be multipotent.  
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6.5 Effect of initial seeding density on ADSC expansion 
Cell seeding density (relative to microcarrier concentration) is a critical 
parameter to optimise cell expansion. If the initial cell to microcarrier ratio is too low 
this will lead to an extensive lag phase (356). Alternatively, if the cell to microcarrier 
ratio is too high, the available surface area for  cell expansion is reduced, limiting the 
potential for cell expansion (382). To maximise the available surface area for cell 
expansion, and hence cell yield, it is important to generate homogenous culture 
conditions, with an even distribution in cells over the microcarrier population. In 
chapter 5, the effect of cell seeding density on ADSC expansion was assessed. Initially, 
a seeding density of 35 cells per microcarrier (equating to 5,000 cells/cm
2
, the 
recommended seeding density in flasks (Invitrogen)) was trialled. However, due to 
inefficient agitation a non-homogenous culture was generated. This led to the formation 
of aggregates of cell laden microcarriers, and hence the culture was terminated after 7. 
In addition, it was difficult to retrieve cells from the culture and determine an accurate 
level of cell expansion. However, the cells remained multipotent, and when placed in 
differentiation induction media showed positive staining for the relevant lineage specific 
histological stains.  
To maximise expansion, several cell seeding densities were tested. An initial 
seeding ratio of 17 cells per bead (cultured in DMEM and 10% MSC qualified FBS) 
yielded the highest number of cells after 14 days (7.3 million cells). This indicated a 
doubling time of 51 hours, or 5.09 population doublings. This is similar to the reported 
doubling rate of ADSCs cultured in DMEM and 10% FBS of approximately 54 hours ± 
4 hours. Alternatively at 1 cell per microcarrier the doubling time was significantly 
reduced to 36.4 hours, indicating 7.7 population doublings over 14 days. This is similar 
to the doubling rate reported for ADSCs in a propriety low serum media (MesenPro RS, 
Invitrogen) of 36 hours ± 4 hours. This correlated to data from Kehoe et al. (2012) who 
also noted an increase in doubling time on microcarriers seeded with higher cell 
densities (111). This is an important result as technologies developed for autologous cell 
therapies need to expand populations of ex vivo MSCs as rapidly as possible. 
 The data presented in this study was generated from the microcarrier system 
developed herein, showed the generated fold increase in ADSCs was higher than any 
value reported in the literature for human MSCs expanded on microcarriers. 
Microcarriers cultured at a ratio of 1 cell per bead had a 207 fold increase in ADSC 
number after 14 days. This was over 14 times higher than a similar study conducted in 
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xeno-free medium by Santos et al. (2011), who expanded ADSC on similarly uncharged 
microcarriers. Furthermore, the expanded ADSC population was capable of 
differentiating into lineage specific progeny when stimulated by induction medium, 
indicating the cells remained multipotent after expansion. It is important that the cells 
remain phenotypically and characteristically unaltered after expansion if they are to be 
utilised in clinical therapies. Despite an upregulation in the early chondrogenesis marker 
aggrecan, cells demonstrated a tri-lineage differentiation potential in line with ISCT 
guidelines to define a multipotent MSC. 
To improve upon the expansion protocol developed herein, the bioreactor design 
would need to be optimised to assess the effects of parameters known to influence cell 
expansion in spinner flasks, for example, shear stress, metabolism, stirring regime and 
cell seeding density. Furthermore, within this project the phenomenon of bead to bead 
transfer was repeatedly observed. This is important in microcarrier based expansion 
systems, as it offers the opportunity to increase cell surface area in a closed system 
without the need for manually passaging cell populations, reducing the risk of 
contamination. In addition, the influence of microcarrier properties, in particular the 
compressibility of the microcarrier, and diameter should be assessed when analysing the 
effects of shear stress on cell viability and growth. During agitation, shear stress on cells 
is not the only factor which effects cell viability, microcarrier collisions also can affect 
cell health. The effects of microcarrier stiffness on these collisions could be assessed 
further. 
6.6 Future Work 
6.6.1 Developing the microfluidic platform to generate a microcarrier array to 
systematically assess MSC function 
It is hypothesised that biochemical and biophysical cues act synergistically to 
control MSC fate. To generate microcarriers with different chemical compositions 
(using the microfluidic platform developed in chapter 3), the MicroPlant has to be 
dissembled, cleaned, the fluidic inputs changed and then reassembled.  This is time 
consuming and restricted the combination of microcarrier compositions that could be 
analysed in this project. Ideally, a microfluidic system that could generate microcarriers 
with a range of chemical compositions by fluid mixing on chip, by altering the fluid 
inputs would be desirable. Theoretically by varying the relative quantities of PEGDMA 
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and synthetic peptides, the mechanical and bio-adhesive properties of the microcarrier 
would be controlled and finely tuned. 
To address this, a microfluidic system with the capacity to vary polymer 
concentration was designed, and both peptide composition and concentration 
simultaneously tuned using on-chip gradient formation within our prototype chip 
designs. Computer controlled syringe drivers can be paired to produce reciprocal flow 
rates ensuring a smooth linear gradient of polymer input on chip. This second 
generation MicroPlant will allow the regulation of compressibility (through polymer 
gradient), peptide display (through peptide gradient), and peptide composition (by 
ratiometrically mixing multiple peptides) within the same production run. In order to 
distinguish between microcarriers of different compositions, the use of fluorescent tags 
was investigated. These would ideally be passively but permanently incorporated into 
the polymer matrix. Preliminary experiments involving fluorescently tagged proteins 
and Q-dots enabled facile distinction between three populations of microcarrier mixed 
in culture (Figure 64). Photostable fluorescent Q-dots, (which have been shown to be 
stably incorporated into microcarriers during manufacture will be used to ascertain a 
ratiometric fluorescent readout indicative of the biomechanical properties within the 
microcarrier. For example Red 625nm Q-dots will be incorporated within 10% polymer, 
green 515nm Q-dots within 20% polymer. Ratiometric fluorescence from both the 
microscope, and from a plate reader assay would allow us to identify beads against 
known controls to give a direct readout of the variable biomechanical properties in the 
sample, whilst also giving an immediate readout that on-chip mixing has been 
successful. Due to the broad excitation and narrow emission spectra of Q-dots, more 
than 6 different solutions could theoretically be mixed, and ratiometrically calculated 
(388). 
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Figure 64 Incorporation of fluorescent antibodies into microcarriers 
To generate microcarriers containing fluorescent tags, fluorescently conjugated antibodies (goat anti-
mouse Alexa 405,488,568 (Invitrogen,UK)) were incorporated into PEGDMA solutions prior to 
microfluidic generation of cross-linked microspheres.  
 
 By manipulating the microfluidic channel size within the MicroPlant, it was 
possible to produce microcarriers of defined sizes whilst maintaining their 
monodispersity. An initial proof of principle study has produced beads of 261, 460 and 
950 micron diameter. Smaller microcarriers carry a greater surface area:volume ratio, 
and so would provide a greater surface area for cell attachment for an equivalent amount 
of starting material (thus reducing material costs). However with a decrease in 
microcarrier size comes a change in surface curvature which could affect cell binding 
efficiency, maintenance of multipotency, and a decrease in cell survivability within a 
stirred bioreactor. Advances in the development of the microfluidic process will 
produce a library of microcarriers that can then be assessed for their effects on stem cell 
biology.  
Microcarriers containing a wide range of topographical, chemical, and 
mechanical properties have been generated. In future applications, (for example when 
generating an array with combinations of all three parameters), it could prove useful to 
track or identify microcarriers by including a unique fluorescent tag. Further work 
would investigate this more thoroughly and determine the effects (if any) on 
cytocompatibility.  
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6.6.2 Generating therapeutically relevant lot sizes of MSCs using the novel 
synthetic microcarrier based expansion 
Typically, MSC infusion therapies require approximately 150-300 million cells 
per treatment.  In this study, the highest yield of ADSCs after 14 day expansion was 7.3 
million cells. This experiment was performed in a 250mL spinner flask containing 
approximately 12,500 microcarriers. To generate the microcarriers used in this 
experiment, the current MicroPlant was run for 1 hour. To generate 150 million cells 
using the current protocol in 14 days, 21 batches of microcarriers (based on 12,667 
microcarriers/hour) would be required. For this technology to be used routinely to 
generate therapeutically relevant quantities of MSCs, it must be scaled up to generate 
more microcarriers per hour. To achieve this, a single chip could be produced 
containing several independent channels running in parallel on the same MicroPlant. 
The manifold would not require extensive changes as the steel base already contains 
several fluid entry points. In addition to scaling up manufacture, downstream processing 
of the microcarriers also needs to be optimised. Currently the microspheres are 
produced in a continuous phase of cytocompatible oil. Subsequently the oil is removed 
by washing using a water and surfactant approach (Chapter 2), which is time consuming 
and impractical at larger scales. As the microcarriers contain peptides which are 
expensive and possibly sensitive to harsh solvents, a careful approach has to be taken 
when removing the oil. In future, a column based approach could be explored, whereby 
the microcarriers are placed within a column containing a porous frit, and are washed 
using a continuous flow of water and surfactant, potentially reducing the handling time 
required to remove the oil and lowers  risk of contamination. 
To successfully implement the novel microcarriers produced herein to expand 
MSCs commercially, the cost of developing and producing the bioreactor culture 
system is crucial. Although bioreactor expansion of MSCs is significantly cheaper than 
conventional tissue culture based practices, specialised media and the microcarrier 
chemical costs are large. To generate the bio-adhesive microcarriers, peptides are bulk 
modified into the hydrogel microcarrier. As the cells are cultured on the microsphere 
surface only these results in large quantities of peptides being wasted. A limiting factor 
in this project was the cost of peptide, at approximately £70 per 1 hour batch of 
microcarriers. To produce the quantity of microcarriers estimated to yield 150 million 
MSCs using the current method and at the current price of peptide would cost £1,450. 
This futher highlights the need for optimisation in all parts of the project. 
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6.6.3 Developing a xeno-free culture system for the expansion of MSCs 
MSCs expanded for clinical therapies must follow rigorous and ever-evolving 
GMP guidelines. As discussed in Chapter 1, this will require the removal of animal 
components from both the culture medium and the microcarrier to prevent potential 
contamination. Charged microcarriers require serum proteins to facilitate cell adhesion 
to their surface. To circumvent this issue Santos et al. (2011) coated uncharged plastic 
microcarriers with CELLstart™, a xeno-free cell attachment substrate (a proprietary 
formulation, Invitrogen). Using the first fully demonstrated  ADSC compatible xeno-
free medium developed during the experimental period of this thesis in 2009 (StemPro 
MSC SFM, Invitrogen), the group demonstrated the feasibility of expanding ADSCs in 
xeno-free conditions (389). However, ~75% of the initial seeded cells were lost and cell 
growth experienced an extensive lag phase. In addition, Santos et al. showed a 14-fold 
increase in ADSC expansion over 14 days. This is significantly higher than MSC fold 
increases previously reported for microcarrier culture. In this study, typical fold 
increases in ADSC number (also over 14 days) ranged from 33 to 207, depending on 
initial cell seeding density. However, direct comparisons are difficult, as cell doubling 
time varies greatly according to medium composition. According to the manufacturers 
of StemPro MSC SFM (Invitrogen), SFM media decreases doubling rates and ‘hMSCs 
grown in classical medium, have a flattened cell morphology and reach confluency 
between 1.0–3.0 x 104 cells/cm2, hMSCs grown in STEMPRO® MSC SFM have a 
much smaller, spindle-shaped morphology and can reach densities >1.0 x 10
5
 cells/cm
2’ 
when compared to classical medium, DMEM and 10% MSC-qualified FBS, (as used in 
this study) (389). This is important as a decrease in cell area increases the surface area 
available for expansion, and therefore has a direct influence on the potential cell yield 
generated from a microcarrier culture. However, it is not evident from the publish 
reports, whether the effect on cell morphology is solely attributable to the media 
composition or the use of CellStart attachment factor. In addition, Timmins et al. (2012) 
could not reproduce the results found by Santos et al. when using human MSCs from a 
different source (92). 
The expansion of ADSCs on microcarriers described in this study is in the 
presence of ‘classical medium’ DMEM containing 10% MSC-qualified FBS. However, 
PEGDMA is resistant to non-specific protein adsorption onto the microcarrier surface 
Therefore, proteins such as vitronectin and fibronectin are not able to bind to the 
microcarrier surface and influence cell attachment. It is hypothesised that the removal of 
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serum will not dramatically affect ADSC attachment or expansion on novel 
microcarriers, as seen in the study by Santos et al.   
6.6.4 Microcarrier cryobanking 
In both chapters 4 and 5 the attachment and growth of ADSCs have been 
demonstrated on a range on novel microcarriers both in static and stirred cultures. In 
addition, ‘on microcarrier’ differentiation into adipocytes, osteocytes and chondrocytes 
has also been demonstrated. A potential application of the technology described in this 
work is drug discovery. The development of biomaterials for stem cell culture is a 
rapidly increasing area of research. A challenge however, is analysing the constructs in 
a high throughput manner. The generation of highly reproducible monodisperse 
synthetic microcarriers using microfluidics, with precise control and uniformity of size 
and chemical composition, which can be transferred using standard pipetting techniques 
could create a homogenous population of cell laden microspheres for testing different 
compounds. In addition to having a library of microcarriers containing different 
characteristics, we have shown a range of microcarriers containing fluorescently 
labelled dyes which can be potentially used to track microcarriers. 
In developing MSCs for autologous and allogeneic therapies, cryobanking 
important area of MSC research, as patients’ cells can be isolated and expanded ex vivo, 
before being stored long term until required. Future work will attempt to cryopreserve 
both expanded ADSCs and lineage specific progeny on microcarriers and characterise 
the effect of cryopreservation on cells to determine both viability and ‘stemness’, i.e. 
where applicable, their multipotent potential.  
Final conclusion 
The study has fulfilled its original aims. A robust, repeatable microfluidic 
system capable of generating synthetic PEGDMA hydrogel microcarriers containing a 
range of chemical, mechanical and topographical cues was established. Furthermore, 
proof of principal compositions were generated, however the method developed herein 
can be used to create microcarriers containing a variety of properties. Microcarriers 
modified to contain fibronectin derived cRGDfC peptide and the laminin based IKVAV 
peptide supported ADSC attachment and growth in a concentration dependent manner 
in static culture. Aggrecan expression, an early chondrogenic differentiation marker was 
upregulated in all conditions tested, which could indicate a heterogeneous culture 
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containing some differentiated cells. However aggrecan has been questioned as a 
marker for chondrogenesis, and so future work should examine a range of chondrogenic 
markers to investigate this further. Our data would also question the validity of this 
marker as ADSCs cultured on cRGDfC modified microcarriers were capable of 
differentiating into osteocytes, chondrocytes and adipocytes on the microcarrier surface, 
indicating culture on microcarriers maintained multipotent potential.  Substrate 
compressibility was found to effect ADSC differentiation, corroborating previous 
literature reports. ADSCs cultured on microcarriers formed spontaneous multicellular 
aggregates containing spatially distinct regions resembling native articular cartilage and 
expressing collagen type II. Bioreactor culture demonstrated successful ADSC 
expansion with fold increases in cell number far higher than have previously been 
reported in the literature. High cell seeding densities produced large quantities of viable 
cells. However, decreasing initial cell seeding density, increased the total fold expansion 
and reduced cell doubling rates. Further optimisation of the system is required, 
especially when switching the system into serum-free medium, however the 
microcarriers developed herein hold great potential for the expansion of ADSCs for 
regenerative medicine and tissue engineering. 
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7.0 Appendix 1 
Comparable effects of CHO cell culture on both commercially available and novel 
microcarriers 
Traditionally, microcarriers are used for the expression of therapeutic antibodies 
and proteins. Therefore to assess the ability of the developed microcarriers to sustain 
cell growth and biological function we compared the previously developed 
microcarriers alongside four commonly used commercially available equivalents with a 
range of properties.  
CHO DP12 cells (a CHO K1 (DHFR-) clone #1934) capable of producing 
humanized monoclonal anti-IL8 antibody (purchased from ATCC) was seeded on 
different microcarrier types and cell viability was monitored over 7 days. In addition 
antibody production was also monitored over 7 days. Results were compared to a non-
transfected CHO K1 cell line. The microcarriers tested comprised of 3 positively 
charged microcarriers Cytodex (1), Cytodex (3), Cytopore (1) and 1 charge-neutral 
microcarrier type, Pronectin F. More information regarding the above microcarrier 
properties can be found in Figure 2.  
 
To measure attachment and viability, CHO K1 and DP12 cells were seeded onto 
various microcarrier types in ultra-low attachment tissue culture plates under static 
culture conditions and their viability was measured using a Prestoblue assay. The 
highest initial attachment was seen on Cytopore microcarriers. Cytopore microcarriers 
are macroporous and provide a large surface area for attachment and have been 
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developed specifically for CHO cell culture. CHO K1 cells showed a general trend of 
growth peaking at day 3-5 but rapidly declining by Day 8. This could be potentially due 
to over confluency. CHO DP12 cell demonstrated a low level of initial attachment, but 
grew steadily over 8 days on all microcarrier types reaching a very high level of 
confluency on both Cytodex 1 and 3 microcarriers. The novel microcarriers developed 
in Chapter 3 demonstrated a comparable level of attachment for both cell types over 8 
days. Pronectin F microcarriers contain a poly-RGD synthetic protein conjugated to its 
surface. 
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The total level of anti-IL-8 produced by CHO DP12 cells on various 
microcarriers was monitored by ELISA over 7 days.  As expected CHO K1 cells 
produced no antibody as they are not transfected with the appropriate vector to express 
the anti-iL8 antibody. All microcarrier types supported antibody production, with 
Cytopore and Cytodex 1 microcarriers yielding the highest concentration of antibody, 
despite viability data suggesting the Cytopore microcarriers after 8 days cell attachment 
was approximately half that of Cytodex 1 microcarriers. The hydrogel microcarriers 
developed in herein produced the lowest quantity of antibody; however this experiment 
demonstrates the ability of hydrogel microcarriers produced to support cell expansion 
and the production of therapeutic proteins.  
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Appendix 2 
The efficiency of the Taqman assay dues (FAM) to amplify a particular locus 
was determined by perfoming RT-PCR on a serial dilution of RNA concentrations 
(Starting concentration 1 µg). The efficiency was calculated automatically using 
RealPlex software.  
Locus position Efficiency R squared value 
AGCN (NM_001135.3) 1.10 0.966 
CD73 (NM_002526.3) 1.11 0.996 
B2M (NM_004048.2) 0.93 0.998 
FABP4 (NM_001442.2) 0.94 0.998 
RGCC (NM_014059.2) 0.91 0.997 
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